TABLE OF CONTENTS

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.   )
Filed by the Registrant ☒
Filed by a Party other than the Registrant   ☐
Check the appropriate box:
 ☐ Preliminary Proxy Statement
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒ Definitive Proxy Statement
 ☐ Definitive Additional Materials
 ☐

Preliminary Proxy Statement

Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12
Aeva Technologies, Inc.
(Name of Registrant as Specified In Its Charter)
 
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
No fee required.
Fee paid previously with preliminary materials.
☒ No fee required.
 ☐ Fee paid previously with preliminary materials.
 ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

TABLE OF CONTENTS


555 Ellis Street
Mountain View, CA 94043
(650) 481-7070
Dear Fellow Stockholder:
On behalf of the Board of Directors and management of Aeva Technologies, Inc., I cordially invite you to attend our annual meeting of stockholders on Friday, NovemberMonday, December 18, 20222023 at 10:00 a.m. (Pacific Time). The 20222023 Annual Meeting will be a virtual meeting of stockholders. You will be able to attend the 20222023 Annual Meeting, vote your shares electronically and submit your questions during the meeting via live webcast by visiting www.virtualshareholdermeeting.com/AEVA2022AEVA2023.
Stockholders will be able to listen, vote, and submit questions from their home or any location with internet connectivity. To participate in the meeting, you must have the 16-digit number that is shown on your Notice of Internet Availability of Proxy Materials or on your proxy card if you elected to receive proxy materials by mail.card. The notice of meeting and proxy statement that follow describe the business that we will consider at the meeting.
We hope that you will be able to attend the meeting via our live webcast. However, regardless of whether you attend the meeting, your vote is very important. We are pleased to offer multiple options for voting your shares. You may vote by telephone, via the internet, by mail or through our live webcast of the Annual Meeting, as described beginning on page one of the proxy statement.this Proxy Statement.
Thank you for your continued support of Aeva Technologies, Inc.
Sincerely yours,

Soroush Salehian Dardashti
Chief Executive Officer

TABLE OF CONTENTS


Notice of 20222023 Annual Meeting of Stockholders
NovemberDecember 18, 20222023
10:00 a.m. (Pacific Time)
www.virtualshareholdermeeting.com/AEVA2022AEVA2023
You can attend the Annual Meeting online through our live webcast, vote your shares electronically and submit your questions during the Annual Meeting, by visiting www.virtualshareholdermeeting.com/AEVA2022AEVA2023. You will need to have the 16-digit number included on your notice or your proxy card (if you received a printed copy of the proxy materials) to join the Annual Meeting.
AGENDA:
1.
Elect the two Class I directorII directors named as nominees in ourthis Proxy Statement to hold office until the 20252026 annual meeting of stockholders (the “2025“2026 Annual Meeting”) and until their respective successors have been duly elected and qualified;
2.
Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;2023;
3.
Approve an amendment to our 2021 Incentive Award Plancertificate of incorporation to (i) increaseprovide the numberBoard of sharesDirectors with the right to decide at its discretion to effect a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-30, with the exact ratio and effective time of the reverse stock split, if any, to be determined by our common stock reserved for issuance, and (ii) implement an evergreen share reserve increase pursuant to whichBoard of Directors at any time within one year of the numberdate of shares of our common stock reserved for issuance under the Incentive Plan will increase on an annual basis;2023 Annual Meeting;
4.
Approve our Employeecertain securities issuances for the purpose of complying with New York Stock Purchase Plan to provide our eligible employees an opportunity to acquire our common stock from us;Exchange rules; and
5.
Advisory (non-binding) vote to approve the compensation of our named executive officers;
6.
Advisory (non-binding) vote on the frequency of future advisory votes on executive compensation;
7.
Transact any other business properly introduced at the Annual Meeting.
The Board reserves the right to withdraw Proposal No. 4 and, if such proposal is withdrawn, all references in this Proxy Statement and any related proxy materials to voting for Proposal No. 4 should be disregarded.
Only stockholders of record as of September 26, 2022October 19, 2023 will be entitled to attend and vote at the Annual Meeting and any adjournments or postponements thereof. A list of these stockholders will be open for examination by any stockholder for any purpose germane to the 20222023 Annual Meeting for a period of 10 days prior to the 20222023 Annual Meeting by contacting our Investor Relationsinvestor relations department at investors@aeva.ai and during the 20222023 Annual Meeting at www.virtualshareholdermeeting.com/AEVA2022.AEVA2023.
Please note that if you held common stock on September 26, 2022October 19, 2023 in “street name” (that is, through a broker, bank or other nominee), you are considered the “beneficial owner” of those shares. As the beneficial owner of those shares, you have the right to direct your broker, bank or other nominee how to vote your shares. You will receive instructions from your broker, bank or other nominee that you must follow in order to have your shares of common stock voted.
We hope that you can attend the 2023 Annual Meeting. Regardless of whether you will attend via our live webcast, please complete and return your proxy so that your shares can be voted at the Annual Meeting in accordance with your instructions.
November 29, 2023

TABLE OF CONTENTS

We are pleased to furnish proxy materials to our stockholders on the internet. We believe that this allows us to provide you with the information that you need while lowering the costs of delivery and reducing the environmental impact of the Annual Meeting.
October 4, 2022
 
By Order of the Board of Directors
 
 
 
Soroush Salehian Dardashti
 
Chief Executive Officer
This Proxy Statement and accompanying proxy card are first being made available on or about October 4, 2022.
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2022 ANNUAL MEETING OF STOCKHOLDERS:November 29, 2023.
Our official Notice of Annual Meeting of Stockholders, Proxy Statement and 20212022 Annual Report on Form 10-K as amended, for the fiscal year ended December 31, 2021,2022, are available electronically at https://investors.aeva.com/financials-and-filings/sec-filings/default.aspx

TABLE OF CONTENTS

Summary Information for the Annual Meeting of Stockholders to be Held on NovemberDecember 18, 2022
2023
This Proxy Statement (this “Proxy Statement”) and our annual reportAnnual Report on Form 10-K for the fiscal year ended December 31, 20212022 (the “Annual Report” and, together with thethis Proxy Statement, the “proxy materials”“Proxy Materials”) are being furnished by and on behalf of the board of directors (the “Board” or “Board of Directors”) of Aeva Technologies, Inc. in connection with our annual meeting of stockholders for the calendar year endedending December 31, 20212023 (the “Annual Meeting” or the “2022“2023 Annual Meeting”). As used herein, the terms “Aeva,” the “Company,” “we,” “us,” or “our” refer Aeva Technologies, Inc. and its consolidated subsidiaries unless otherwise stated or the context otherwise requires. The Company was a special purpose acquisition company called InterPrivate Acquisition Corp. (“IPV”) prior to the closing of the merger (the “Closing”) of privately held Aeva, Inc. (“Legacy Aeva”) with and into WLLY Merger Sub Corp., a wholly-owned subsidiary of IPV, resulting in Legacy Aeva becoming a wholly-owned subsidiary of IPV on March 12, 2021 (the “Closing Date”). On the Closing Date, IPV changed its name to Aeva Technologies, Inc.
To assist you in reviewing the proposals to be voted upon at our 20222023 Annual Meeting, we have summarized important information contained in this Proxy Statement. This summary does not contain all of the information that you should consider, and you should carefully read the entire Proxy Statement and our Annual Report on Form 10-K before voting.
Voting
Stockholders of record as of September 26, 2022October 19, 2023 may cast their votes in any of the following ways:





 
Internet
Phone
Mail
Via webcast during the Annual Meeting
Visit www.proxyvote.com. You will need the 16-digit number included in your proxy card or voter instruction form or notice.form.
Call 1 800-690-6903 or the number on your voter instruction form. You will need the 16-digit number included in your proxy card or voter instruction form or notice.form.
Send your completed and signed proxy card or voter instruction form to Vote Processing c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.S11717.
Visit www.virtualshareholdermeeting.com/
AEVA2022. AEVA2023. You will need the 16-digit number included in your proxy card or voter instruction form or notice.form. Online access begins at 10:00 a.m. (Pacific time).
Voting Matters and Board Recommendation
Proposal
Board Vote Recommendation
Elect Class I DirectorII Directors (page 2)
FOR each Director Nominee
 
 
 
Ratify the Appointment of Independent Registered Public Accounting Firm for 20222023 (page 1112)
FOR
 
 
 
Approve an Amendment to our 2021 Incentive Award PlanCertificate of Incorporation to Provide the Board of Directors with the Right to Decide at its Discretion to Effect a Reverse Stock Split (page 1415)
FOR
 
 
 
Approve our Employee Stock Purchase PlanCertain Securities Issuances for Purposes of Complying with NYSE Rules (page 2123)
FOR
Advisory (non-binding) vote to approve the compensation of our named executive officers; (page 25)
FOR
Advisory (non-binding) vote on the frequency of future advisory votes on executive compensation; (page 26)
FOR “three years”

TABLE OF CONTENTS

TABLE OF CONTENTS
i

TABLE OF CONTENTS

ABOUT AEVA
Founded in 2016 by former Apple engineers Soroush Salehian Dardashti and Mina Rezk and led by a multidisciplinary team of engineers and operators experienced in the field of sensing and perception, our mission is to bring the next wave of perception technology to broad applications from automated driving to industrial automation and consumer electronics. Our products are based on our proprietary Frequency Modulated Continuous Wave (FMCW) sensing technology. Our 4D LiDAR-on-chip combines silicon photonics technology that is proven in the telecom industry with precise instant velocity measurements and long-range performance, along with our proprietary signal processing algorithms and perception software applications for commercialization.
1

TABLE OF CONTENTS

PROPOSAL 1: ELECT CLASS I DIRECTORII DIRECTORS
Our business and affairs are managed under the direction of our Board. As of the date of this Proxy Statement, our Board consists of fiveeight directors. On September 26, 2022, the Board increased the size of the Board to nine directors. Also on September 26, 2022, the Board appointed Erin Polek as a Class I director and Christopher Eberle as a Class III director, in each case, such Board appointment effective November 11, 2022. On September 29, 2022, the Board appointed Stephen Zadesky to serve as a Class II director, such Board appointment effective November 11, 2022. Ms. Polek was appointed as a member of the Audit Committee (effective November 11, 2022) and Mr. Eberle was appointed as a member of the Compensation Committee (effective November 11, 2022).
Our amendedSecond Amended and restated certificateRestated Certificate of incorporationIncorporation (our “Certificate of Incorporation”) provides that, subject to the right of holders of any series of preferred stock, our Board will be divided into three classes of directors, with the classes to be as nearly equal in number as possible, and with the directors serving staggered three-year terms, with only one class of directors being elected at each annual meeting of stockholders. As a result, approximately one-third of our Board will be elected each year.
Ahmed Fattouh,Our Board as nominated Hrach Simonian and Stephen Zadesky for election as Class II Directors with a Class I director as of the date of this Proxy Statement, is not seeking re-election and histhree-year term will expireexpiring at the conclusion of the2026 Annual Meeting.
Unless otherwise specified in the proxy, the shares voted pursuant thereto will be cast for Erin Polek.Hrach Simonian and Stephen Zadesky. If, for any reason, at the time of election theany nominee named should decline or be unable to accept herhis nomination or election, it is intended that such proxy will be voted for a substitute nominee, who would be recommended by our Board. Our Board, however, has no reason to believe that the nomineenominees will be unable to serve as a director.
The following biographical information is furnished as to each nominee for election as a director, and each of our directors, as of October 4, 2022.
Nominee for Election to the Board of Directors for a Three-Year Term Expiring at the 2025 Annual Meeting
Erin L. Polek, 48. Erin Polek is expected to begin service as a Director of the Company on November 11, 2022. Ms. Polek has been Senior Vice President, Corporate Controller and Chief Accounting Officer of QUALCOMM Incorporated (“Qualcomm”), a global leader in the development of foundational technologies used in mobile devices and other wireless products, since December 2018. Ms. Polek’s principal responsibilities at Qualcomm include oversight of the global accounting department and external financial reporting and related compliance. She joined Qualcomm in February 2006 and has held a variety of leadership positions. Prior to joining Qualcomm, Ms. Polek was a Manager at PricewaterhouseCoopers LLP. She received a Bachelor of Science in Business Administration, with an emphasis in Accounting from San Diego State University. We believe Ms. Polek is well-qualified to serve as one of our directors based on her extensive leadership, accounting, compliance and business experience.15, 2023.
Members of the Board of Directors Continuing in Office forwith a Term Expiring at the 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”)
Shahin Farshchi, 43.44. Shahin Farshchi serves as a Director of the Company. Mr. Farshchi served as a member of Legacy Aeva’sthe Board of Directors of Aeva, Inc., our privately held predecessor (“Legacy Aeva”), from its inception in December 2016 tillthrough the Closingclosing of theits merger (the “merger”) with and into a subsidiary of Aeva Technologies, Inc., (f/k/a InterPrivate Acquisition Corp.), and has served on our Board of Directors since its inception in March 2021. Mr. Farshchi serves as a partner at Lux Capital, a venture capital firm he joined in 2006. Mr. Farshchi currently serves on the board of directors of numerous private companies. Mr. Farshchi holds a Bachelor of Science in Electrical Engineering and Computer Science from The University of California, Berkeley, a Master of Science degree, and a Doctor of Philosophy from the University of California, Los Angeles. We believe Mr. Farshchi is well-qualified to serve on our Board of Directors due to his extensive experience in identifying, investing in and building next-generation technologies and companies.
Hrach Simonian, 39.41. Hrach Simonian serves as a Director of the Company. Mr. Simonian served as a member of Legacy Aeva’s Board of Directors from November 2017 tillthrough the Closingclosing of the merger, and has served on our Board of Directors since its inception in March 2021. Mr. Simonian serves as a General Partner at Canaan Partners, an early-stage venture capital firm he joined in 2007. Mr. Simonian currently serves on the Board of Directors of numerous private companies. Mr. Simonian holds a Bachelor of Science in Electrical Engineering from The University of California, Los Angeles, a Master of Science in Electrical Engineering from the University of Michigan, Ann Arbor, and a Master of Business Administration from the Stanford Graduate School of Business. We believe Mr. Simonian is well-qualified to serve on our Board of Directors due to his extensive experience in investing and developing companies.
2

TABLE OF CONTENTS

Stephen Zadesky, 50.52. Stephen Zadesky is expected to begin servicehas served as a Director of the Company onsince November 11, 2022. Mr. Zadesky is currently advising a number of companies in the transportation, robotics and clean technology sectors. Prior to his advising work, Mr. Zadesky served in various management roles at Apple from March 1999 till April 2019, including Vice President Product Design for iPhone and iPod engineering. Prior to joining Apple, Mr. Zadesky worked at Ford Motor Company for three years in a variety of positions. Mr. Zadesky earned a Bachelor of Science in Mechanical Engineering (BSME) from the University of California, Berkeley and a Master of Science in Mechanical Engineering (MSME) from Stanford University. We believe Mr. Zadesky is well-qualified to serve as one of our directors based on his proficiency and understanding of the transportation and technology sectors, as well as his extensive advisory and leadership experience.
Members of the Board of Directors Continuing in Office for a Term Expiring at the 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”)
Soroush Salehian Dardashti, 34.35. Soroush Salehian Dardashti serves as the Company’s Chief Executive Offer and is a member of the Board. Mr. Salehian co-founded Aeva with Mr. Rezk in December 2016 and has served as its Chief Executive Officer and on thea member of its Board of Directors since that time. From February 2012 to November 2016, Mr. Salehian worked at Apple as a Manager, Product Development where he led teams developing consumer products
2

TABLE OF CONTENTS

and sensing systems. Mr. Salehian holds a Bachelor of Science in Mechanical Engineering from Stanford University. We believe Mr. Salehian is well-qualified to serve on our Board of Directors due to his technical and operational expertise gained from serving as Chief Executive Officer and Co-Founder of Aeva and his professional and educational experience in high-technology manufacturing industries.
Mina Rezk, 37.39. Mina Rezk serves as the President, Chief Technology Officer, and Chairman of the Board of Directors and a director of the Company. Mr. Rezk co-founded Aeva with Mr. Salehian in December 2016 and has served as its Chief Technology Officer and on thea member of its Board of Directors since that time. Mr. Rezk became Chair of the Board of Directors in 2021. From January 2015 to November 2016, Mr. Rezk served as Sensing Engineering Manager - Special Projects Group at Apple. Before that, Mr. Rezk served in various roles, including as Hardware Development Manager, at Nikon Metrology from February 2004 to February 2015. Mr. Rezk has over 17 years of experience developing sensor fusion systems for the automotive and aerospace industries. Mr. Rezk holds Bachelor of Science and Master of Science degrees in Electrical Engineering from George Mason University. We believe Mr. Rezk is well-qualified to serve on our Board of Directors due to his technical and manufacturing expertise gained from serving as the Chief Technology Officer of Aeva and over 17 years of experience in the technology industry.
Christopher Eberle, 42.43. Christopher Eberle is expected to begin servicehas served as a Director of the Company onsince November 11, 2022. Mr. Eberle has served as Global Head of Semiconductor and Hardware Investments at Sylebra Capital Limited (“Sylebra”), a global investment manager operating in the technology, media and telecommunications space, since July 2020. Mr. Eberle’s principal responsibilities at Sylebra include managing investments across the global semiconductor, semiconductor capital equipment, and global semiconductor supply chain. Prior to joining Sylebra, Mr. Eberle served as a senior equity research analyst at Instinet, LLC, the independent equity trading arm of Nomura Group, from August 2017 until July 2020. He served as a portfolio manager focused on the global technology space at Folger Hill Asset Management from January 2015 to August 2017. Mr. Eberle received a Bachelor of Science in Finance from Canisius College in 2003, and a Master’s of Science in Finance from DePaul University Driehaus College of Business in 2008. We believe Mr. Eberle is well-qualified to serve as Sylebra’s designee on our Board based on his business and management experience as well as his extensive experience in the technology, media and telecommunications industries.
Non-Continuing DirectorMembers of the Board of Directors Continuing in Office for a Term Expiring at the 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”)
Ahmed M. Fattouh.Erin L. Polek, 49. Mr. Fattouh servesErin Polek has served as a Director of the Company. Mr. FattouhCompany since November 2022. Ms. Polek has been working part-time at Qualcomm Incorporated (“Qualcomm”), a global leader in the development of foundational technologies used in mobile devices and other wireless products, providing guidance and leadership in preparing for regulatory reporting over ESG data in anticipation of the proposed regulations from the SEC and the issued CSRD regulations in the EU since December 2022. Prior to such time, Ms. Polek was Senior Vice President, Corporate Controller and Chief Accounting Officer of Qualcomm from December 2018 through December 2022. Ms. Polek’s principal responsibilities at Qualcomm included the oversight of the global accounting department and external financial reporting and related compliance. She joined Qualcomm in February 2006 and has held a variety of leadership positions. Prior to joining Qualcomm, Ms. Polek was a Manager at PricewaterhouseCoopers LLP. She received a Bachelor of Science in Business Administration, with an emphasis in Accounting from San Diego State University. We believe Ms. Polek is well-qualified to serve as one of our directors based on her extensive leadership, accounting, compliance and business experience.
Stefan Sommer, PhD, 60. Dr. Stefan Sommer has served as a Director of the Company since November 2023. Dr. Sommer began his professional career as a development engineer at ITT Teves. In 1997, Dr. Sommer moved to Continental Automotive Systems as director of Electronics & Sensor Development. After holding several positions within the Continental Group, Dr. Sommer joined ZF Sachs AG in 2008 as a member of the Board of Management for the Chassis Systems Division. In 2010, Dr. Sommer was appointed to the central Board of Management of ZF AG, where he assumed responsibility for the Materials Management business. From 2012 through December 2017 he served as Chief Executive Officer of ZF AG. Dr. Sommer was a member of the Board of Management of Volkswagen AG with responsibility for the Components and Procurement business from September 2018 to June 2020. He has served as a member of Aeva’sthe Supervisory Board at Knorr-Bremse AG, a global leader in safety technology for the automotive and rail industries, since 2021. He has served as chair of the Board of Directors of JOST Werke SE since its merger with InterPrivate Acquisition Corp., where he2022. He has served as Chairman and CEO from December 2019 to March 2021. Since 2017, he has been the Chief Executive Officer of InterPrivate LLC, a private equity and growth capital investment firm and serial SPAC sponsor. In 2001, Mr. Fattouh founded Landmark Value Investments, an alternative asset management firm managing various hedge fund strategies. Previously, Mr. Fattouh was a memberMember of the private equity group at Investcorp InternationalManaging Board of the GÜNTHER Group, a company that makes injection systems for the plastics and the M&A Department of Morgan Stanley & Co. in New York. He has executed transactions involvingsilicone processing industry, leaders including RJR Nabisco, Mobil Corporation, Ampolex, IBM, Elf Atochem, Tivoli Systems, Eagle Industries, Amerace, Washington Energy,with responsibility for GÜNTHER Heisskanaltechnik
3

TABLE OF CONTENTS

Puget Power, Synergy Gas, KKR, Saks Fifth Avenue, Werner Ladder, Falcon Building Products, LVMH, Bliss, Eastern Software,GmbH and Fidelity National. Mr. Fattouh currently servesits subsidiaries since January 2023. Dr. Sommer studied Mechanical Engineering and earned his Engineering Doctorate from Ruhr University Bochum. We believe Dr. Sommer is well-qualified to serve as one of our directors based on his extensive executive leadership experience with leading organizations in the Board of Directors of InterPrivate II Acquisition Corp. InterPrivate III Financial Partners Inc. and InterPrivate IV InfraTech Partners Inc. Mr. Fattouh has served as a director of Columbia Medical Products, the Del Grande Dealer Group, Massmedium, Open Road Capital, InterPayments and Collective Sense. Mr. Fattouh received a Bachelor of Science in Foreign Service from Georgetown University.automotive industry, including component manufacturers.
Required Vote
Our bylaws provide for a plurality voting standard for the election of directors. Under this voting standard, once a quorum has been established, the nominee(s)nominees who receive the largest number of votes are elected as director(s)directors up to the maximum number of directors to be elected at the meeting. This means thatOur Board has nominated two persons for election as Class II Directors at the nominee2023 Annual Meeting and, as a result, the two nominees receiving the highest number of votes at the 20222023 Annual Meeting will be elected, even if these votes do not constitute a majority of the votes cast. Only votes cast “FOR” a nominee will be counted in the election of directors. Votes that are “WITHHELD” with respect to one or more nominees will result in those nominees receiving fewer votes but will not count as a vote against the nominees.
Recommendation
OUR BOARD UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” EACH OF THE NOMINEE.NOMINEES, HRACH SIMONIAN AND STEPHEN ZADESKY.
4

TABLE OF CONTENTS

CORPORATE GOVERNANCE
We have structured our corporate governance in a manner we believe closely aligns our interests with those of our stockholders. Notable features of this corporate governance include:
independent director representation on our Audit, Compensation and Nominating and Corporate Governance Committees, and our independent directors will meet regularly in executive sessions without the presence of our corporate officers or non-independent directors; and
at least one of our directors qualifies as an “audit committee financial expert” as defined by the Securities and Exchange Commission (the “SEC”).
Composition of the Board of Directors
Our business and affairs are managed under the direction of our Board of Directors. Our Board of Directors is staggered in three classes. Ms. Polek is expected to serve as aclasses, with members of each class serving staggered three-year terms. As of the date hereof, our Board consists of two director in Class I director beginning November 11, 2022, with her term expiring(Ms. Polek and Dr. Sommer), three directors in Class II (Mr. Farshchi, Mr. Simonian and Mr. Zadesky) and three directors in Class III (Mr. Dardashti, Mr. Rezk and Mr. Eberle). The Class I Directors will next be up for election at the 2025 Annual Meeting, the Class II Directors are up for election at this Annual Meeting; Messrs. Farshchi, SimonianMeeting and Zadesky serve aswill next be up for election at our 2026 Annual Meeting and the Class III Directors will next be up for election at our 2024 Annual Meeting. Following the 2023 Annual Meeting, our Board will consist of two Class I Directors, two Class II directors (in the case of Mr. Zadesky, such service expected to begin November 11, 2022), with terms expiring at the Company’s 2023 annual meeting of stockholders;Directors, and Messrs. Salehian, Rezk and Mr. Eberle serve asthree Class III directors (in the caseDirectors for a total of Mr. Eberle, such service expected to begin November 11, 2022), with terms expiring at the Company’s 2024 annual meeting of stockholders.seven directors.
Director Independence
A majority of the Board shall be comprised of directors meeting the independence requirements of the NYSE.New York Stock Exchange (the “NYSE”). The Company defines an “independent” director in accordance with Section 303A.02 of the NYSE’s Listed Company Manual. The NYSE independence definition includes a series of objective tests, including that the director is not an employee of the Company and has not engaged in various types of business dealings with the Company. Because it is not possible to anticipate or explicitly provide for all potential conflicts of interest that may affect independence, the Board is also responsible for determining affirmatively, as to each independent director, that no material relationships exist which, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, the Board will broadly consider all relevant facts and circumstances, including information provided by the directors and the Company with regard to each director’s business and personal activities as they may relate to the Company and the Company’s management. As the concern is independence from management, the Board does not view ownership of even a significant amount of stock, by itself, as a bar to an independence finding. No director may serve on the Audit Committee or the Compensation Committee of the Board unless such director meets all of the applicable criteria established for service in each such committee by NYSE rules and any other applicable rules or laws.
The Board shall make an affirmative determination as to the independence of each director. The Board has determined that each of Messrs. Eberle, Farshchi and Simonian, and EberleDr. Sommer and Ms. Polek qualify as independent directors under applicable SEC and NYSE rules.
Board Committees
Our Board of Directors directs the management of our business and affairs, as provided by Delaware law, and conducts its business through meetings of the Board of Directors and standing committees. We have a standing audit committee (the “Audit Committee”), nominating and corporate governance committee (the “Nominating and Corporate Governance Committee”) and compensation committee.committee (the “Compensation Committee”). In addition, from time to time, special committees may be established under the direction of the Board of Directors when necessary to address specific issues.
Audit Committee
Our Audit Committee is responsible for, among other things:
appointing, compensating, retaining, evaluating, terminating and overseeing our independent registered public accounting firm;
5

TABLE OF CONTENTS

discussing with our independent registered public accounting firm their independence from management;
reviewing, with our independent registered public accounting firm, the scope and results of their audit;
5

TABLE OF CONTENTS

approving all audit and permissible non-audit services to be performed by our independent registered public accounting firm;
overseeing the financial reporting process and discussing with management and our independent registered public accounting firm the quarterly and annual financial statements that we file with the SEC;
overseeing our financial and accounting controls and compliance with legal and regulatory requirements;
reviewing our policies on risk assessment and risk management;
reviewing related person transactions; and
establishing procedures for the confidential anonymous submission of concerns regarding questionable accounting, internal controls or auditing matters.
OurAs of the date hereof, our Audit Committee consists of Messrs. Farshchi, Simonian Fattouh and beginning November 11, 2022, Ms. Polek. Mr. Simonian serves as chair of our Audit Committee. Mr. Fattouh is not seeking re-election and his term will expire at the conclusion of the Annual Meeting. Rule 10A-3 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and the NYSE rules require that our Audit Committee have at least one independent member who qualifies as a financial expert, and be composed entirely of independent members. Our Board of Directors has affirmatively determined that Messrs. Farshchi and Simonian, FattouhDr. Sommer and Ms. Polek each meet the definition of “independent director” for purposes of serving on the audit committee under Rule 10A-3 of the Exchange Act and the NYSE rules. Each member of our Audit CommitteeMessrs. Farshchi and Simonian, Dr. Sommer and Ms. Polek also meets the financial literacy requirements of the NYSE listing standards.Continued Listing Standards. In addition, our Board of Directors has determined that Mr. Simonian and Ms. Polek each qualify as an “audit committee financial expert,” as such term is defined in Item 407(d)(5) of Regulation S-K. Immediately following the conclusion of the 2023 Annual Meeting, the Board expects our Audit Committee to consist of Mr. Simonian, Dr. Sommer and Ms. Polek, with Ms. Polek becoming chair of this committee.
Our Board of Directors has adopted a written charter for the Audit Committee, which is available on our corporate website at www.aeva.com. The information on any of our websites is deemed not to be incorporated in or to be a part of this Proxy Statement.
Compensation Committee
Our Compensation Committee is responsible for, among other things:
reviewing and approving the corporate goals and objectives, evaluating the performance of and reviewing and approving, (either alone or, if directed by the Board of Directors, in conjunction with a majority of the independent members of the Board of Directors) the compensation of our Chief Executive Officer;
overseeing an evaluation of the performance of and reviewing and setting or making recommendations to our Board of Directors regarding the compensation of our other executive officers;
reviewing and approving or making recommendations to our Board of Directors regarding our incentive compensation and equity-based plans, policies and programs;
reviewing and approving or making recommendations to our Board of Directors regarding all employment agreements and severance arrangements for our executive officers;
recommendations to our Board of Directors regarding the compensation of our directors; and
retaining and overseeing any compensation consultants.
OurAs of the date hereof, our Compensation Committee consists of Messrs. Eberle, Farshchi Simonian, Fattouh and beginning November 11, 2022, Mr. Eberle. Mr. Fattouh is not seeking re-election and his term will expire at the conclusion of the Annual Meeting.Simonian. Mr. Farshchi has served as chair of our Compensation Committee since November 29, 2021. Prior to such date, Mr. Simonian served as chair of the Compensation Committee. Our Board of Directors has affirmatively determined that Messrs. Farshchi, Simonian Fattouh and Eberle and Ms. Polek each meet the definition of “independent director” for purposes of serving on the Compensation Committee under the NYSE rules, including the heightened independence standards for members of a Compensation Committee,Committee. In addition, our Board of Directors has
6

TABLE OF CONTENTS

determined that each of Messrs. Eberle, Farshchi and Simonian and Ms. Polek are “non-employee directors” as defined in Rule 16b-3 of the Exchange Act. Immediately following the conclusion of the 2023 Annual Meeting, the Board expects our Compensation Committee to consist of Messrs. Eberle and Simonian and Ms. Polek, with Mr. Eberle becoming chair of this committee.
Our Board of Directors has adopted a written charter for the Compensation Committee, which is available on our corporate website at www.aeva.com. Our Compensation Committee has engaged an independent compensation consultant, Aon Human Capital Solutions practice, a division of Aon plc (“Aon”). The scope of the engagement with Aon is described in the Compensation Discussion and Analysis under the heading “Use of Competitive Market Data and Peer Groups.” The information on any of our websites is deemed not to be incorporated in or to be a part of this Proxy Statement.
Compensation Consultant Role
6
Our Compensation Committee is authorized under its charter to retain the services of one or more executive compensation advisors in connection with the establishment of our compensation programs and related policies. Our Compensation Committee engaged an independent compensation consultant, Aon Human Capital Solutions practice, a division of Aon plc (“Aon”), for fiscal 2022 and fiscal 2023. Our Compensation Committee engaged Aon to assist with the following objectives:

developing a group of peer companies to help us determine the appropriate level of overall compensation for our executive officers in fiscal 2022 and 2023;

TABLE OF CONTENTS

evaluating the overall competitiveness of our compensation program for our executive officers in fiscal 2022 and 2023; and
assessing each separate element of compensation, with a goal of ensuring that the compensation we offer to our executive officers in fiscal 2022, 2023 and beyond is deemed appropriate, competitive and fair.
Aon reported directly to the Compensation Committee. Aon met with the Compensation Committee and with management to solicit input on job scope, performance, retention issues and other relevant factors. Aon worked with the Compensation Committee to develop recommendations for the compensation of our senior management team. Aon also advised the Compensation Committee on compensation-related developments and best practices.
Aon did not provide the Company with any services other than services that it provided to the Compensation Committee and to management in a limited capacity in connection with the preparation of the Company’s SEC-mandated compensation disclosure. The Compensation Committee does not believe that the work performed by Aon for the Compensation Committee or management raised any conflict of interest.
Nominating and Corporate Governance Committee
Our Nominating and Corporate Governance committeeCommittee is responsible for, among other things:
identifying individuals qualified to become members of our Board of Directors, consistent with criteria approved by our Board of Directors;
periodically reviewing our Board of Directors’ leadership structure and recommending any proposed changes to our Board of Directors;
overseeing an annual evaluation of the effectiveness of our Board of Directors and its committees; and
developing and recommending to our Board of Directors a set of corporate governance guidelines.
OurAs of the date hereof, our Nominating and Corporate Governance Committee consists of Messrs. Farshchi Fattouh and Simonian, with Mr. Farshchi serving as chair. Mr. Fattouh is not seeking re-election and his term will expire atImmediately following the conclusion of the 2023 Annual Meeting. OurMeeting, the Board expects our Nominating and Corporate Governance Committee to consist of Directors has affirmatively determined that Messrs. Farshchi, FattouhMr. Simonian and Ms. Polek, with Mr. Simonian each meet the definitionbecoming chair of “independent director” under the NYSE rules. this committee.
Our Board of Directors has adopted a written charter for our Nominating and Corporate Governance Committee, which is available on our corporate website at www.aeva.com. The information on any of our websites is deemed not to be incorporated in or to be a part of this Proxy Statement.
Risk Oversight
Our Board of Directors is responsible for overseeing our risk management process. Our Board of Directors focuses on our general risk management strategy, the most significant risks facing us, and oversees the implementation of risk mitigation strategies by management. Our Audit Committee is also responsible for discussing our policies with respect to risk assessment and risk management.
Compensation Committee Interlocks and Insider Participation
None of our executive officers serves as a member of the board of directors or compensation committee (or other committee performing equivalent functions) of any entity that has one or more executive officers serving on our Board of Directors or Compensation Committee.
7

TABLE OF CONTENTS

Code of Business Conduct and Ethics
We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code is posted on the corporate governance section of our corporate website. In addition, we intend to post on our website all disclosures that are required by law or the NYSE listing standards concerning any amendments to, or waivers from, any provision of the code. The information on any of our websites is deemed not to be incorporated in or to be a part of this Proxy Statement.
Director Nomination Rights
We are party to several agreements to provide for certain governance matters relating to the Company.
Pursuant to the terms of the 2021 Stockholders Agreement (as defined below), subject to the rules of the NYSE, each of Mr. Rezk and Mr. Dardashti is entitled to nominate himself to continue to serve on the Board of Directors until such time as he holds less than 5% of our outstanding common stock (or his earlier death or incapacity). In addition, Mr. Rezk will serve as Chairman of the Board of Directors for so long as he is a director and, in the event Mr. Rezk is no longer a director, then Mr. Salehian will serve as the Chairman of the Board of Directors so long as he is a director. Messrs. Dardashti and Rezk also have the right to appoint an Audit Committee Qualified Director (as defined in the 2021 Stockholders Agreement) whom will be subject to the approval of the remaining members of the Board of Directors. None of the current directors were appointed pursuant to this right. For more information, see “Certain Relationships and Related Transactions—2021 Stockholders Agreement.”
Pursuant to the terms of the Sylebra Stockholders Agreement, for as long as Sylebra and its affiliates beneficially own at least (i) 9.0% of our outstanding common stock (on an as converted basis), Sylebra will have the right to nominate one director, who will initially be Mr. Eberle, Global Head of Semiconductor and Hardware Investments at Sylebra, and (ii) 14.0% of our outstanding common stock (on an as converted basis), Sylebra will have the right to nominate an additional director, who shall be an automotive executive or relevant industry expert. Sylebra has waived its right to designate such additional director until the election of the Class I directors in 2025. For more information, see “Certain Relationships and Related Transactions—Common Stock Financing Transactions—Sylebra Stockholder Agreement.” Mr. Eberle was initially appointed to our Board of Directors pursuant to the terms of the Sylebra Letter Agreement (as defined below), which provides, among other things, that Mr. Eberle be appointed as a Class III director with a term expiring at the Company’s 2024 Annual Meeting. For more information, see “Certain Relationships and Related Transactions—Sylebra Letter Agreement.”
Board Member Selection Criteria
In considering director candidates, the Board intends to considerconsiders such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, dedication to the Company’s mission, having the ability to exercise sound business judgment and having the commitment to represent the interests of the Company’s stockholders. Candidates for director nominees will be reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the Board considers diversity, age, skills, and such other factors as it deems appropriate given the current needs of the Board and the Company, to maintain a balance of knowledge, experience and capability. In the case of incumbent directors whose terms of office are set to expire, the Board intends to review such directors’ overall service to the Company during their term, including the number of meetings attended, level of participation, quality of performance, and any relationships and transactions that might impair such directors’ independence. In the case of new director candidates, the Board also intends to determine whether the nominee will be independent for NYSE purposes. From time to time, the Board (or the Nominating and Corporate Governance Committee) may change the criteria for membership of the Board to maximize the opportunity to achieve success.
7

TABLE OF CONTENTS

Board Leadership Structure
It is our policy that the positions of Chief Executive Officer and ChairmanChairperson be held by different persons. The Board recognizes, however, that there may be circumstances that arise in the future that would lead it to combine these offices.
8

TABLE OF CONTENTS

Meetings and Attendance
During the year ended December 31, 20212022, there were sevennine meetings of the Board, three meetings of the Audit Committee, threefive meetings of the Compensation Committee, and twothree meetings of the Nominating and Corporate Governance Committee. Each of our directors attended at least 75%of the aggregate meetings of the Board and the committees of the Board on which they served during the period they served in 2021.2022. Our independent directors meet regularly in executive session. All members of the Board are strongly encouraged to attend our annual meetings of stockholders. We did not hold anAll of our then directors attended our annual meeting of stockholders last year.in 2022.
Corporate Governance Guidelines
Our Board has adopted corporate governance guidelines which describe the principles and practices that our Board will follow in carrying out its responsibilities. These guidelines cover a number of areas including the role, responsibilities, size and composition of the Board, director selection criteria, independence of directors, selection of Chairperson of the Board and Chief Executive Officer, director compensation, change in present job responsibility, director orientation and continuing education, lead director, term limits, Board meetings, Board committees, expectations of directors, management succession planning, evaluation of Board performance, Board compensation, and executive sessions. A copy of our corporate governance guidelines is available on our investor relations website.
Board Evaluation
Our Nominating and Corporate Governance Committee is responsible for conducting and overseeing annual self-assessments of the Board as a whole and its committees. These assessments include an evaluation of the Board’s and each committee’s contribution as a whole and effectiveness in serving the best interests of the Company and its stockholders, specific areas in which the Board and management believe that the performance of the Board and its committees could be improved, and overall Board composition and makeup.
Succession Planning
Our Nominating and Corporate Governance Committee is responsible for periodically reviewing with our Chief Executive Officer the Company’s succession plans for the role of Chief Executive Officer and other key executive officers. The Nominating and Corporate Governance Committee is also responsible for making recommendations to our Board with respect to the selection of appropriate individuals to succeed to these positions.
Code of Ethics
We have adopted a Code of Business Conduct and Ethics (our “Code of Ethics”) applicable to our directors, officers, employees and consultants. A copy of our Code of Business Conduct and Ethics is available on our investor relations website. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics on our investor relations website.
Compensation Clawback Policy
We intend to adopt a “clawback” policy as necessary by December 1, 2023 to comply with the NYSE Continued Listing Standards.
Policy Against Speculative Trading, Hedging and Pledging
Our Insider Trading Policy prohibits our directors, officers and other employees from directly or indirectly selling any equity security of the Company if they do not own the security sold. In addition, such persons are prohibited from purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars, and exchange funds) or otherwise engaging in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company’s equity securities. The independent members of our Board have granted a waiverwaivers of this policy to Mina Rezk, our founder, President and Chief Technology Officer, to allow Mr. Rezk to pledge shares with a value of up to $10 million.shares. The independent members of the Board determined this waiver wasthese waivers were necessary to enable Mr. Rezk to relocate himself and his family from Virginia to California to be closer to the Company’s headquarters.headquarters as well as support the request for additional collateral requested by the lender. It was determined that the waiver was appropriate in this instance as it mitigated the need for Mr. Rezk and the lender to sell Company shares to address his relocation.shares.
89

TABLE OF CONTENTS

Communications with Our Board
Stockholders and other interested parties may write to our Board, the Chairman, any of the members of the Audit Committee, the Nominating and Corporate Governance Committee and the Compensation Committees, or to our independent directors as a group at Aeva Technologies, Inc., Attn: Vice PresidentHead of Legal, 555 Ellis Street, Mountain View, California 94043. The Board will consider stockholder questions and comments to be important and endeavor to respond promptly and appropriately, even though the Board may not be able to respond to all stockholder inquiries directly.
Our Board has developed a process to assist with managing inquiries and communications. The Vice PresidentOur head of Legallegal will review and compile any stockholder communications and may summarize such communications prior to forwarding to the appropriate party. The Vice Presidenthead of Legallegal will not forward communications that are not relevant to the duties and responsibilities of the Board and are more appropriately addressed by management, including spam, junk mail and mass mailings, product or service inquiries, new product or service suggestions, resumes or other forms of job inquiries, opinion surveys and polls, business solicitations or advertisements, or other frivolous communications.
Stockholder Recommendations of Director Candidates
Stockholders who would like to recommend a director candidate for consideration by our Nominating and Corporate Governance Committee must send notice to Aeva Technologies, Inc., Attn: Vice PresidentHead of Legal, 555 Ellis Street, Mountain View, California 94043, by registered, certified or express mail, and provide us with a brief biographical sketch of the recommended candidate, a document indicating the recommended candidate’s willingness to serve if elected, and evidence of the stock ownership of the person recommending such candidate. The Nominating and Corporate Governance Committee or its chair will then consider the recommended director candidate in accordance with the same criteria applied to other director candidates, including those described in our corporate governance guidelines and the charter of the Nominating and Corporate Governance Committee, each of which is available on our investor relations website.
Submission of Stockholder Proposals and Board Nominees
If you would like to include a proposal for stockholder consideration in our 20232024 proxy statement or bring business before our 20232024 Annual Meeting, you must send notice to Aeva Technologies, Inc., Attn: Vice PresidentHead of Legal, 555 Ellis Street, Mountain View, California 94043, by registered, certified, or express mail and provide the required information and follow the other procedural requirements described below.
Stockholder Proposals for Inclusion in the 20232024 Proxy Statement
Stockholders who wish to present a proposal in accordance with SEC Rule 14a-8 for inclusion in our proxy materialsProxy Materials to be distributed in connection with our 20232024 Annual Meeting must submit their proposals in accordance with that rule so that they are received by the Vice Presidenthead of Legallegal at the address set forth above no later than the close of business on June 6, 2023.July 30, 2024. If the date of our 20232024 Annual Meeting is more than 30 days before or after NovemberDecember 18, 2023,2024, then the deadline to timely receive such material shall be a reasonable time before we begin to print and send our proxy materials.Proxy Materials. Failure to deliver a proposal in accordance with this procedure may result in it not being deemed timely received. As the rules of the SEC make clear, simply submitting a timely proposal does not guarantee that it will be included in our proxy materials.Proxy Materials.
Other Stockholder Proposals or Nominations for Presentation at the 20232024 Annual Meeting
If a stockholder wishes to bring business to a meeting for consideration other than a matter brought pursuant to SEC Rule 14a-8, the stockholder must give our Secretary written notice of the stockholder’s intent to do so and provide the information required by the provision of our bylaws dealing with stockholder proposals and director nominations. The notice of such a proposal or director nomination must be delivered to (or mailed to and received at) the address set forth above no earlier than July 18, 2023August 20, 2024 and no later than August 17, 2023,September 19, 2024, unless our 20232024 Annual Meeting of stockholders is to be held more than 30 days before, or more than 60 days after, NovemberDecember 18, 2023,2024, in which case the stockholder’s notice must be delivered not earlier than the close of business on the 120th day prior to the 20232024 Annual Meeting and not later than the close of business on the later of the 90th day prior to the 20232024 Annual Meeting or, if later, the 10th day after public announcement of the date of the 20232024 Annual Meeting is first made. In the event that the number of directors to be elected at the annual meeting is increased and no public announcement naming allafter the deadline for the receipt of the nominees or specifying the size of the increased Board has been made by August 17, 2023, then notice of astockholder director nominees as set forth above in this paragraph, then notice
910

TABLE OF CONTENTS

of a stockholder’s nomination to fill the new position or positions may be delivered to (or mailed to and received at) the address set forth above no later than the close of business on the 10th day after public announcement of such increase is first made. The requirements for such stockholder’s notice are set forth in our bylaws, which are filed as an exhibit to our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. To be timely for purposes of SEC Rule 14a-19, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19, which must be received in accordance with the requirements of our bylaws as described above. In addition, to the extent that any information required by Rule 14a-19 is not required under our bylaws to be included with your notice, we must receive such additional information by October 21, 2024, or if the date of our 2024 Annual Meeting is more than 30 days before or after December 18, 2024, then the deadline to timely receive such material shall be 60 calendar days prior to the date of the 2024 Annual Meeting or, if later, the 10th day after public announcement of the date of the 2024 Annual Meeting.
We will submit all candidates nominated by a stockholder pursuant to the procedures and requirements outlined in this Other Stockholder Proposals or Nominations for Presentation at the 20232024 Annual Meeting” section to the Nominating and Corporate Governance Committee for its review, and this submission may include an analysis of the candidate from our management. Any stockholder making a nomination in accordance with the foregoing process will be notified of the Nominating and Corporate Governance Committee’s decision. The information contained on or accessible through our corporate websites is not part of or incorporated by reference into this Proxy Statement.
1011

TABLE OF CONTENTS

PROPOSAL 2: RATIFY APPOINTMENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM
The Audit Committee of our Board appointed Deloitte & Touche LLP (“Deloitte”) as our independent registered public accounting firm to audit our consolidated financial statements for the fiscal year ending December 31, 2022.2023. During fiscal year 2021,2022, Deloitte has audited and reported on our consolidated financial statements for that year. Deloitte has been our independent auditorregistered public accounting firm at all times since 2020.
The Audit Committee intends to periodically consider whether to rotate our independent auditorregistered public accounting firm in order to assure continuing auditorindependent registered public accounting firm independence. The Board and the members of the Audit Committee believe that the continued retention of Deloitte as the Company’s independent auditorregistered public accounting firm for the fiscal year ending December 31, 20222023 is in the best interests of the Company and its stockholders.
We expect that representatives of Deloitte will attend the 2023 Annual Meeting and will have the opportunity to make a statement if they so desire and to respond to appropriate questions.
Although stockholder ratification is not required, the appointment of Deloitte is being submitted for ratification at the Annual Meeting with a view towards soliciting stockholders’ opinions, which the Audit Committee will take into consideration in future deliberations. If Deloitte’s selection is not ratified at the Annual Meeting, the Audit Committee will consider the engagement of other independent accountants.registered public accounting firms. The Audit Committee may terminate Deloitte’s engagement as our independent accountantregistered public accounting firm without the approval of our stockholders whenever the Audit Committee deems termination appropriate.
Required Vote
Approval of this Proposal 2 requires the affirmative vote (i.e., “FOR” votes) of a majority of the shares present or represented and entitled to vote thereon at our 20222023 Annual Meeting. A vote to “ABSTAIN” will count as “present” for purposes of this proposal and so will have the same effect as a vote “AGAINST” this proposal. In the absence of instructions, your broker may vote your shares on this proposal. For more information, see “General Information about the Annual Meeting and Frequency Asked Questions – Questions—Voting Instructions and Information – Information—What happens if I do not vote? What is the effect of broker non-votes?”
Recommendation
OUR BOARD UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2022.2023.
1112

TABLE OF CONTENTS

AUDIT AND OTHER FEES
The following table sets forth the aggregate fees incurred for Deloitte, our independent registered accounting firm for the fiscal years ended December 31, 20212022 and 2020.2021. These fees are categorized as audit fees, audit-related fees, tax fees, and all other fees. The nature of the services provided in each category is described below the table.
 
2021
2020
Audit Fees
$1,250,700
$259,000
Audit-Related Fees
498,700
267,000
Tax Fees
All Other Fees
Total
$1,749,400
$526,100
 
2022
2021
Audit Fees
$1,334,300
$1,250,700
Audit-Related Fees
20,000
498,700
Tax Fees
All Other Fees
2,000
Total
$1,356,300
$1,749,400
Audit Fees. Consists of services rendered for the audits of annual consolidated financial statements (including the review of quarterly interim consolidated financial statements), statutory audits required for certain of our non-U.S. subsidiaries, consents, assistance and review of documents filed with the SEC and other services normally provided in connection with statutory or regulatory filings or engagements. For the yearsyear ended December 31, 2021,2022, the audit fee includes fees associated with services provided in connection with the audit of our internal controlcontrols over financial reporting as required under Section 404 of the Sarbanes Oxley Act of 2002.procedures.
Audit-Related Fees. Consists of amounts billed in connection with the filing of our Registration Statement on Form S-1, S-4 and other regulatory filings.
All Other Fees. The fees billed by Deloitte for professional services rendered for other compliance purposes for the fiscal year ended December 31, 2022 relate to an accounting research tool subscription. There were no fees billed by Deloitte for professional services rendered for other compliance purposes for the fiscal yearsyear ended December 31, 2021 and 2020.2021.
Pre-Approval Policies and Procedures
The Audit Committee’s policy is to pre-approve all audit and permissible non-audit services rendered by Deloitte, our independent registered public accounting firm. The Audit Committee pre-approves specified services in defined categories of audit services, audit-related services and tax services up to specified amounts, as part of the Audit Committee’s approval of the scope of the engagement of Deloitte or on an individual case-by-case basis before Deloitte is engaged to provide a service. The Audit Committee has determined that the rendering of the services other than audit services by Deloitte is compatible with maintaining the principal accountant’s independence.
1213

TABLE OF CONTENTS

AUDIT COMMITTEE REPORT
The Audit Committee of the Board assists the Board in performing its oversight responsibilities for the Company’s financial reporting process and audit process as more fully described in the Audit Committee’s charter. Management has the primary responsibility to establish and maintain a system of internal control over financial reporting, for the financial statements and the reporting process. The Company’s independent registered public accounting firm is responsible for performing an independent audit of its financial statements and internal control over financial reporting in accordance with the auditing standards of the Public Company Accounting Oversight Board (United States) (the “PCAOB”) and to issue reports thereon. The Audit Committee does not provide any expert or other special assurance as to the Company’s financial statements or any expert or professional certification as to the work of our independent registered public accounting firm.
In the performance of its oversight function, the Audit Committee reviewed and discussed the Company’s audited financial statements for the fiscal year ended December 31, 20212022 with the Company’s management and its independent registered public accounting firm. The Audit Committee also discussed with the Company’s independent registered public accounting firm the matters required to be discussed by the applicable requirements of the PCAOB and the SEC. In addition, the Audit Committee received and reviewed the written disclosures and the letter from the Company’s independent registered public accounting firm required by the applicable requirements of the PCAOB regarding such accounting firm’s communications with the Audit Committee concerning independence and has discussed with the Company’s independent registered public accounting firm that firm’s independence and considered whether any “non-audit” services provided by the independent registered public accounting firm are compatible with maintaining its independence.
Based on the reviews and discussions described above, the Audit Committee recommended to the Board that the audited financial statements be included in the Company’sour Annual Report on Form 10-K for the fiscal year ended December 31, 20212022 filed with the SEC.
THE AUDIT COMMITTEE
Hrach Simonian, Committee Chair
Shahin Farshchi
Ahmed FattouhErin Polek
Notwithstanding any statement in any of our filings with the SEC that might be deemed to incorporate part or all of any filings with the SEC by reference, including this Proxy Statement, the foregoing Audit Committee Report is not incorporated into any such filings.
1314

TABLE OF CONTENTS

PROPOSAL 3 - AMEND3: APPROVAL OF AN AMENDMENT TO OUR 2021 INCENTIVE AWARD PLANCERTIFICATE
OF INCORPORATION TO (I) INCREASEPROVIDE THE NUMBERBOARD OF SHARES OF OUR COMMONDIRECTORS WITH THE RIGHT TO DECIDE
AT ITS DISCRETION TO EFFECT A REVERSE STOCK RESERVED FOR ISSUANCE, AND (II) IMPLEMENT AN EVERGREEN SHARE RESERVE.SPLIT
TheOur Board of Directors unanimously recommends that you vote “FOR” Proposal No. 3, the Approval of
Amendment No. 1has approved, subject to the Aeva Technologies, Inc. 2021 Incentive Award Plan
We are seeking stockholder approval, ofand is recommending to our stockholders for approval, an amendment to our 2021 Incentive Award PlanCertificate of Incorporation (the “Incentive Plan”“Reverse Stock Split Amendment”) to effect a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-30 (the “Reverse Stock Split”), with the exact ratio and effective time of the Reverse Stock Split to be determined by our Board of Directors at any time within one year of the date of the 2023 Annual Meeting (the “Reverse Stock Split Proposal”). The full text of the proposed Reverse Stock Split Amendment is set forth in orderAnnex A to increasethis Proxy Statement.
If stockholders approve the Reverse Stock Split Proposal, our Board of Directors will cause the Reverse Stock Split Amendment to be filed with the Delaware Secretary of State and effect the Reverse Stock Split only if the Board determines that the Reverse Stock Split would be in the best interests of Aeva and its stockholders. The Reverse Stock Split could become effective as soon as the business day immediately following the 2023 Annual Meeting. Our Board of Directors also may determine in its discretion not to effect the Reverse Stock Split and not to file the Reverse Stock Split Amendment. No further action on the part of stockholders will be required to either implement or abandon the Reverse Stock Split.
As of October 19, 2023, a total of 223,309,007 shares of our common stock were issued and outstanding and no shares were held in treasury. Based on such number of shares of our common stock reserved for issuanceissued and outstanding, immediately following the effectiveness of the Reverse Stock Split (and without giving any effect to the payment of cash in lieu of fractional shares), we will have, depending on the reverse stock split ratio selected by our Board of Directors, issued and outstanding shares of common stock as illustrated in the table below under the Incentive Plan by an additional 26,325,300 shares, to increaseheading “—Effects of the aggregate numberReverse Stock Split—Effect on Shares of shares that may be issued underCommon Stock.”
The Reverse Stock Split Amendment will not result in a reduction of the Incentive Plan pursuant to the exercise of incentive stock options, and to implement an evergreen share reserve increase pursuant to which thetotal number of shares of our common stock reservedthat Aeva is authorized to issue by a corresponding ratio, and, as a result, the number of authorized shares of common stock available for issuance will increase. See “—Effects of the Reverse Stock Split—Effect on Shares of Common Stock” for the number of shares of common stock authorized but not outstanding or reserved that will remain available for issuance immediately following the effectiveness of the Reverse Stock Split.
All holders of our common stock will be affected proportionately by the Reverse Stock Split. No fractional shares of common stock will be issued as a result of the Reverse Stock Split. Instead, any stockholder who would have been entitled to receive a fractional share as a result of the Reverse Stock Split will receive cash payments in lieu of such fractional shares. Each common stockholder will hold the same percentage of the outstanding common stock immediately following the Reverse Stock Split as that stockholder did immediately prior to the Reverse Stock Split, except to the extent that the Reverse Stock Split results in stockholders receiving cash in lieu of fractional shares. The par value of our common stock will continue to be $.0001 per share (see “—Effects of the Reverse Stock Split—Reduction in Stated Capital”).
Reasons for the Reverse Stock Split
Reverse Stock Split
Our Board has determined that it is in the best interests of Aeva and our stockholders to consider a possible combination our shares of common stock within a range of 1-for-2 to 1-for-30, as determined by our Board at a later date, in order to reduce the number of shares of common stock outstanding. Our Board may authorize the reverse split of our common stock with the primary intent of increasing the per share trading price of our common stock in order to meet the NYSE’s price criteria for continued listing on that exchange. Our common stock is publicly traded and listed on the NYSE under the Incentive Plan will increase on an annual basis as described more fullysymbol “AEVA.” Accordingly, for these and other reasons discussed below, (the “Amendment”).we believe that effecting the Reverse Stock Split is in Aeva’s and our stockholders’ best interests.
On September 26, 2022,21, 2023, we were notified in writing by the Board of Directors approvedNYSE that the Amendment, subject to stockholder approval. If stockholders approve this proposal, the Amendment will become effective as of the date of stockholder approval. If stockholders do not approve this proposal, the Amendment will not take effect and the Incentive Plan will continue in effect in its present form and we will continue to grant awards under the terms of such plan until the shares remaining available for issuance are exhausted.
The remainder of this discussion, when referring to the Incentive Plan, refers to the amended Incentive Plan as if this proposal is approved by our stockholders, unless otherwise specified or the context otherwise references the Incentive Plan prior to the Amendment.
Our continuing ability to offer equity incentive awards under the Incentive Plan is critical to our ability to attract, motivate and retain qualified personnel. The Amendment is essential to meet our forecasted needs in respect of equity incentives.
Corporate Governance Best Practices:
The Incentive Plan provides for the following good corporate governance practices:
Stockholder approval is required for any repricing of options or stock appreciation rights;
Administered by a committee composed of independent directors;
No automatic single-trigger vesting upon a change in control;
Specific limits on total director compensation; and
No dividends will be paid on any unvested award until the award vests.
The Amendment is necessary to promote our long-term success and the creation of stockholder value by:
Enabling us to continue to attract and retain the services of key employees who would be eligible to receive grants;
Aligning participants’ interests with the interests of stockholders through incentives that are based upon the performanceaverage closing trading price of our common stock;stock was below the criteria of the NYSE’s continued listing standards, as the average per share closing price of our common stock over a consecutive 30-trading-day period was less than $1.00. In the letter, the NYSE stated that we have a six-month cure period that started on September 21, 2023 to bring the price of our common stock and the 30-trading-day average closing price of our common stock above $1.00. In the letter, the NYSE further stated that in the event a $1.00 share price and a $1.00 average share price over the preceding 30 trading days are not attained at the expiration of the six-month cure period, the NYSE will commence suspension and delisting
Motivating participants, through equity incentive awards,
15

TABLE OF CONTENTS

procedures. The NYSE has reserved the right to achieve long-term growth inreevaluate its continued listing determinations relating to companies who are notified of non-compliance like Aeva with respect to the NYSE’s qualitative listing standards, including if our business, inshares trade at sustained levels that are considered to be abnormally low. We promptly responded to the NYSE with respect to our intent to cure the deficiency by considering available alternatives to regain compliance.
In addition to short-term financial performance;bringing the per-share trading price of our common stock back above $1.00, we also believe that the Reverse Stock Split may make our common stock more attractive to a broader range of institutional and
Providing a long-term equity incentive program other investors, as we have been advised that is competitive withthe current per share trading price of our common stock may affect its acceptability to certain institutional investors, professional investors and other members of the investing public. Many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. In addition, some of those at companies with which we compete for talent.
We currently grant stock-based incentive awards to our employees under the Incentive Plan. As of September 1, 2022, there are 1,731,492 shares remaining available for issuance under the Incentive Plan. The remaining shares available for issuance under the Incentive Plan will be insufficient to permit uspolicies and practices may function to make annual incentive awardsthe processing of trades in low-priced stocks economically unattractive to our executives, directors and other employees. As a development stage company, we will need to hire additional employees to support our commercialization efforts and grow our business.brokers.
The Incentive Plan, as amended byReducing the Amendment, would authorize a totalnumber of 39,063,679outstanding shares of our common stock through the Reverse Stock Split is intended, absent other factors, to increase the per share trading price of our common stock. However, other factors, such as our financial results, market conditions and the market perception of our business may adversely affect the per share trading price of our common stock. As a result, there can be no assurance that the Reverse Stock Split, if completed, will result in the intended benefits described above, that the per share trading price of our common stock will increase following the Reverse Stock Split or that the per share trading price of our common stock will not decrease in the future.
Criteria to Be Used for grantsDetermining Whether to participants, representing anImplement the Reverse Stock Split
In determining whether to implement the Reverse Stock Split and which reverse stock split ratio to implement, if any, following receipt of stockholder approval of the Reverse Stock Split Proposal, the Board may consider, among other things, various factors, such as:
the historical trading price and trading volume of our common stock;
the NYSE Continued Listing Standards requirements;
the then-prevailing trading price and trading volume of our common stock and the expected impact of the Reverse Stock Split on the trading market for our common stock in the short- and long-term; and
prevailing general market and economic conditions.
Certain Risks and Potential Disadvantages Associated with the Reverse Stock Split
We cannot assure you that the proposed Reverse Stock Split will increase our stock price.
We expect that the Reverse Stock Split will increase the per share trading price of 26,325,300our common stock. However, the effect of the Reverse Stock Split on the per share trading price of our common stock cannot be predicted with any certainty, and the history of reverse stock splits for other companies is varied, particularly since some investors may view a reverse stock split negatively. It is possible that the per share trading price of our common stock after the Reverse Stock Split will not increase in the same proportion as the reduction in the number of our outstanding shares of common stock following the Reverse Stock Split, and the Reverse Stock Split may not result in a per share trading price that would attract investors who do not trade in lower priced stocks. In addition, although we believe the Reverse Stock Split may enhance the marketability of our common stock to certain potential investors, we cannot assure you that, if implemented, our common stock will be more attractive to investors. Even if we implement the Reverse Stock Split, the per share trading price of our common stock may decrease due to factors unrelated to the Reverse Stock Split, including our future performance. If the Reverse Stock Split is consummated and the per share trading price of the common stock declines, the percentage decline as an absolute number and as a percentage of our overall market capitalization may be greater than would occur in the absence of the Reverse Stock Split.
The proposed Reverse Stock Split may decrease the liquidity of our common stock and result in higher transaction costs.
The liquidity of our common stock may be negatively impacted by the Reverse Stock Split, given the reduced number of shares that would be available underoutstanding after the Incentive Plan (the “Share Reserve Increase”). The Incentive Plan,Reverse Stock Split, particularly if the per share trading price does not increase as amended bya result of the Amendment, wouldReverse Stock Split. In addition, if the Reverse Stock Split is implemented, it will increase
1416

TABLE OF CONTENTS

the number of our stockholders who own “odd lots” of fewer than 100 shares of common stock. Brokerage commission and other costs of transactions in odd lots are generally higher than the costs of transactions of more than 100 shares of common stock. Accordingly, the Reverse Stock Split may not achieve the desired results of increasing marketability of our common stock as described above.
Potential Anti-Takeover Effect
The Reverse Stock Split would result in an increased proportion of unissued authorized shares to issued shares, which could have possible anti-takeover effects and could be used by us to oppose a hostile takeover attempt or to delay or prevent changes in our control or management (for example, by permitting issuances that maywould dilute the stock ownership of a person seeking to effect a change in the composition of the board of directors or contemplating a tender offer or other transaction for the combination of us with another company). These authorized but unissued shares could (within the limits imposed by applicable law) be issued pursuantin one or more transactions that could make a change of control of the Company more difficult, and therefore more unlikely, or used to resist or frustrate a third-party transaction that is favored by a majority of the exerciseindependent stockholders. For example, without further stockholder approval, our board of incentive stock options underdirectors could (within the Incentive Plan to 39,063,679 (the “ISO Limit Increase”). Finally, the Incentive Plan, as amendedlimits imposed by the Amendment, would provide for the automatic increase in the number ofapplicable law) strategically sell shares of common stock in a private transaction to purchasers who would oppose a takeover or favor our then current Board of Directors, or the shares could be available for potential issuance pursuant to a shareholder rights plan. The additional authorized shares could be used to discourage persons from attempting to gain control of us by diluting the voting power of shares then outstanding or increasing the voting power of persons that would support the Board of Directors in a potential takeover situation, including by preventing or delaying a proposed business combination that is opposed by our Board although perceived to be desirable by some stockholders. The issuance of additional shares to certain persons allied with our management could have the effect of making it more difficult to remove our current management by diluting the stock ownership or voting rights of persons seeking to cause such removal. Despite these possible anti-takeover effects, this Reverse Stock Split Proposal has been prompted by business and financial considerations and not by the threat of any hostile takeover attempt or any effort of which we are aware to accumulate our stock or to obtain control of our company by means of a merger, tender offer, solicitation in opposition to management or otherwise (nor is our board of directors currently aware of any such attempts directed at us). Nevertheless, stockholders should be aware that approval of this proposal could facilitate future efforts by us to deter or prevent changes in our control, including transactions in which the stockholders might otherwise receive a premium for their shares over then current market prices.
Effective Time
The effective time of the Reverse Stock Split (the “Effective Time”), if approved by stockholders and implemented by Aeva, will be the date and time set forth in the Reverse Stock Split Amendment that is filed with the Delaware Secretary of State. Such filing may take place as soon as promptly following the 2023 Annual Meeting, assuming the stockholders approve the Reverse Stock Split Amendment and, as a result, the Effective Time could occur as soon as the business day immediately following the 2023 Annual Meeting. However, the exact timing of the filing of the Reverse Stock Split Amendment will be determined by our Board of Directors based on January 1 of each calendar year commencing in calendar year 2023 equalits evaluation as to when such action will be the most advantageous to the lesser of (i) 5%Company and our stockholders.
If, at any time prior to the filing of the total numberReverse Stock Split Amendment with the Delaware Secretary of State, notwithstanding stockholder approval, and without further action by the stockholders, the Board, in its sole discretion, determines that it is in Aeva’s best interests and the best interests of our stockholders to delay the filing of the Reverse Stock Split Amendment or abandon the Reverse Stock Split, the Reverse Stock Split may be delayed or abandoned.
Fractional Shares
Stockholders will not receive fractional shares of common stock outstandingin connection with the Reverse Stock Split. Instead, the transfer agent will aggregate all fractional shares and sell them as soon as practicable after the Effective Time at the then-prevailing prices on the last dayopen market, on behalf of the immediately preceding calendar year, or (ii) a lower number of shares of common stock as determined by the Board (the “Evergreen Share Reserve”).
Key Metrics
Dilutive effect of Share Reserve Increase
9.7%
Total potential dilution, including outstanding awards
19.5%
Annual burn rate
4.66%
Potential Dilution Calculation:
Equity awards outstanding, plus the Share Reserve Increase plus 1,731,492 shares as our existing share reserve; divided by shares of common stock outstanding, plus equity awards outstanding, plus the Share Reserve Increase plus existing share reserve. Equity awards outstanding includes outstanding stock options and restricted stock units.
Burn Rate Calculation:
The number of shares subject to time vesting equity awards granted in a fiscal year; divided by the basic weighted average common shares outstanding at the end of that fiscal year.
Awards canceled or forfeited are not excluded from the calculation
Year
Time-Vesting
Full-Value
Shares
Granted
Options
Granted
Total
Awards
Basic Weighted
Average Common
Shares Outstanding
as of 12/31/2021
Burn Rate =
Total Awards/
Outstanding
2022
7,207,201
1,335,000
8,542,201
183,181,262
4.66%
The Share Reserve Increase is intended to manage our equity compensation needs for the next 12 months, based on our past grant practices and the recent trading prices of our shares. The Evergreen Share Reserve is intended to ensure we have sufficient shares available for issuance to enable us to attract, motivate and retain highly-qualified employees, directors and other service providers while we expand and grow our business.
Total Outstanding Awards
The table below shows the total number of outstanding options and other awards granted under the Incentive Plan and the 2016 Stock Incentive Plan, the Company’s previous equity incentive plan, as of September 1, 2022.
Plan Name
Awards
2021 Incentive Award Plan
13,288,140
2016 Stock Incentive Plan
11,550,382
As of September 1, 2022, the fair market value of a share of common stock (as determined by the closing price on the NYSE on that date) was $2.78 per share.
The Incentive Plan will continue to permit the discretionary award of stock options, including incentive stock options (“ISOs”) and nonqualified stock options (“NSOs”), stock appreciation rights (“SARs”), restricted stock, dividend equivalents, restricted stock units (“RSUs”) and other stock or cash-based awards to participant. Such awards may continue tothose stockholders who would otherwise be granted under the Share Reserve Increase beginning on the date of stockholder approval of the Amendment and continuing through March 11, 2031, or earlier termination of the Incentive Plan, and beginning on January 1, 2023 and each year thereafter through January 1, 2031, awards may be granted utilizing shares reserved under the Evergreen Share Reserve.
Text of the Incentive Plan
The complete text of the Incentive Plan is attached as Annex A to this Proxy Statement – marked to show the proposed changes contained in the Amendment. Stockholders are urged to review the Incentive Plan together with
15

TABLE OF CONTENTS

the following information, which is qualified in its entirety by reference to Annex A. If there is any inconsistency between this Proposal 3 and the Incentive Plan terms, or if there is any inaccuracy in this Proposal 3, the terms of the Incentive Plan shall govern.
Key Features of the Incentive Plan
Certain key features of the Incentive Plan are summarized as follows:
If not terminated earlier by the Board, the Incentive Plan will terminate on March 11, 2031
The Incentive Plan will generally be administered by a committee comprised solely of independent members of the Board, which will be the Compensation Committee unless otherwise designated by the Board - the Board or Compensation Committee may designate a separate committee to make awards to employees who are not Section 16 officers
Employees, consultants and non-employee directors are eligibleentitled to receive awards, but the Compensation Committee has the discretion to determine (i) who shall receive any awards and (ii) the terms and conditions of such awards
The purpose of the Incentive Plan is to enhance our ability to attract, retain and motivate persons who make (or are expected to make) important contributions by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Equity awards and equity-linked compensatory opportunities are intended to motivate high levels of performance and align the interests of directors, employees and consultants with those of stockholders by giving directors, employees and consultants the perspective of an owner with an equity or equity-linked stake in our company and providing a means of recognizing their contributions to our success. The Board believes that equity awards are necessary for us to remain competitive in our industry and are essential to recruiting and retaining highly qualified employees.
Eligibility and Administration
Our employees, consultants and directors, and employees and consultants of our subsidiaries, may be eligible to receive awards under the Incentive Plan. As of September 1, 2022, we have approximately 277 employees, 12 consultants, three non-employee directors and no other individual service providers who may be eligible to receive awards under the Incentive Plan.
The Incentive Plan will be administered by the Board, which may delegate its duties and responsibilities to one or more committees of its directors and/or officers of the company (collectively, the “plan administrator”), subject to the limitations imposed under the Incentive Plan, Section 16 of the Exchange Act, stock exchange rules and other applicable laws. The Compensation Committee currently administers the Incentive Plan.
The plan administrator will have the authority to take all actions and make all determinations under the Incentive Plan, to interpret the Incentive Plan and award agreements and to adopt, amend and repeal rules for the administration of the Incentive Planfractional share as it deems advisable. The plan administrator will also have the authority to determine which eligible service providers receive awards, grant awards and set the terms and conditions of all awards under the Incentive Plan, including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the Incentive Plan.
Shares Available for Awards
The aggregate number of shares of common stock that will be available for issuance under the Incentive Plan will be equal to 39,063,679 shares (assuming this Proposal 3 is approved), plus the number of shares that become available for issuance each January 1 beginning on January 1, 2023 pursuant to the Evergreen Share Reserve. As a result of the ISO Limit Increase, the maximum number of shares of common stock may be issued pursuant to the exercise of incentive stock options (“ISOs”) granted under the Incentive Plan will be equal to 39,063,679.
If an award under the Incentive Plan or the Aeva, Inc. 2016Reverse Stock Incentive Plan (the “Aeva 2016 Plan”) is forfeited, expires or is settled for cash, any shares subject to such award may, to the extent of such forfeiture, expiration or cash settlement, be used again for new grants under the Incentive Plan. The payment of dividend equivalents in cash in conjunction with any awards under the Incentive Plan or Aeva 2016 Plan will not reduce the shares available for grant under the Incentive Plan. Furthermore, shares purchased on the open market with the cash proceeds from the exercise of options, and shares tendered or withheld to satisfy the exercise price or tax withholding obligation for any award will again be available for awards under the Incentive Plan.
16

TABLE OF CONTENTS

Awards granted under the Incentive Plan upon the assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under the Incentive Plan (nor increase the number of shares available for issuance under the Incentive Plan) but shares acquired by the exercise of a substitute ISO will count against the maximum number of shares that may be issued upon the exercise of ISOs.
The Incentive Plan providesSplit. We expect that the sum of any cash compensationtransfer agent will conduct the sale in an orderly fashion at a reasonable pace and the aggregate grant date fair value (determined asthat it may take several days to sell all of the date of the grant under Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of all awards granted to a non-employee director as compensation for services as a non-employee director during any fiscal year, or director limit, may not exceed $750,000, increased to $1,000,000 in the fiscal year of a non-employee director’s initial service as a non-employee director. The plan administrator may make exceptions to the director limit for individual non-employee directors in extraordinary circumstances, as the plan administrator may determine in its discretion, but the non-employee director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee directors.
Types of Awards
The Incentive Plan provides for the grant of stock options, including ISOs NSOs, SARs, restricted stock, dividend equivalents, RSUs and other stock or cash-based awards. Certain awards under the Incentive Plan may constitute or provide for payment of “nonqualified deferred compensation” under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), which may impose additional requirements on the terms and conditions of such awards. All awards under the Incentive Plan will be evidenced by award agreements, which will detail the terms and conditions of awards, including any applicable vesting and payment terms and post-termination exercise limitations. Awards other than cash awards generally will be settled in shares of our common stock, but the applicable award agreement may provide for cash settlement of any award. A brief description of each award type follows.
Stock Options and SARs. Stock options provide for the purchase of shares of our common stock in the future at an exercise price set on the grant date. ISOs, in contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. Unless otherwise determined by the plan administrator, the exercise price of a stock option or SAR may not be less than 100% of the fair market value of the underlying share on the grant date (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute awards granted in connection with a corporate transaction. Unless otherwise determined by the plan administrator, the term of a stock option or SAR may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders).
Restricted Stock. Restricted stock is an award of non-transferable shares of our common stock that are subject to certain vesting conditions and other restrictions.
RSUs. RSUs are contractual promises to deliver shares of our common stock in the future or an equivalent in cash and other consideration determined by the plan administrator, which may also remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares (i.e., dividend equivalent rights). The plan administrator may provide that the delivery of the shares (or payment in cash) underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to RSUs will be determined by the plan administrator, subject to the conditions and limitations contained in the Incentive Plan.
Other Stock or Cash Based Awards. Other stock or cash-based awards are awards of cash, fully vested shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on,aggregated fractional shares of our common stock. Other stock or cash-based awards may be grantedAfter the transfer agent’s completion of such sale, stockholders who would have been entitled to participants and may also be available as a fractional share will instead receive a cash payment formfrom the transfer agent in the settlement of other awards, as standalone payments and as payment in lieu of compensationan amount equal to which a participant is otherwise entitled.
Dividend Equivalents. Dividend equivalents represent the right to receive the equivalent value of dividends paid ontheir respective pro rata shares of our common stock and may be granted alone or in tandem with awards other than stock options or SARs. Dividend equivalents are credited asthe total proceeds of the dividend record dates during the period between the date an award is granted and the date such award vests, is exercised, is distributed or expires, as determinedthat sale net of any brokerage costs incurred by the plan administrator.transfer agent to sell such stock.
17

TABLE OF CONTENTS

Certain Transactions
The plan administrator has broad discretionStockholders will not be entitled to take actionreceive interest for the period of time between the Effective Time and the date payment is made for their fractional share interest. You should also be aware that, under the Incentive Plan, as well as make adjustmentsescheat laws of certain jurisdictions, sums due for fractional interests that are not timely claimed after the funds are made available may be required to be paid to the terms and conditionsdesignated agent for each such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds may have to obtain the funds directly from the state to which they were paid.
If you believe that you may not hold sufficient shares of existing and future awards,Aeva’s common stock at the Effective Time to prevent the dilution or enlargement of intended benefits and facilitate necessary or desirable changesreceive at least one share in the event of certain transactionsReverse Stock Split and events affectingyou want to continue to hold our common stock such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate transactions. In addition, inafter the event of certain non-reciprocal transactions with our stockholders known as “equity restructurings,” the plan administrator will make equitable adjustments to the Incentive Plan and outstanding awards. In the event ofReverse Stock Split, you may do so by either:
purchasing a change in control (as defined in the Incentive Plan), to the extent that the surviving entity declines to continue, convert, assume or replace outstanding awards, then all such awards will become fully vested and exercisable in connection with the transaction.
No Repricing
Except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that reduces the exercise price of any stock option or SAR, or cancels any stock option or SAR in exchange for cash, other awards or stock options or SARs with an exercise price per share that is less than the exercise price per share of the original stock options or SARs.
Plan Amendment and Termination
The Board may amend or terminate the Incentive Plan at any time; however, no amendment, other than an amendment that increases thesufficient number of shares available under the Incentive Plan, may materially and adversely affect an award outstanding under the Incentive Plan without the consent of the affected participant, and stockholder approval will be obtained for any amendment to the extent necessary to comply with applicable lawsour common stock; or to increase the director limit. The Incentive Plan will remain in effect until the March 11, 2031, unless earlier terminated. No awards may be granted under the Incentive Plan after its termination, although awards granted prior to its termination will continue to remain outstanding in accordance with their terms.
Non-U.S. Participants, Claw-Back Provisions, Transferability and Participant Payments
The plan administrator may modify award terms, establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above, in order to facilitate grants of awards subject to the laws and/or stock exchange rules of countries outside of the United States. All awards will be subject to any company claw-back policy as set forth in such claw-back policy or the applicable award agreement. Awards under the Incentive Plan are generally non-transferrable, except by will or the laws of descent and distribution, or, subject to the plan administrator’s consent, pursuant to a domestic relations order, and are generally exercisable only by the participant. With regard to tax withholding, exercise price and purchase price obligations arising in connection with awards under the Incentive Plan, the plan administrator may, in its discretion, accept cash or check,if you have shares of our common stock in more than one account, consolidating your accounts;
in each case, so that meet specified conditions,you hold a “marketnumber of shares of our common stock in your account prior to the Reverse Stock Split that would entitle you to receive at least one share of common stock in the Reverse Stock Split. Shares of our common stock held in registered form and shares of our common stock held in “street name” (that is, through a broker, bank or other holder of record) for the same stockholder will be considered held in separate accounts and will not be aggregated when effecting the Reverse Stock Split.
Effects of the Reverse Stock Split
General
After the effective date of the Reverse Stock Split, if implemented by the Board, each stockholder will own a reduced number of shares of common stock. The principal effect of the Reverse Stock Split will be to proportionately decrease the number of outstanding shares of our common stock based on the reverse stock split ratio selected by our Board of Directors.
Voting rights and other rights of the holders of our common stock will not be affected by the Reverse Stock Split, other than as a result of the treatment of fractional shares as described above. For example, a holder of 2% of the voting power of the outstanding shares of our common stock immediately prior to the effectiveness of the Reverse Stock Split will generally continue to hold 2% (assuming there is no impact as a result of the payment of cash in lieu of issuing fractional shares) of the voting power of the outstanding shares of our common stock after the Reverse Stock Split. The number of stockholders of record will not be affected by the Reverse Stock Split (except to the extent any are cashed out as a result of holding fractional shares). If approved and implemented, the Reverse Stock Split may result in some stockholders owning “odd lots” of less than 100 shares of our common stock. Odd lot shares may be more difficult to sell, order”and brokerage commissions and other costs of transactions in odd lots are generally somewhat higher than the costs of transactions in “round lots” of even multiples of 100 shares. Our Board believes, however, that these potential effects are outweighed by the benefits of the Reverse Stock Split.
Because the proposed Reverse Stock Split Amendment does not result in a reduction in the total number of shares of common stock that we are authorized to issue, the implementation of the Reverse Stock Split will have the effect of increasing the number of available authorized shares of common stock. The resulting increase in such availability in the authorized number of shares of common stock could have a number of effects on our stockholders depending upon the exact nature and circumstances of any actual issuances of authorized but unissued shares. Because holders of our common stock have no preemptive rights to purchase or such other considerationsubscribe for any unissued common stock of Aeva, the issuance of additional shares of authorized common stock that will become newly available as it deems suitable.a result of the implementation of the Reverse Stock Split will reduce the current stockholders’ percentage ownership interest in the total outstanding shares of our common stock.
Certain Federal Income Tax InformationEffect on Shares of Common Stock
The following table contains approximate information relating to our outstanding common stock based on reverse stock split ratios within the proposed range and information regarding our authorized shares assuming that the Reverse Stock Split Proposal is a general summary,approved and the Reverse Stock Split is implemented, in each case based on share information as of September 1, 2022,October 19, 2023 as adjusted to give effect to the issuance of an aggregate of 36,802,299 shares of common stock on November 9, 2023 as part of the principal United States federal income tax consequences to usCommon Stock Financing Transactions. For more information, see “Certain Relationships and to participants for awards granted under the Incentive Plan.Related Transactions—Common Stock Financing Transactions—Subscription Agreement.” The federal tax laws may change and the federal, state and local tax consequences for any participant will depend upon his or her individual circumstances. Tax consequences for any particular individual may be different. This summary is not intended to be exhaustive andinformation below does not discussgive effect to the tax consequences of a participant’s death or provisions of income tax laws of any municipality, state or other country. We advise participants to consult with a tax advisor regarding the tax implications of their awards under the Incentive Plan.
Incentive Stock Options (ISOs). For federal income tax purposes, the holder of an ISO has no taxable income at the time of the grantpotential issuance, conversion, or exercise, of the ISO. If such person retains the common stock acquired under the ISO for a period of at least two years after the stock option is granted and one year after the stock option is exercised, then any gain upon the subsequent sale of the common stock will be taxed as a long-term capital gain. A participant who disposes of shares acquired by exercise of an ISO prior to the expiration of two years after the stock option is granted or before one year after the stock option is exercised will realize ordinary income as of the date of exercise equal to the difference between the exercise price and fair market value of the stock. Any additional gain or loss recognized upon any later disposition of the shares would be a short- or long-term capital gain or loss, depending on whether the shares
18

TABLE OF CONTENTS

applicable, of the Facility Preferred Stock (as defined below) or Sylebra Warrants (as defined below) to be issued pursuant to the Facility Agreement (as defined below). For more information, see “Certain Relationships and Related Transactions—Common Stock Financing Transactions—Facility Agreement.”
 
Number of Shares of
Common Stock Issued
and Outstanding Prior
to Reverse Stock Split
Number of Shares of
Common Stock Issued
and Outstanding After
Reverse Stock Split
Number of Shares of
Common Stock
Authorized for Issuance
After Reverse Stock Split
Number of Shares of
Common Stock
Authorized and Available
for Issuance After
Reverse Stock Split(1)
1-for-2 Reverse Stock Split
260,111,306
130,055,653
422,000,000
250,193,469
1-for-10 Reverse Stock Split
260,111,306
26,011,130
422,000,000
387,638,695
1-for-15 Reverse Stock Split
260,111,306
17,340,753
422,000,000
399,092,464
1-for-20 Reverse Stock Split
260,111,306
13,005,565
422,000,000
404,819,348
1-for-25 Reverse Stock Split
260,111,306
10,404,452
422,000,000
408,255,479
1-for-30 Reverse Stock Split
260,111,306
8,670,376
422,000,000
410,546,233
(1)
Based on (i) 71,042,878 shares of common stock reserved for future issuance under the Stock Plans (as defined below), inclusive of outstanding equity awards, and (ii) 12,458,880 shares of common stock reserved for future issuance upon the exercise of outstanding warrants, in each case, on a pre-Reverse Stock Split basis as of October 19, 2023.
After the effective date of the Reverse Stock Split that our Board of Directors elects to implement, our common stock would have been helda new Committee on Uniform Securities Identification Procedures number, or CUSIP number, used to identify our common stock.
Our common stock is currently registered under Section 12(b) of the Securities Exchange Act of 1934, or the Exchange Act, and we are subject to the periodic reporting and other requirements of the Exchange Act. The Reverse Stock Split will not affect the registration of our common stock under the Exchange Act or the listing of our common stock on the NYSE. Following the Reverse Stock Split, our common stock will continue to be listed on the NYSE under the symbol “AEVA,” although it will be considered a new listing with a new CUSIP number.
No Effect on Preferred Stock Authorization
Our Certificate of Incorporation currently authorizes the issuance of 10,000,000 shares of preferred stock, $.0001 par value per share, none of which is currently issued or outstanding. The proposed Reverse Stock Split would not increase the authorized number of shares of our preferred stock.
No Effect on Par Value
The proposed Reverse Stock Split Amendment will not affect the par value of our common stock, which will remain at $.0001.
Reduction in Stated Capital
As a result of the Reverse Stock Split, upon the Effective Time, the stated capital on our balance sheet attributable to our common stock, which consists of the par value per share of our common stock multiplied by the participantaggregate number of shares of our common stock issued and outstanding, will be reduced in proportion to the size of the Reverse Stock Split, subject to a minor adjustment in respect of the treatment of fractional shares, and the additional paid-in capital account will be credited with the amount by which the stated capital is reduced. Our stockholders’ equity, in the aggregate, will remain unchanged.
Effect on Aeva’s Stock Plans
Under our 2016 Stock Incentive Plan, our 2021 Incentive Award Plan, and our 2022 Employee Stock Purchase Plan (collectively, our “Stock Plans”), the Compensation Committee has the power to determine the appropriate adjustment to the awards granted and shares reserved for more than one year.issuance under our Stock Plans in the event of a reverse
19

TABLE OF CONTENTS

stock split. Accordingly, if the Reverse Stock Split is approved and effected, we expect that the Compensation Committee will proportionately adjust the number of shares available for issuance under the Stock Plans, as well as the number of shares subject to any outstanding award under the Stock Plans, and the exercise, grant price or purchase price relating to any such award or right under the Stock Plans to reflect the Reverse Stock Split. The difference betweenCompensation Committee will also determine the optiontreatment of fractional shares subject to stock options and other outstanding awards under the Stock Plans. In addition, pursuant to the authority provided under the Stock Plans, the Compensation Committee is expected to authorize the Company to effect any other changes necessary, desirable or appropriate to give effect to the Reverse Stock Split, including any applicable technical, conforming changes to our Stock Plans.
Specifically, it is expected that the number of shares subject to awards under the Stock Plans will be adjusted in each case to equal the product of the number of shares subject to the applicable award immediately prior to the Reverse Stock Split multiplied by the reverse stock split ratio (rounded down to the nearest whole share), that the exercise price of any stock option will be adjusted to equal the quotient of the number of shares subject to the applicable stock option immediately prior to the Reverse Stock Split divided by the reverse stock split ratio (rounded up to the nearest whole cent), and that the stock price goal of any performance-based restricted stock units will be adjusted in each case to equal the product of the applicable price goal in effect immediately prior to the Reverse Stock Split multiplied by the reverse stock split ratio (rounded up to the nearest whole cent).
Effect on Warrants
If the Reverse Stock Split is approved and effected, our outstanding warrants to purchase shares of our common stock will be proportionately adjusted to reflect the Reverse Stock Split, including the number of shares purchasable upon exercise of such warrants and their exercise prices. Any Sylebra Warrants issued pursuant to the Facility Agreement prior to the Reverse Stock Split and the fair market valueright of the Sylebra Purchasers to acquire the Sylebra Warrants pursuant to the Facility Agreement, including the number of shares purchasable upon exercise of such warrants and their exercise prices, will likewise be proportionately adjusted to reflect the Reverse Stock Split. For more information about the Sylebra Warrants, see “Certain Relationships and Related Transactions—Common Stock Financing Transactions—Facility Agreement.”
Effect on Preferred Stock
The issue price and conversion price of any shares of Facility Preferred Stock issued pursuant to the exerciseFacility Agreement will be proportionately adjusted to reflect the Reverse Stock Split. For more information about the Sylebra Warrants, see “Certain Relationships and Related Transactions—Common Stock Financing Transactions—Facility Agreement.”
Shares Held in Book-Entry and Through a Broker, Bank, or Other Holder of Record
If you hold registered shares of our common stock in a book-entry form, you do not need to take any action to receive your post-Reverse Stock Split shares of our common stock in registered book-entry form or your cash payment in lieu of fractional shares, if applicable. If you are entitled to post-Reverse Stock Split shares of our common stock, a transaction statement will automatically be sent to your address of record as soon as practicable after the Effective Time indicating the number of shares of our common stock you hold. In addition, if you are entitled to a payment of cash in lieu of fractional shares, a check will be mailed to you at your registered address as soon as practicable after the Effective Time. By signing and cashing this check, you will warrant that you owned the shares of our common stock for which you received a cash payment.
At the Effective Time, we intend to treat stockholders holding shares of our common stock in “street name” (that is, through a broker, bank or other holder of record) in the same manner as registered stockholders whose shares of our common stock are registered in their names. Brokers, banks or other holders of record will be instructed to effect the Reverse Stock Split for their beneficial holders holding shares of our common stock in “street name”; however, these brokers, banks or other holders of record may apply their own specific procedures for processing the Reverse Stock Split. If you hold your shares of our common stock with a broker, bank or other holder of record, and you have any questions in this regard, we encourage you to contact your holder of record.
Certain U.S. Federal Income Tax Consequences of the Reverse Stock Split
The following discussion is a general summary of certain U.S. federal income tax consequences of the Reverse Stock Split that may be relevant to holders of our common stock that hold such stock as a capital asset for U.S. federal income tax purposes (generally, property held for investment). This summary is based upon the provisions of the
20

TABLE OF CONTENTS

Internal Revenue Code of 1986, as amended (the “Code”), Treasury regulations promulgated thereunder, administrative rulings and judicial decisions as of the date hereof, all of an ISO is an adjustmentwhich may change, possibly with retroactive effect, resulting in computing the holder’s alternative minimum taxableU.S. federal income tax consequences that may differ from those discussed below.
This discussion applies only to holders that are U.S. Holders (as defined below) and does not address all aspects of federal income taxation that may be relevant to such holders in light of their particular circumstances or to holders that may be subject to anspecial tax rules, including: (i) holders subject to the alternative minimum tax; (ii) banks, insurance companies, or other financial institutions; (iii) tax-exempt organizations; (iv) dealers in securities or commodities; (v) regulated investment companies or real estate investment trusts; (vi) partnerships (or other flow-through entities for U.S. federal income tax purposes and their partners or members); (vii) traders in securities that elect to use a mark-to-market method of accounting for their securities holdings; (viii) U.S. Holders (as defined below) whose “functional currency” is not the U.S. dollar; (ix) persons holding our common stock as a position in a hedging transaction, “straddle,” “conversion transaction” or other risk reduction transaction; (x) persons who acquire shares of our common stock in connection with employment or other performance of services; or (xi) U.S. expatriates. If a partnership (including any entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds shares of our common stock, the tax treatment of a holder that is a partner in the partnership generally will depend upon the status of the partner and the activities of the partnership.
We have not sought, and will not seek, an opinion of counsel or a ruling from the Internal Revenue Service (“IRS”) regarding the U.S. federal income tax consequences of the Reverse Stock Split and there can be no assurance that the IRS will not challenge the statements and conclusions set forth below or a court would not sustain any such challenge. The following summary does not address any U.S. state or local or any foreign tax consequences, any estate, gift or other non-U.S. federal income tax consequences, or the Medicare tax on net investment income.
EACH HOLDER OF COMMON STOCK SHOULD CONSULT SUCH HOLDER’S TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT TO SUCH HOLDER.
For purposes of the discussion below, a “U.S. Holder” is a beneficial owner of shares of our common stock that for U.S. federal income tax purposes is: (1) an individual citizen or resident of the United States; (2) a corporation (including any entity taxable as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state or political subdivision thereof; (3) an estate the income of which is paidsubject to U.S. federal income taxation regardless of its source; or (4) a trust, if such tax exceeds(i) a court within the participant’s regularUnited States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (ii) the trust has a valid election in effect to be treated as a U.S. person.
The Reverse Stock Split is intended to be treated as a “recapitalization” for U.S. federal income tax forpurposes. As a result, a U.S. Holder generally should not recognize gain or loss upon the year.
Non-QualifiedReverse Stock Options.Split, except with respect to cash received in lieu of a fractional share of our common stock, as discussed below. A participant who receives a non-qualifiedU.S. Holder’s aggregate tax basis in the shares of our common stock option generally will not realize taxable income onreceived pursuant to the grantReverse Stock Split should equal the aggregate tax basis of the shares of our common stock surrendered (excluding any portion of such option, but will realize ordinary income atbasis that is allocated to any fractional share of our common stock), and such U.S. Holder’s holding period in the timeshares of exerciseour common stock received should include the holding period in the shares of our common stock surrendered. Treasury regulations promulgated under the Code provide detailed rules for allocating the tax basis and holding period of the shares of our common stock optionsurrendered to the shares of our common stock received pursuant to the Reverse Stock Split. Holders of shares of our common stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares.
A U.S. Holder that receives cash in lieu of a fractional share of our common stock pursuant to the Reverse Stock Split should generally recognize capital gain or loss in an amount equal to the difference between the option exercise priceamount of cash received and the fair market valueU.S. Holder’s tax basis in the shares of theour common stock on the date of exercise. Any additionalsurrendered that is allocated to such fractional share.
Such capital gain or loss recognized upon any later disposition of the shares wouldshould generally be a short- or long-term capital gain or loss depending on whetherif the shares had been held by the participantU.S. Holder’s holding period for more than one year.
Stock Appreciation Rights. No taxable income is generally reportable when a stock appreciation right is granted to a participant. Upon exercise, the participant will recognize ordinary income in an amount equal to the amount of cash received plus the fair market value of any shares received. Any additional gain or loss recognized upon any later disposition of any shares received would be a short- or long-term capital gain or loss, depending on whether the shares had been held by the participant for one year or more.
Restricted Stock. A participant will generally not have taxable income upon grant of unvested restricted shares unless he or she elects to be taxed at that time pursuant to an election under Section 83(b) of the Code. Instead, he or she will recognize ordinary income at the time(s) of vesting equal to the fair market value (on each vesting date) of the shares or cash received minus any amount paid for the shares.
Restricted Stock Units. No taxable income is generally reportable when unvested restricted stock units are granted to a participant. Upon settlement of the vested restricted stock units, the participant will recognize ordinary income in an amount equal to the value of the payment received pursuant to the vested restricted stock units.
Other Awards. Participants will generally recognize ordinary income at the time of payment of dividend equivalents and cash based awards in an amount equal to the value of the payment received.
Income Tax Effects for the Company. We generally will be entitled to a tax deduction in connection with an award under the Incentive Plan in an amount equal to the ordinary income realized by a participant at the time the participant recognizes such income (for example, upon the exercise of a non-qualified stock option), subject to the limitation on deductibility under Section 162(m) of the Code.
Section 409A of the Code. Section 409A of the Code governs the federal income taxation of certain types of nonqualified deferred compensation arrangements. A violation of Section 409A of the Code generally results in an acceleration of the recognition of income of amounts intended to be deferred and the imposition of a federal excise tax of 20% on the employee over and above the income tax owed, plus possible penalties and interest. The types of arrangements covered by Section 409A of the Code are broad and may apply to certain awards available under the Incentive Plan (such as restricted stock units). The intent is for the Incentive Plan, including any awards available thereunder, to comply with the requirements of Section 409A of the Code to the extent applicable. As required by Section 409A of the Code, certain non-qualified deferred compensation payments to specified employees may be delayed to the seventh month after such employee’s separation from service.
New Plan Benefits
All Incentive Plan awards will be made at the discretion of the plan administrator and are not currently determinable. The value of the awards granted under the Incentive Plan will depend on a number of factors, including the fair market value of our common stock on future dates,surrendered exceeded one year at the exercise decisions made byEffective Time.
21

TABLE OF CONTENTS

No Appraisal Rights
Under the participants and the extent to which any applicable performance goals necessary for vesting or payment are achieved. Therefore, the benefits and amounts that will be received or allocated under the Incentive PlanDelaware law, stockholders are not presently determinable.entitled to appraisal rights with respect to the Reverse Stock Split, and we will not independently provide our stockholders with any such right.
Vote Required for ApprovalVote
Approval of this Proposal 3 requires the affirmative vote (i.e., “FOR” votes) of the holders of a majority of the outstanding shares entitled to vote thereon at the 2023 Annual Meeting. A vote to “ABSTAIN” and a broker non-vote, will have the same effect as a vote “AGAINST” this proposal. We expect that the Reverse Stock Split Proposal will be considered a “routine” matter under NYSE rules and, as a result, if you hold shares of our common stock in street name, in the absence of instructions, your broker may vote your shares on this proposal. For more information, see “General Information about the Annual Meeting and Frequency Asked Questions—Voting Instructions and Information—What happens if I do not vote? What is the effect of broker non-votes?”
Recommendation
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” APPROVAL OF AN AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT.
22

TABLE OF CONTENTS

PROPOSAL 4: APPROVAL OF CERTAIN SECURITY ISSUANCES FOR PURPOSES OF COMPLYING WITH NYSE RULES
Our Board is asking stockholders to consider and vote upon a proposal to approve, for the purposes of complying with NYSE Listing Rule 312.03(b)(i), the issuance of Series A Warrants (as defined below), shares of the Facility Preferred Stock (as defined below) and Pre-Funded Warrants (as defined below and, together with the Series A Warrant, the “Sylebra Warrants”), as well as the issuance of the shares of common stock issuable upon the exercise or conversion, as applicable, of the Sylebra Warrants and Facility Preferred Stock, in each case, to certain entities affiliated with Sylebra (the “Sylebra Purchasers”) and to the extent such NYSE Rule is deemed to apply to such transaction.
The Common Stock Financing Transactions
On November 8, 2023, we entered into a series of transactions with the Sylebra Purchasers and Adage Capital Management that we refer to collectively as the “Common Stock Financing Transactions.” As part of the Common Stock Financing Transactions, we entered into a Standby Equity Purchase Agreement (the “Facility Agreement”) with the Sylebra Purchasers. The Facility Agreement provides, among other things, for:
the right of the Company to sell to the Sylebra Purchasers up to $125.0 million in shares of its preferred stock (the “Facility Preferred Stock”), at the Company’s request until November 8, 2026, upon the satisfaction of certain conditions;
that, to the extent conversion of shares of the Facility Preferred Stock purchased by the Sylebra Purchasers would result in any person becoming the beneficial owner of more than 19.9% of our outstanding common stock (the “Stock Issuance Cap”), we will issue to such converting holder a pre-funded warrant (the “Pre-Funded Warrant”) to be exercisable for such number of shares of common stock as would have been issuable upon conversion of such shares of Facility Preferred Stock, but for the Stock Issuance Cap, at an exercise price of $0.0001 per share;
for the payment by the Company of certain fees to and expenses of the Sylebra Purchasers; and
for the issuance, upon receipt of stockholder approval, of Series A Warrants to purchase an aggregate of 15,000,000 shares of common stock at an exercise price of $1.00 per share (the “Series A Warrants”) to the Sylebra Purchasers.
Additional information about the Common Stock Financing Transactions, the Facility Agreement, the Facility Preferred Stock, the Pre-Funded Warrants and the Series A Warrants is set forth in the section entitled “Related Person Transaction—Common Stock Financing Transactions” in this proxy statement, which disclosure is incorporated by reference into this Proposal 4.
The Facility Preferred Stock and Pre-Funded Warrants
When and if issued, the Facility Preferred Stock will be issued at a price per share of $10,000. Holders of Facility Preferred Stock will be entitled to a quarterly dividend at the rate of 7.0% per annum payable in cash or in kind at our option. The Facility Preferred Stock will have an initial liquidation preference of 120% of the issuance price, plus accrued dividends. The Facility Preferred Stock will have no voting rights as a class or series except in such instances as required by Delaware law or certain matters enumerated in the certificate of designations related to the protection of the Facility Preferred Stock.
The Facility Preferred Stock will be convertible at the option of the holders into a number of shares of common stock equal to $10,000 divided by the then-applicable conversion price, which will be equal to the lesser of (i) the average five day closing price from the date of sale of such Facility Preferred Stock (each sale, an “Advance”), or (ii) the closing price per share of common stock on the date of each Advance subject to certain customary anti-dilution adjustments. At any time after the two year anniversary of any issuance of any series of Facility Preferred Stock, we will have the option to convert all (but not less than all) of any series of then-outstanding Facility Preferred Stock by paying a make-whole payment, in either stock or cash, equal to three years of dividends, provided that the closing price of the common stock exceeds 250% of the then-applicable conversion price for at least 20 out of 30 consecutive trading days prior to the date of conversion. To the extent, if any, a conversion would result any the holder thereof becoming the beneficial owner of more than 19.9% of our outstanding common stock, we will issue such investor a Pre-Funded Warrant. The Facility Preferred Stock will be subject to customary pre-emptive rights. The Pre-Funded Warrants, if issued, would be issued for no additional cash consideration.
23

TABLE OF CONTENTS

The rights, preferences and privileges of the Facility Preferred Stock, when and if issued, will be set out in a certificate of designation in substantially the form attached as Annex B hereto, the full text of which, is incorporated into this Proposal 4 by reference. The Pre-Funded Warrants, when and if issued, would be issued in the form attached as Annex C hereto, the full text of which, is incorporated into this Proposal 4 by reference.
The Series A Warrants
Pursuant to the Facility Agreement, we have agreed, upon receipt of stockholder approval, to issue the Series A Warrant to the Sylebra Purchasers for no cash consideration. The Series A Warrants will be issued substantially in the form attached as Annex D hereto, the full text of which, is incorporated into this Proposal 4 by reference.
Reason for Seeking Stockholder Approval
Under NYSE Listing Rule 312.03(b)(i), a NYSE-listed company is required to obtain stockholder approval prior to the issuance of common stock, or of securities convertible into or exercisable for common stock, to a director, officer or substantial security holder of the company (a “Related Party”) if the number of shares of common stock to be issued, or the number of shares of common stock into which the securities may be convertible or exercisable, exceeds 1% of the number of shares of common stock outstanding before the issuance and the transaction is not a cash sale for a price that is at least the Minimum Price (as defined by NYSE Listing Rule 312.04). The 15,000,000 shares of common stock that may be issued upon exercise of the Series A Warrants may exceed 1% of the number of shares of common stock outstanding before such issuance. In addition, while the number of shares of common stock that may be issued upon conversion or exercise, as applicable, of the Facility Preferred Stock and the Pre-Funded Warrants, if issued, cannot be determined as the date hereof, these issuances may exceed 1% of the number of shares of common stock outstanding before such issuance.
NYSE Listing Rule 312.04(e) defines a substantial stockholder as the holder of an interest of 5% or more of either the number of shares of common stock outstanding. As the Sylebra Purchasers or their affiliates currently beneficially own more than 5% of our outstanding common shares in the aggregate, the Sylebra Purchasers are considered substantial security holders under NYSE Listing Rule 312.04(e).
Stockholder approval of this Proposal 4 will constitute stockholder approval for purposes of NYSE Listing Rule 312.03(b)(i)of the issuance of the Sylebra Warrants and shares of the Facility Preferred Stock, as well as the issuance of the shares of common stock issuable upon the exercise or conversion, as applicable, of the Sylebra Warrants and Facility Preferred Stock to the extent such transactions are deemed to require stockholder approval pursuant to NYSE Listing Rule 312.03(b)(i). In the event that this Proposal 4 is not approved by our stockholders the Series A Warrants, the issuance of which is conditioned on stockholder approval, will not be issued and we will be obligated under the Facility Agreement to seek stockholder approval the Series A Warrants again in the future. In addition, in the event this Proposal 4 is not approved by our stockholders and the issuance of the Facility Preferred Stock and Pre-Funded Warrants is deemed to require stockholder approval pursuant to the aforementioned NYSE Listing Rule, our ability to sell shares of our Facility Preferred Stock to the Sylebra Purchasers pursuant to the Facility Agreement may be jeopardized.
Interests of Certain Persons
When you consider the Board’s recommendation to vote in favor of Proposal 4, you should be aware that our directors and executive officers and existing stockholders may have interests that may be different from, or in addition to, the interests of other of our stockholders. In particular, Sylebra and the Sylebra Purchasers, as counterparties to the transactions described above, have an interest in the approval of this Proposal 4. In addition, Christopher Eberle, one of our directors, is an employee of Sylebra. Mr. Eberle was initially appointed to serve on our Board of Directors pursuant to the Sylebra Letter Agreement (as defined below) and is serving as Sylebra’s the first director appointee pursuant to the Sylebra Stockholder Agreement that was entered into in connection with the Common Stock Financing Transactions. See the section entitled “Security Ownership of Certain Beneficial Owners and Management” in this proxy statement for information on Sylebra’s beneficial ownership of our common stock and the section entitled “Related Person Transactions” for information on Sylebra’s director nomination rights. The final terms of the Common Stock Financing Transactions were approved by our Board of Directors upon the recommendation of our Audit Committee, of which Mr. Eberle was not a member.
Potential Adverse Effects — Dilution
If our stockholders vote to approve the issuance of the Sylebra Warrants and Facility Preferred Stock, the exercise or conversion, as applicable, of the Sylebra Warrants and Facility Preferred Stock, when and if issued, into shares of
24

TABLE OF CONTENTS

common stock will not require any additional approval by our common stockholders. The issuance of such common stock will have a dilutive effect on current stockholders other than the Sylebra Purchasers in that the percentage ownership of the Company held by such other current stockholders will decline as a result of the issuance of such common stock. Issuance of such common stock will also have a dilutive effect on book value per share and any future earnings per share. Dilution of equity interests could also cause prevailing market prices for our common stock to decline. The dilutive impact of the Facility Preferred Stock and the Pre-Funded Warrants, if issued, cannot be determined as the date hereof because the number of shares into which such securities may be converted or exercised will not be known until the applicable conversion date of the Facility Preferred Stock.
Effect of Reverse Stock Split
The information set forth below does not reflect the potential approval of the Reverse Stock Split Proposal and consummation of a Reverse Stock Split. In the event the Reverse Stock Split becomes effective, any outstanding Sylebra Warrants or shares of Facility Preferred Stock, and any rights to acquire such securities pursuant to the Facility Agreement, will be proportionately adjusted to reflect the Reverse Stock Split, including, where applicable, the number of shares purchasable or issuable and applicable issue, exercise and conversion prices.
Board Discretion to Withdraw this Proposal
The Board reserves the right to withdraw this Proposal No. 4 and, if this proposal is withdrawn, all references in this Proxy Statement and any related proxy materials to voting for this Proposal No. 4 should be disregarded.
Required Vote
Approval of this Proposal 4 requires the affirmative vote (i.e., “FOR” votes) of a majority of the shares present or represented and entitled to vote thereon at theour 2023 Annual Meeting. A vote to abstain“ABSTAIN” and a broker non-vote will count as “present” for purposes of this proposal and so will have the same effect as a vote against“AGAINST” this proposal. A broker non-vote will not count as present and so will have no effect on determining the outcome of the proposal.
19

TABLE OF CONTENTS

Recommendation
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” PROPOSAL NO. 3 – APPROVAL OF AMENDMENT NO. 1 TO THE AEVA TECHNOLOGIES, INC. 2021 INCENTIVE AWARD PLAN.
20

TABLE OF CONTENTS

PROPOSAL 4 – APPROVE THE COMPANY’S EMPLOYEE STOCK PURCHASE PLAN
The Board of Directors unanimously recommends that you vote “FOR” Proposal No. 4,
the Approval of the Aeva Technologies, Inc. Employee Stock Purchase Plan
We are seeking stockholder approval of the Aeva Technologies Inc. Employee Stock Purchase Plan (the “ESPP”). Our Compensation Committee and Board of Directors unanimously approved the ESPP, subject to stockholder approval at the Annual Meeting.
The following sections summarize the material terms of the ESPP. However, these sections are qualified in their entity by reference to the full text of the ESPP, which is included as Annex B to this Proxy Statement. Stockholders are urged to review the ESPP together with the following information, which is qualified in its entirety by reference to Annex B. If there is any inconsistency between this Proposal 4 and the ESPP terms, or if there is any inaccuracy in this Proposal 4, the terms of the ESPP shall govern.
Purpose
The purpose of the ESPP is to provide eligible employees an opportunity to acquire shares of our common stock from us. We believe that employees who participate in the ESPP will have a closer alignment with us and our other stakeholders by virtue of their ability to participate as stockholders in our success.
General
The ESPP permits eligible employees to use payroll deductions to purchase share of our common stock at a discount to the market price.
The ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code of 1986, as amended (the “Code”), and permits participants to be eligible to receive favorable tax treatment of shares acquired under the ESPP, as described below. However, the Compensation Committee, as administrator, may also authorize offerings under the ESPP that are not intended to comply with the requirements of Section 423 of the Code, which offerings will be made pursuant to any rules, procedures or sub-plans adopted by the Compensation Committee for such purpose.
Effective Date and Term
If approved by stockholders, the ESPP will become effective on March 1, 2023. The ESPP will continue in effect for a term of 10 years, unless earlier terminated by the Compensation Committee in accordance with the terms of the ESPP.
Administration
The ESPP will be administered by the Board or the Compensation Committee. For the purposes of this summary, references to the “Compensation Committee” include the Compensation Committee and the Board as well as any administrator, including management or third-party vendors or brokers, to which the Compensation Committee has delegated any of its responsibilities and powers. Subject to the ESPP terms and applicable law, the Compensation Committee has the full and final authority to construe and interpret the ESPP and adopt rules and procedures for the administration of the ESPP as the Compensation Committee deems appropriate. The Compensation Committee may also adopt sub-plans relating to the operation and administration of the ESPP to accommodate specific requirements of local laws and procedures for non-U.S. jurisdictions that will not be required to comply with Section 423 of the Code to the extent they are inconsistent with the requirements of those regulations, the terms of which may take precedence over the terms of the ESPP.
Shares Reserved for the ESPP
The aggregate number of shares of common stock available for issuance under the ESPP may not exceed 1,831,812, which number will automatically increase on the first day of each fiscal year, beginning with January 1, 2023, in an amount equal to the lesser of (i) 5% of the total number of all classes of common stock outstanding on the last day of the immediately preceding fiscal year or (ii) a lower number of shares of common stock as determined by the Board. The number of shares of our common stock that may be issued or transferred pursuant to the rights granted
21

TABLE OF CONTENTS

under the Section 423 component of the ESPP may not exceed an aggregate of 36,636,240 shares. The number of shares issuable under the ESPP and the terms of options to acquire such shares are subject to adjustment in connection with certain corporate and recapitalization events as described in the ESPP.
Enrollment and Contributions
Eligible employees may become participants in the ESPP by enrolling during an open enrollment period. Eligible employees enroll by completing the appropriate forms and agreements, as directed by the Compensation Committee. Following the end of each Offering Period, each participant will be automatically re-enrolled in the next Offering Period using the same rate of payroll contributions in effect during the prior Offering Period, unless the participant requests otherwise or chooses to withdraw from the ESPP, or if the participant is ineligible to continue to participate, in each case, in accordance with the terms of the ESPP.
The amount of payroll deductions that a participant may select must be a whole percentage of at least 1%, but not more than 15%, of the participant’s base salary or wages. The aggregate amount of the specified percentage will be deducted from the participant’s paychecks on an after-tax basis in installments each pay period during the term of the Offering Period. Payroll deductions will begin with the first Offering Period following a participant’s enrollment and will remain in effect for successive Offering Periods unless a change is made. A participant may not make separate cash payments into his or her account except as permitted by the Compensation Committee.
All contributions made by a participant will be credited (without interest) to his or her account. A participant may withdraw from an Offering Period and the ESPP by the deadline prescribed by the Compensation Committee during such Offering Period and his or her contributions will be refunded, without interest. If permitted by the Compensation Committee in its sole discretion, a participant may, on a single occasion during an Offering Period, reduce his or her rate of contribution during, or suspend his or her contributions for the remainder of, an ongoing Offering Period.
Eligible Participants
Subject to the Administrator’s ability to exclude certain groups of employees on a uniform and nondiscriminatory basis, including Section 16 officers and/or non-U.S. employees, generally, all of our employees will be eligible to participate if they are employed by the Company or any designated company for at least five consecutive calendar months of service since his or her last date of hire, or any lesser period of time as may be determined by the Compensation Committee in its discretion. In no event will an employee who is deemed to own 5% or more of the total combined voting power or value of all classes of our capital stock or the capital stock of any parent or subsidiary be eligible to participate in the ESPP, and no participant in the ESPP may purchase shares of our common stock under any employee stock purchase plans of our Company to the extent the option to purchase shares accrue at a rate that exceeds $25,000 of the fair market value of such shares of our common stock, determined as of the first day of the offering period, for each calendar year in which such option is outstanding.
We estimate that, as of September 1, 2022, approximately 277 of our employees are eligible to participate in the ESPP.
Offering Periods
The ESPP provides for two Offering Periods in each calendar year unless otherwise determined by the Compensation Committee. The first Offering Period under the ESPP shall commence on the date determined by the Compensation Committee and shall end on the last trading day on or immediately preceding the August 31st or February 28th/29th that next occurs after the commencement of the applicable Offering Period. Unless the Compensation Committee determines otherwise, following the completion of the first Offering Period, a new Offering Period shall commence on the first trading day on or following March 1 and September 1 of each calendar year and end on or following the last trading day on or immediately preceding August 31 and February 28/29, respectively, approximately six months later. The Compensation Committee may choose to start a new Offering Period as it may determine from time to time as appropriate.
Purchase of Shares
On the first trading day of an Offering Period, a participant will be granted an option to purchase on each exercise date during the Offering Period a number of shares of common stock at the applicable purchase price. Subject to the limit below, the number of shares of common stock is determined by dividing the amount of the participant’s
22

TABLE OF CONTENTS

contributions accumulated as of the last trading day of the Offering Period by the applicable purchase price. No participant may purchase shares of common stock with a fair market value (determined as of the date the option to purchase is granted) in excess of $25,000 per calendar year or $12,500 in any Offering Period. The Compensation Committee may modify the per-Offering Period limit from time to time. The number of shares subject to options will be adjusted as necessary to conform to the above limitations.
The purchase price will be 85% (or such greater percentage as determined by the Compensation Committee prior to the commencement of any Offering Period) of the lesser of (i) the fair market value per share of our common stock as determined on the purchase date or (ii) the fair market value per share of our common stock as determined on the first day of the applicable Offering Period (however, in no event may the purchase price be less than the par value per share of our common stock).
A participant’s option to purchase shares of common stock during any Offering Period will be exercised automatically on the purchase date unless the participant withdraws from the ESPP prior to the end of the Offering Period or his or her participation is terminated. Subject to the terms of the ESPP, an option to purchase will generally terminate on the earlier of the date of the participant’s termination of employment or the last day of the applicable Offering Period. A participant’s option to purchase shares is not transferable other than by will or the laws of descent and distribution. A participant will have no rights as a stockholder with respect to the shares of our common stock that the participant has an option to purchase in any Offering Period until those shares have been issued to the participant.
Amendment or Termination
The Board or the Compensation Committee, in its sole discretion, may amend, suspend or terminate the ESPP, or any part thereof, at any time and for any reason.
Adjustments; Effect of a Change of Control
In the event that any subdivision or consolidation of outstanding shares of our common stock, declaration of a dividend payable in shares of our common stock or other stock split, other recapitalization or capital reorganization of the Company, any consolidation or merger of the Company with another corporation or entity, the adoption by the Company of any plan of exchange affecting our common stock or any distribution to holders of our common stock of securities or property (other than normal cash dividends or dividends payable in our common stock), the Compensation Committee, in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, will, in such manner as it may deem equitable, adjust the number and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares of common stock covered by each option under the ESPP that has not yet been exercised, and the limits on (i) the number of shares of our common stock that can be purchased during any Offering Period or any calendar year and (ii) the number of shares of our common stock reserved under the ESPP.
In addition, in the event of a merger or change in control, each outstanding option under the ESPP will be assumed or an equivalent right to purchase shares of stock substituted by the successor corporation (or a parent or subsidiary thereof). In the event that the successor corporation in a change in control refuses to assume or substitute for the option, then the Offering Period then in progress will be shortened and the Compensation Committee will select a date on which all outstanding options will be exercised on or prior to the consummation date of the merger or change in control.
Plan Benefits
Benefits under the ESPP will depend on participants’ elections to participate and the fair market value of our common stock at various future dates. As a result, it is not possible as of the date of this proxy statement to determine future benefits that will be received by executive officers and other employees. Each participant is limited to the $25,000 annual purchase restriction as well as the participant purchase restrictions for any Offering Period described above.
We anticipate filing a registration statement on Form S-8 with the SEC to register shares of common stock under the ESPP, subject to and effective upon stockholder approval, as soon as practicable following stockholder approval of the ESPP.
Federal Tax Consequences
The following summary generally describes the principal U.S. federal (and not state, foreign or local) income tax consequences under the ESPP to us and participating employees as of the date of this proxy statement. The summary
23

TABLE OF CONTENTS

is general in nature and is not intended to cover all the tax consequences that may apply to a particular employee or to us. The provisions of the Code and related regulations concerning these matters are complicated, and their impact in any one case may depend upon the particular circumstances.
As noted above, the ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Code. Participating employees will, however, recognize income when they sell or dispose of the shares purchased under the ESPP. If an employee disposes of such shares after two years from the date of grant of the option and after one year from the date of the purchase of such shares (or if the employee dies), the employee will recognize ordinary income for the year in which such disposition occurs (or the employee’s taxable year ending with his or her death) in an amount equal to the lesser of:
the excess of the fair market value of such shares at the time of disposition (or death) over the purchase price; or
the excess of the fair market value of the shares at the time of the grant of the option over the option price on the date of the option grant.
Except in the case of the employee’s death, the employee’s basis in the shares disposed of will be increased by an amount equal to the amount includable in his or her income as ordinary income. Any additional gain or loss will be a long-term capital gain or loss. We will not be entitled to a tax deduction when the shares are disposed of after the expiration of the two-year and one-year periods.
If an employee disposes of the shares purchased under the ESPP within such two-year or one-year periods, the employee will recognize ordinary income for the year in which such disposition occurs in an amount equal to the excess of the fair market value of such shares on the date of purchase over the purchase price. The employee’s basis in such shares disposed of will be increased by an amount equal to the amount includable in his or her income as ordinary income, and any gain or loss computed with reference to such adjusted basis that is recognized at the time of disposition will be a capital gain or loss, either short-term or long-term, depending on the holding period for such shares. In the event of a disposition within such two-year or one-year periods, we will be entitled to a tax deduction equal to the amount the employee is required to include as ordinary income as a result of such disposition to the extent the amount represents reasonable compensation and an ordinary and necessary business expense, subject to any required income tax reporting.
The Compensation Committee may authorize offerings that are not intended to comply with Section 423 of the Code, in which case different tax consequences will apply. Upon the purchase of shares under the ESPP, the employee will recognize ordinary income in an amount equal to the excess of the fair market value of such shares on the date of purchase over the purchase price paid by the employee for such shares, and we will be entitled to a corresponding deduction for U.S. federal income tax purposes. In addition, upon the disposition of such shares, the employee will recognize a capital gain or loss in an amount equal to the difference between the selling price of such shares and the fair market value of such shares on the date of purchase. We will not receive a deduction for U.S. federal income tax purposes with respect to any capital gain or loss recognized by the employee.
Board Approval
The ESPP was adopted by the Compensation Committee and the Board, conditioned on and subject to obtaining stockholder approval of the ESPP.
Required Vote
Approval of this Proposal 4 requires the affirmative vote of a majority of the shares present or represented and entitled to vote thereon at the Annual Meeting. A vote to abstain will have the same effect as a vote against this proposal. A broker non-vote will not count as present and so will have no effect on determining the outcome of the proposal.
Recommendation
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” PROPOSAL NO. 4, THE APPROVAL OF CERTAIN SECURITIES ISSUANCES FOR THE AEVA TECHNOLOGIES, INC. EMPLOYEE STOCK PURCHASE PLAN.
24

TABLEPURPOSES OF CONTENTS

PROPOSAL 5 – ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS
Pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”) and corresponding proxy rules under Section 14A of the Exchange Act, the Company is presenting its stockholders with an advisory (non-binding) vote on the executive compensation programs for the Company’s named executive officers (sometimes referred to as “Say on Pay”).
The advisory vote on executive compensation is a non-binding vote on the compensation of the Company’s named executive officers as described in the section titled “Executive Compensation,” including the tabular disclosure regarding such compensation, and the accompanying narrative disclosure, included in this Proxy Statement. Please read the Executive Compensation section for a discussion about the Company’s executive compensation programs, including information about compensation of the Company’s named executive officers for the fiscal year ended December 31, 2021.
The advisory vote on executive compensation is not a vote on the Company’s general compensation policies, the compensation of the Company’s Board of Directors, or the Company’s compensation policies as they may relate to risk management.
The Compensation Committee oversees and administers the Company’s executive compensation program, including the determination and implementation of the Company’s compensation philosophy, policies, and objectives. The Compensation Committee has designed the executive compensation program to align executive compensation with the achievement of the Company’s business goals and strategies, both short- and long-term. The Compensation Committee also seeks to provide executive compensation at levels that will allow the Company to continue to be able to attract and retain the best possible executive candidates.
The Company believes that the most significant components of its executive compensation program reflect sound governance practices and are consistent with industry standards. The Board of Directors believes that executive compensation is appropriately allocated between base salary and equity compensation opportunities so as to encourage strong short- and long-term performance, create clear alignment with stockholders and discourage excessive risk-taking. Accordingly, we are asking stockholders to vote for the following resolution:
“RESOLVED, that the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the 2022 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, compensation tables and narrative discussion contained under “Executive Compensation” is hereby APPROVED”.
The vote solicited by this Proposal 5 is advisory, and therefore is not binding on the Company, the Company’s Board of Directors or the Compensation Committee. The outcome of the vote will not require the Company, the Board of Directors or the Compensation Committee to take any action, and will not be construed as overruling any decision by the Board of Directors or the Compensation Committee. However, the Board of Directors and the Compensation Committee value the opinions expressed by stockholders in their votes on this proposal and will consider the outcome of the vote when making future compensation decisions regarding named executive officers.
Required Vote; Recommendation of the Board
Approval will be obtained if the number of votes of our common stock cast “FOR” the proposal at the Annual Meeting exceeds the number of votes “AGAINST” the proposal.
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” THE ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.COMPLYING WITH NYSE RULES.
25

TABLE OF CONTENTS

PROPOSAL 6 – ADVISORY (NON-BINDING) VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION
In addition to providing our stockholders with the opportunity to cast an advisory vote on the compensation of our named executive officers (see Proposal 5), we also are seeking a non-binding, advisory vote on how frequently such say-on-pay vote should be presented to our stockholders. At the Annual Meeting, our stockholders will be given the opportunity to vote on whether they prefer to have future say-on-pay votes occur:
every year;
every two years; or
every three years
or alternatively, stockholders may abstain from casting a vote.
In accordance with SEC rules, our stockholders will have the opportunity at least every six years to recommend the frequency of future say-on-pay votes.
The Board of Directors believes that future say-on-pay votes should occur every three years in order to allow our stockholders the ability to provide timely, direct input on our executive compensation philosophy, policies and practices as disclosed in the proxy statement each year.
Because the vote on this proposal is advisory in nature, it will not be binding on the Board of Directors. However, the Board of Directors will consider the outcome of the vote along with other factors when making its decision about the frequency of future “say-on-pay” votes. We will disclose the decision of the Board of Directors with respect to the frequency of future “say-on-pay” votes in a Current Report on Form 8-K to be filed in relation to the Annual Meeting.
Required Vote; Recommendation of the Board
For the advisory (non-binding) vote on the frequency of future stockholder advisory votes to approve the compensation paid to the company’s named executive officers, the option among the choices that receives the votes of the holders of a majority of the voting power of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting voting for or against the choices will be deemed to be the frequency preferred by the stockholders. In the event that no option receives a majority of the votes as described in the immediately preceding sentence, the Company will consider the option that receives the most votes cast to be the frequency preferred by our stockholders.
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE FOR “THREE YEARS” AS THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
26

TABLE OF CONTENTS

EXECUTIVE OFFICERS
Our named executive officers for the fiscal year ended December 31, 20212022 were:
Soroush Salehian Dardashti, Chief Executive Officer;
Mina Rezk, President and Chief Technology Officer; and
Saurabh Sinha, Chief Financial Officer.
Summary biography of our Chief Financial Officer is provided below. Information on Mr. Dardashti and Mr. Rezk can be found under “Proposal 1: Elect Class I Director.II Directors.” All of our executive officers serve at the discretion of our Board.
Saurabh Sinha, 4445. Mr. Sinha serves as Chief Financial Officer of the Company. Mr. Sinha has served as Aeva’s Chief Financial Officer since September 2020. Prior to joining Aeva, Mr. Sinha was the Chief Accounting Officer of JUUL Labs from July 2018 to August 2020 and served as its interim Chief Financial Officer from January 2020 to May 2020. Prior to joining JUUL Labs, Mr. Sinha held various finance leadership roles, from March 2014 to June 2018, at InvenSense Inc., a motion sensors company. Mr. Sinha received his Bachelor of Commerce degree from the University of Delhi, India and his Master of Business Administration from The Wharton School of the University of Pennsylvania.
2726

TABLE OF CONTENTS

EXECUTIVE AND DIRECTOR COMPENSATION
This section describes the compensation program for our named executive officers and directors.
Compensation Discussion and Analysis
Compensation Philosophy
Our executive compensation program is designed to achieve the following objectives:
Attract and retain a highly talented team of executives;
Ensure that the interests of our executive officers are aligned with the interests of our stockholders;
Reward our executive officers for their performance and motivate them to achieve the Company’s strategic goals; and
Ensure that the total compensation paid to each of our named executive officers is fair, reasonable and competitive.
We provide our executive officers with a significant portion of their compensation through cash incentive compensation determined based upon the achievement of financial, operational and individual performance metrics as well as through equity compensation that vests on the basis of performance milestones and/or continued service.
The following features of our compensation program are designed to align our executive team with stockholder interests and with market best practices:
What We Do
What We Don’t Do
Maintain an industry-specific peer group for evaluating the competitiveness of our pay
Provide tax gross-up payments for any change-in-control payments
Consult with an independent compensation consultant on compensation levels and practices
Provide special or supplemental executive retirement plans that are exclusive to the executive population
Deliver executive compensation primarily through performance-based pay
Executive Compensation Determination Process
Our Compensation Committee expects to review our compensation program for our executive officers annually. In setting executive base salaries and target bonuses and granting equity incentive awards, the Compensation Committee considers compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our Company.
Our Compensation Committee reviews and discusses management’s proposed compensation with the Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, taking into account the factors noted above, the Compensation Committee then approves, without members of management present, the compensation for each executive officer. The Compensation Committee may also make recommendations to the Board of Directors with respect to the compensation of executive officers.
28

TABLE OF CONTENTS

Use of Competitive Market Data and Peer Groups
Our Compensation Committee is authorized under its charter to retain the services of one or more executive compensation advisors in connection with the establishment of our compensation programs and related policies. In late 2021, as part of the process of transforming the Company’s compensation processes and programs to those expected of a U.S. based publicly traded company, the Compensation Committee sought to engage an external compensation consultant, and ultimately retained a national compensation consultant, Aon Human Capital Solutions practice, a division of Aon in January 2022. Our Compensation Committee engaged Aon to assist with the following objectives:
Developing a group of peer companies to help us determine the appropriate level of overall compensation for our executive officers in fiscal 2022;
Evaluating the overall competitiveness of our compensation program for our executive officers in fiscal 2022;
Evaluating the appropriateness and overall competitiveness of our Company-wide equity compensation guidelines, burn rate and the size of our equity plan share reserve; and
Assessing each separate element of compensation, with a goal of ensuring that the compensation we offer to our executive officers in fiscal 2022 and beyond is deemed appropriate, competitive and fair.
The Compensation Committee directs Aon to provide it with competitive market data and analysis based on a select group of peers and companies and published compensation survey data, as well as information about current market practices and trends, compensation structures and peer group compensation ranges. The competitive market data Aon provides is based on a compensation peer group selected and approved by the Compensation Committee with input and guidance from Aon and published compensation survey data from Radford Surveys in cases where there is insufficient data for specific executive positions with the peer group companies. The compensation peer group is comprised of companies that are considered similar to us at the time of selection based on industry, business focus, and various financial criteria, including revenue, market capitalization, total shareholder return, and research and development expense.
Based on the foregoing criteria, our peer group, as approved by our Compensation Committee in January 2022, is comprised of the following 17 companies:
Cerence Inc.
Canoo Inc.
C3.ai, Inc.
Fisker Inc.
FormFactor, Inc.
FuelCell Energy, Inc.
Hyliion Holdings Corp.
JFrog Ltd.
Luminar Technologies, Inc.
Nikola Corporation
nLIGHT, Inc.
PAR Technology Corporation
Power Integrations, Inc.
QuantumScape Corporation
SiTime Corporation
Velodyne Lidar, Inc.
Virgin Galactic Holding, Inc.
We believe that the compensation practices of our peer group will provide us with appropriate compensation data for purposes of the objectives identified above.
Notwithstanding the similarities of our Company to those of our peer group, due to the nature of our business, we compete for executive talent with many public companies that are larger and more established than we are or that possess greater resources than we do, and with smaller private companies that may be able to offer greater equity compensation upside potential. In large part because we had not yet adopted a peer group until January 2022, we did not target any specific percentile of our peer group with respect to the 2021 compensation program as described in this section; however, the Compensation Committee considered the peer group data provided by Aon as a factor in determining the size of the bonuses to award the named executive officers based on the Company’s performance in 2021. Although the Compensation Committee may target compensation in future years to a specific percentile of the peer group data, they also expect to consider other criteria, including market factors, the experience level of the executive and the executive’s performance against established company goals, in determining variations to this general target range.
29

TABLE OF CONTENTS

2021 Executive Compensation
Base Salary
We provide base salaries to our named executive officers to compensate them with a fair and competitive base level of compensation for services rendered during the year. Our Board of Directors has historically determined our executives’ base salaries; however, base salaries are now determined by the Compensation Committee.
In March 2021 we approved increases in base salary for Mr. Dardashti and Mr. Rezk, retroactive to January 1, 2021, based on the increased responsibilities associated with their roles as named executive officers of a publicly traded company following the deSPAC transaction. Mr. Sinha’s employment commenced in September 2020, and we determined that no adjustment to his base salary was needed due to the limited period of time that had elapsed between his hire date and the effective date of the 2021 merit increases for the other executive officers. The table below sets forth the adjustments to base salary that were approved for each of Mr. Dardashti and Mr. Rezk:
Name and Principal Position
FY2020 Salary
FY2021 Salary
Soroush Salehian Dardashti
Chief Executive Officer
$320,000
$450,000
Mina Rezk
President and Chief Technology Officer
$370,000
$500,000
2021 Bonuses
Transaction Bonuses. In connection with the completion of the deSPAC transaction, the Board of Directors approved the payment of the following transaction-based bonuses to our named executive officers in March 2021.
deSPAC Cash Transaction Bonus
Name
Soroush Salehian Dardashti
$1,000,000
Mina Rezk
$1,000,000
Saurabh Sinha
$100,000
Spot Bonuses.In response to the competitive market for talent at all levels in the San Francisco Bay Area where we are headquartered, and to show the Company’s appreciation for the hard work of the Company’s employees at all levels, in December 2021 each of the Company’s employees, including the Company’s named executive officers, were awarded a spot bonus in the amount of $1,000.
Annual Bonuses. We have historically paid discretionary annual bonuses and continued to do so with respect to 2021. In May 2022, the Company awarded Messrs. Dardashti, Rezk and Sinha cash bonuses of $550,000, $1,000,000, and $210,000, respectively, for services in 2021. These amounts were determined to be appropriate to reward our named executive officers for their performance in 2021 along with the achievement of certain company milestones. Mr. Rezk’s bonus was increased by an amount intended to facilitate the relocation of himself and his family from Virginia to California and account for the expense associated with the exploration of the relocation.
30

TABLE OF CONTENTS

2021 Summary Compensation Table
The following table sets forth the total compensation awarded to, earned by and paid during the fiscal years ended December 31, 20212022 and December 31, 20202021 for each of our named executive officers.
Name and Principal Position
Year
Salary
($)
Bonus
($)(1)
Option
Awards
($)
Stock
Awards
($)
All other
compensation
($)
Total
($)
Soroush Salehian Dardashti
Chief Executive Officer
2021
450,000
1,551,000
12,300(2)
2,013,300
2020
320,000
120,000
2,070,051
2,510,051
Mina Rezk
President & Chief Technology Officer
2021
500,000
2,001,000
129,878(3)
2,630,878
2020
370,000
120,000
3,848,697
105,156
4,443,853
Saurabh Sinha
Chief Financial Officer
2021
300,000
311,000
 
 
611,000
2020
76,367
8,026,241
8,102,608
Name and Principal Position
Year
Salary
($)
Bonus
($)
Option
Awards
($)
Stock
Awards
($)
All other
compensation
($)
Total
($)
Soroush Salehian Dardashti
Chief Executive Officer
2022
550,000
495,000(1)
11,300(3)
1,056,300
2021
450,000
1,551,000(2)
12,300(3)
2,013,300
Mina Rezk
President & Chief Technology Officer
2022
550,000
495,000(1)
163,725(4)
1,208,725
2021
500,000
2,001,000(2)
129,878(4)
2,630,878
Saurabh Sinha
Chief Financial Officer
2022
450,000
263,250(1)
1,065,823
 
5,500(5)
1,784,573
2021
300,000
311,000(2)
611,000
1)(1)
Represents cash bonus paid in May 2023 with respect services in 2022.
(2)
2021 bonus amounts reflect (i) discretionary bonuses paid to the named individual upon the completion of the Company’s deSPAC transaction, as detailed in the “deSPAC Cash Transaction Bonus” table above;de-SPAC transaction; (ii) a Company-wide spot bonus in the amount of $1,000 awarded in December 2021; and (iii) the 2021 annual bonus paid in May 2022, whereby the Company awarded Messrs. Dardashti, Rezk and Sinha cash bonuses of $550,000, $1,000,000, and $210,000, respectively, for services in 2021.
2)(3)
Amount shown for 2022 reflects a $1,050 meal allowance and a 401(k) plan matching contribution in the amount of $10,250. Amount shown for 2021 reflects a $3,600 meal allowance and a 401(k) plan matching contribution in the amount of $8,700.
3)(4)
Amount shown for 2022 reflects $57,175 in housing and living expense, $95,250 in Company paid airfare, $1,050 in meal allowance and $10,250 in 401(k) matching contributions. Amount shown for 2021 reflects $56,204 in housing and living expense, $40,785 in Company paid airfare, $20,598 for payments made under the Company’s patent award program, $3,600 in meal allowance and $8,700 in 401(k) matching contributions for Mr. Rezk.contributions.
Grants of Plan-Based Awards
(5)
Amount shown reflects a $1,050 meal allowance and a 401(k) plan matching contribution in the amount of $4,500.
No equity awards were made to our named executive officers in the 2021 fiscal year.
27

TABLE OF CONTENTS

Outstanding Equity Awards at Fiscal Year End
The following table presents information regarding all outstanding equity awards held by each of our named executive officers on December 31, 2021.2022.
 
 
Option Awards(1)
 
 
Stock Awards
Name
Grant
Date
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
Option
Exercise
Price
($)
Option
Expiration
Date
Number
Of
Shares
or Units
of Stock
That
Have
Not
Vested
(#)
Market
Value of
Shares
or Units
of Stock
That
Have
Not
Vested
($)(4)
Soroush Salehian Dardashti
1/23/2020(2)
868,930
944,491
0.5476
1/23/2030
 
2/6/2019
1,880,461
0.2622
2/6/2029
Mina Rezk
1/23/2020(2)
1,615,540
1,756,023
0.5476
1/23/2030
 
2/6/2019
3,496,203
0.2622
2/6/2029
 
Saurabh Sinha
11/18/2020(3)
 
820,940
6,206,306
Name
Grant
Date
Option Awards(1)
Option
Exercise
Price
($)
Option
Expiration
Date
Stock Awards
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
Number
Of
Shares
or Units
of Stock
That
Have
Not
Vested
(#)
Market
Value of
Shares
or Units
of Stock
That
Have
Not
Vested
($)(3)
Soroush Salehian Dardashti
1/23/2020
1,322,286
491,135
0.5476
1/23/2030
2/6/2019
1,880,461
0.2622
2/6/2029
Mina Rezk
1/23/2020
2,458,431
913,132
0.5476
1/23/2030
2/6/2019
3,496,203
0.2622
6/2/2029
Saurabh Sinha
5/26/2022
168,437
566,563
2.92
5/26/2032
11/18/2020(2)
540,090
734,522
1)
Each option grant is subject to the terms of our 2016 Stock Incentive Plan (“2016 Plan”). Shares underlying each award granted under our 2016 Plan are shares of common stock of the Company.
2)(1)
Shares subject to the stock option vest in 48 equal installments on each monthly anniversary of the grant date, subject to accelerated vesting upon a termination of employment with the Company without “cause” or a resignation for “good reason” (each such term as defined in the applicable award agreement) that occurs in connection with or 12 months after the closing of a Business Combination (as defined in the applicable awardemployment agreement).
3)(2)
The restricted stock unit award to Mr. Sinha became eligible to vest only in the event a certain business combination was successfully completed, which occurred in connection with the completion of the deSPACde-SPAC transaction. With respect to 864,155 of the shares subject to the restricted stock unit award, 25% of such shares vested on September 28, 2021, and the remaining 75% of such underlying shares vest in six equal semi-annual installments thereafter and with respect to 172,827 of the shares subject to the restricted stock unit award, 25% of such shares vested on March 12, 2022 and the remaining 75% of such underlying shares will vest in six equal semi-annual installments thereafter; however all of the shares subject to the restricted stock unit award will vest upon the termination of the recipient’s service to the company without cause (as defined in the 2016 Plan) or by Mr. Sinha for good reason (as defined in the recipient’s applicable employment offer letter)agreement) within 12 months following a change in control.
4)(3)
The market value is based on the $7.56$1.36 fair market value of our common stock on December 31, 2021,30, 2022, the closing selling price of our common stock on such date.
31

TABLE OF CONTENTS

Option Exercises and Stock Vested
The following table shows information regarding the vesting of stock awards held by our named executive officers during fiscal year 2021. None of our named executive officers exercised stock options during 2021.
 
Stock Awards
Name
Number of Shares Acquired on
Vesting (#)
Value Realized on Vesting ($)
Saurabh Sinha
216,042
1,698,090
Pension Benefits and Nonqualified Deferred Compensation.
We do not maintain any pension or non-qualified deferred compensation plans or arrangements.
Employment Agreements
We have entered into employment agreements with each of our named executive officers which provide for “at will” employment.
Each of our named executive officers is also subject to a non-competition, non-solicitation, confidentiality, and assignment agreement, which provides for a perpetual post-termination confidentiality covenant as well as non-competition and non-solicitation of customers, employees and consultants covenants that apply during employment and for one year following termination, subject to the type of termination in the case of the non-competition provision.
Chief Executive Officer Employment Agreement
On May 27, 2022, the Company entered into a new employment agreement with Mr. Dardashti (the “CEO Employment Agreement”), which amends and supersedes the terms of Mr. Dardashti’s prior offer letter dated December 15, 2016, pursuant to which Mr. Dardashti will continue to serve as our Chief Executive Officer and report to the Company’s Board of Directors. Mr. Dardashti’s duties, responsibilities and permitted activities are substantially identical to his original offer letter. The CEO Employment Agreement provides that, during the term, Mr. Dardashti will be eligible to receive (i) an annual base salary of $550,000, (ii) annual cash bonuses (as described below), and (iii) customary health and retirement benefits.
Commencing in calendar year 2022, Mr. Dardashti’s initial target annual incentive compensation shallwill be 100% of his base salary with a maximum achievement of 150% of the base salary. The actual amount of the annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time.
28

TABLE OF CONTENTS

President and Chief Technology Officer Employment Agreement
On May 27, 2022, the Company entered into a new employment agreement with Mr. Rezk (the “CTO Employment Agreement”), which amends and supersedes the terms of Mr. Rezk’s prior offer letter dated December 15, 2016, pursuant to which Mr. Rezk will continue to serve as our President and Chief Technology Officer and report to the Chief Executive Officer. Mr. Rezk’s duties, responsibilities and permitted activities are substantially identical to his original offer letter. The CTO Employment Agreement provides that, during the term, Mr. Rezk will be eligible to receive (i) an annual base salary of $550,000, (ii) annual cash bonuses (as described below), (iii) a relocation allowance (as described below), and (iv) customary health and retirement benefits.
Commencing in calendar year 2022, Mr. Rezk’s initial target annual incentive compensation shallwill be 100% of his base salary with a maximum achievement of 150% of his base salary. The actual amount of the annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time.
To facilitate and incent Mr. Rezk’s permanent relocation to the Company’s headquarters, Mr. Rezk shall be entitled to a one-time payment of $130,000 for moving expenses and a monthly stipend of $30,000 for 36 months beginning on the date Mr. Rezk has relocated to within 60 miles of the Company’s headquarters.
Chief Financial Officer Employment Agreement
On May 27, 2022, Aeva entered into a new employment agreement with Saurabh Sinha (the “CFO Employment Agreement”), which amends and supersedes the terms of Mr. Sinha’s prior offer letter dated September 29, 2020,
32

TABLE OF CONTENTS

pursuant to which Mr. Sinha will continue to serve as our Chief Financial Officer and report to the Chief Executive Officer. Mr. Sinha’s duties, responsibilities and permitted activities are substantially identical to his original offer letter.
The CFO Employment Agreement provides that, during the term, Mr. Sinha will be eligible to receive (i) an annual base salary of $450,000, (ii) annual cash bonuses (as described below), and (iii) customary health and retirement benefits.
Commencing in calendar year 2022, Mr. Sinha’s initial target annual incentive compensation shallwill be 65% of his base salary. The actual amount of the annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time.
Severance and Change of Control Arrangement
In the event Mr. Dardashti, Rezk or Sinha’s employment is terminated by the Company without Cause (as defined in the applicable employment agreement) or by the officer for Good Reason (as defined in the applicable employment agreement) other than during the period commencing 90 days prior to and ending 12 months following a Change in Control (as defined in the applicable employment agreement), subject to execution and non-revocation of a Separation Agreement, each officer would be entitled to:
12 months (9 months in the case of Mr. Sinha) of the then-current base salary, payable in a lump sum in cash;
An amount equal to the target bonus for the then-current year, payable in a lump sum in cash;
Company-paid coverage under the Company’s group health plan or monthly payments necessary to cover the full premiums for continued coverage under the Company’s plan through COBRA, which payments will be grossed up for applicable taxes, for up to 12 months following the date of termination (but ceasing once equivalent employer-paid coverage is otherwise available).
In the event that Mr. Dardashti, Rezk or Sinha’s employment is terminated during the period commencing 90 days prior to and ending 12 months following a Change in Control, subject to his execution and non-revocation of a Separation Agreement, each officer would be entitled to:
12 months of the then-current base salary (or the officer’s base salary in effect immediately prior to the Change in Control, if higher), payable in a lump sum in cash;
An amount equal to the target bonus for the then-current year (or the target bonus in effect immediately prior to the Change in Control, if higher), payable in a lump sum in cash;
29

TABLE OF CONTENTS

accelerated vesting of all outstanding stock options and other stock-based awards that are subject solely to time-based vesting; and
continued health benefits as described above.
In the case of a termination of Mr. Rezk’s employment for the reasons described above, Mr. Rezk will also be entitled to a lump sum cash payment equal to the monthly stipend multiplied by 36 minus the total amount of all monthly stipends paid by the Company to Mr. Rezk prior to his termination.
Potential Payments Upon Termination or Change of Control
The amount of compensation and benefits payable to each of our named executive officers upon a change in control has been estimated in the table below.
Each outstanding equity award held by our named executive officers provides that such award will vest on an accelerated basis in the event the executive officer’s service relationship is terminated by the company without “cause” or in the event the executive officer resigns for “good reason” (each such term as defined in the applicable award agreement) in connection with or 12 months after a change in control.
The value of the accelerated vesting was calculated based on the assumption that the change in control and executive officer’s employment termination occurred on December 31, 2021 under circumstances that constituted a termination without “cause” or a resignation for “good reason.” The per share closing price of the Company’s stock on the New York Stock Exchange as of December 31, 2021 was $7.56, which was used as the value of the Company’s stock
33

TABLE OF CONTENTS

in the change in control. The value of the option vesting acceleration was calculated by multiplying the number of unvested option shares outstanding on December 31, 2021, by the difference between $7.56 and the per share exercise price for such unvested option shares. The value of restricted share unit vesting acceleration was calculated by multiplying the number of unvested restricted share units as of December 31, 2021, by the per share closing price of the Company’s stock as of December 31, 2021.
Executive
Executive Benefits and
Payment upon Termination
Termination by
Company without
Cause or Voluntary
Resignation for
Good Reason within 12 months
Following a Change in Control ($)
Soroush Salehian Dardashti
Acceleration of Option Shares
$6,623,148
Acceleration of Restricted Stock Units
Mina Rezk
Acceleration of Option Shares
$12,313,935
Acceleration of Restricted Stock Units
Saurabh Sinha
Acceleration of Option Shares
Acceleration of Restricted Stock Units
$6,206,306
Chief Executive Officer Pay Ratio
As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (“Dodd-Frank”), we are providing the following information about the relationship between the annual total compensation of our median employee and the annual total compensation of our Chief Executive Officer.
When determining our median compensated employee, we included annual base salary for our employee population of approximately 226 employees, of which all but one are full-time, other than our Chief Executive Officer, as of December 31, 2021 (the “Determination Date”), and annualized the base salary for all employees hired between January 1, 2021 and December 31, 2021, and remained actively employed on December 31, 2021.
For fiscal 2021,2022, the annual total compensation for the median employee of Aeva (other than our Chief Executive Officer) was $208,228. The CEO Employment Agreement will result in an$214,100 and the annual total compensation determined as of the date of this filing of our Chief Executive Officer was $2,013,300.$561,300. Based on this information, for fiscal year 2021,2022, we estimate that the ratio of the annual total compensation of our Chief Executive Officer to the annual total compensation of the median employee was 103 to 1.
The pay ratio described above is a reasonable estimate calculated in a manner consistent with Item 402(u) of Regulation S-K. SEC rules for identifying the median employee permit companies to use a wide range of methodologies, assumptions and exclusions. As a result, it may not necessarily be meaningful to compare pay ratios reported by other companies.
This information is being provided for compliance purposes. Neither the Compensation Committee nor management of the company used the foregoing pay ratio measure in making compensation decisions.
Long-Term IncentivesPotential Payments Upon Termination or Change of Control
Although we do not have a formal policy with respect to the grant ofEach outstanding equity incentive awards to our named executive officers, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention over the vesting period.
Our Compensation Committee expects to periodically review the equity-based incentive compensation holdings of our named executive officers and may grant equity incentive awards that vest on the basis of performance metrics and/or a service-based vesting schedule from time to time. In fiscal 2021, the Compensation Committee determined that the size and value of outstanding unvested equity awardsaward held by our named executive officers represented a significant incentive to retain those executive officersprovides that such award will vest on an accelerated basis in the near term. As a result, we did not grant equity awards to our namedevent the executive officers in fiscal 2021, although we may do so in oneofficer’s service relationship is terminated by the company without “cause” or more future years. We previously granted stock option awards to purchase shares of our stock to Messrs. Dardashti and Rezk in fiscal years preceding 2021, and restricted stock units to Mr. Sinha in fiscal year 2020 that vest over a four year period, as described in more detail in the “2021 Summary Compensation Table” above.
34

TABLE OF CONTENTS

The marketevent the executive officer resigns for qualified and talented employees and executives“good reason” (each such term as defined in the San Francisco Bay Area where our offices are headquartered is highly competitive and we compete for talent with many companies that have significantly greater resources than we do. Accordingly, we believe the potential upside of equity compensation is a crucial component of any competitive executive compensation package we offer. In connection with our engagement of Aon, we began the process of evaluating the appropriateness and overall competitiveness of our Company-wide equity compensation guidelines, burn rate and the size of our equity plan share reserve.
In determining the form, size, frequency, and material terms of named executive officer equity awards in 2022 and beyond, our Compensation Committee expects to consider, among other factors, each executive officer’s role criticality relative to others at our company and the Company’s major strategic initiatives, company and individual performance, the equity awards provided to executive officers in similar roles of our peer companies, any outstanding contractual obligations toapplicable award equity to an executive officer, and the determination of our Compensation Committee, Chief Executive Officer, and compensation consultants of the essential need to retain these executive officers.
Benefits and Other Compensation
Health and Welfare Benefits
Other compensation to our executives consists primarily of the broad-based benefits we provide to all full-time employees in the United States, including medical and dental insurance, and a 401(k) plan.
Our tax-qualified 401(k) plan provides eligible employees with an opportunity to save for retirement on a tax-advantaged basis. Under our 401(k) plan, employees may elect to defer up to 100% of their eligible compensation subject to applicable annual limits set pursuant to the Internal Revenue Code. Our 401(k) plan permits participants to make both pre-tax and certain after-tax (Roth) deferral contributions. The retirement plan is intended to qualify under Section 401(a) of the Code. We match 50% of employees’ contributions to the 401(k) plan up to 3% of compensation. Employees are 100% vested in their contributions to the 401(k) plan, and a vesting schedule is applied to the company match.
Perquisites
Our compensation philosophy is generally not to provide significant perquisites to our named executive officers. However, we believe that Mr. Rezk’s presence in our Silicon Valley offices is critical to our culture and to the commercialization of our technology. As a result, Mr. Rezk, who is based in Virginia, received company-paid airfare, housing and living expense benefits from usagreement) in connection with his frequent business travel to our Silicon Valley offices. We believe the provision of such airfare and housing and living expenses is appropriate and necessary to our culture, the commercialization of our technology, and to assist himor 12 months after a change in the performance of his duties. His airfare, housing and other travel-based commuting benefits represented an aggregate payment during 2021 of $96,989.
Pension and Deferred Compensation Plans
We do not offer any defined benefit pension plans or nonqualified deferred compensation arrangements for our employees.control.
Director Compensation
OnIn September 26, 2022, ourthe Compensation Committee, comprised solely of independent directors, recommended to the Board adoptedfor approval a compensation planpolicy for non-employee Directors servingdirectors (the “Director Compensation Policy”) after consideration of market data and based on ourthe recommendation of its independent compensation consultant. Our Board (the “2022approved the Director Compensation Plan”) in order to attract and retain qualified individuals. We do not compensate our Chairperson or our CEO, each of whom is employed by us, for serving as directors. Prior to the adoptionPolicy was effective November 11, 2022. The Director Compensation Policy consists of the 2022 Director Compensation Plan, we did not compensate our non-employee directors for service on the Board.
The 2022 Director Compensation Plan provides for:following:
a $50,000 annual cash retainer;
an additional $10,000 cash retainer for service on each committee; and
$150,000 annual RSU grant with a grant date of the annual meeting and vesting on the first anniversary of the grant date (subject to continued service) or upon a change of control.
In addition, non-employee directors are reimbursed for reasonable out-of-pocket expenses.
3530

TABLE OF CONTENTS

Tax and Accounting Considerations
Deductibility of Executive Compensation
Generally, Section 162(m) of the Code (“Section 162(m)”) disallows a federal income tax deduction for public corporations of remuneration in excess of $1 million paid in any fiscal year to certain specified executive officers. Those executive officers generally consist of a public corporation’s chief executive officer, chief financial officer and up to three other executive officers whose compensation is required to be disclosed to stockholders under the Securities Exchange Act as amended, because they are our most highly-compensated executive officers, and certain former executive officers.
In designing our executive compensation program and determiningThe following table sets forth information concerning the compensation of our executive officers, including our named executive officers,non-employee directors during the Compensation Committee considers a variety of factors, including the potential impact of the Section 162(m) deduction limit. However, the Compensation Committee will not necessarily limit executive compensation to that which is or may be deductible under Section 162(m). The Compensation Committee will consider various alternatives to preserving the deductibility of compensation payments and benefits to the extent consistent with its compensation goals. The Compensation Committee believes that our stockholders’ interests are best served if its discretion and flexibility in awarding compensation is not restricted, even though some compensation awards may result in non-deductible compensation expense.year ended December 31, 2022.
Taxation of “Parachute” Payments
Sections 280G and 4999 of the Code provide that executive officers and directors who hold significant equity interests and certain other service providers may be subject to significant additional taxes if they receive payments or benefits in connection with a change in control of the company that exceeds certain prescribed limits, and that the company (or a successor) may forfeit a deduction on the amounts subject to this additional tax. We have not agreed to provide any executive officer, including any named executive officers, with a “gross-up” or other reimbursement payment for any tax liability that the executive officer might owe as a result of the application of Sections 280G or 4999 of the Code.
Section 409A of the Internal Revenue Code
Section 409A of the Code imposes additional significant taxes in the event that an executive officer, director or service provider receives “deferred compensation” that does not satisfy the requirements of Section 409A of the Code. Although we do not maintain a nonqualified deferred compensation plan, Section 409A of the Code may apply to certain severance arrangements, bonus arrangements and equity awards. We intend to structure all our severance arrangements, bonus arrangements and equity awards in a manner to either avoid the application of Section 409A or, to the extent doing so is not possible, to comply with the applicable requirements of Section 409A of the Code.
Accounting for Stock-Based Compensation
We follow the Financial Accounting Standards Board (“FASB”) ASC 718 for our stock-based compensation awards. FASB ASC 718 requires us to measure the compensation expense for all share-based payment awards made to our employees and non-employee members of our Board of Directors, including options to purchase shares of our common stock and other stock awards, based on the grant date “fair value” of these awards. This calculation is performed for accounting purposes and reported in the executive compensation tables required by the federal securities laws, even though the recipient of the awards may never realize any value from their awards.
Name
Fees
Earned or
Paid in Cash
($)
Stock Awards
($)
Total
($)
Shahin Farshchi
$11,000
$150,000
$161,000
Hrach Simonian
11,000
150,000
161,000
Erin L. Polek
8,200
150,000
158,200
Christopher Eberle
8,200
150,000
158,200
Stephen Zadesky
6,800
150,000
156,800
Compensation Risk Assessment
We believe that our executive compensation program does not encourage excessive or unnecessary risk taking. As described more fully above, we structure our pay to consist of both fixed and variable compensation, particularly in connection with our pay-for-performance compensation philosophy. We believe this structure motivates our executives to produce superior short- and long-term results that are in the best interests of our Company and stockholders in order to attain our ultimate objective of increasing stockholder value, and we have established, and our Compensation Committee endorses, several controls to address and mitigate compensation related risk. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on us.
3631

TABLE OF CONTENTS

REPORT OF THE COMPENSATION COMMITTEEPay versus Performance Information
The information contained in this report shall not be deemed to be (1) “soliciting material,” (2) “filed”In accordance with rules adopted by the SEC (3) subjectpursuant to Regulations 14A or 14C ofDodd-Frank, we are providing the Exchange Act, or (4) subject tofollowing disclosure regarding executive compensation for our principal executive officer (“PEO”) and Non-PEO named executive officers (“NEOs”) and Company performance for the liabilities of Section 18 of the Exchange Act. This report shall not be deemed incorporated by reference into any of our other filings under the Exchange Act or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.
fiscal years listed below. The Compensation Committee has reviewed and discusseddid not consider the Compensation Discussion and Analysis sectionpay versus performance disclosure below in making its pay decisions for any of this Proxy Statement with management. Based on the review and discussions,years shown.
Year
Summary Compensation Table Total for Soroush Salehian Dardashti1
($)
Compensation Actually Paid to Soroush Salehian Dardashti1,2,3
($)
Average Summary Compensation Table Total for Non-PEO NEOs1
($)
Average Compensation Actually Paid to Non-PEO NEOs1,2,3
($)
Value of Initial Fixed $100 Investment based on TSR4
($)
Net Income
($ Millions)
(a)
(b)
(c)
(d)
(e)
(f)
(g)
2022
1,056,300
(3,736,128)
1,496,649
(5,522,762)
9.35
(147)
2021
2,013,300
(7,334,216)
1,620,939
(10,655,305)
51.99
(102)
1.
Soroush Salehian Dardashti was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.
2021
2022
Mina Rezk
Mina Rezk
Saurabh Sinha
Saurabh Sinha
2.
The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.
3.
Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.
Year
Summary
Compensation
Table Total for
Soroush Salehian
Dardashti
($)
Exclusion of Stock
Awards and
Option Awards for
Soroush Salehian
Dardashti
($)
Inclusion of Equity
Values for Soroush
Salehian Dardashti
($)
Compensation
Actually Paid to
Soroush Salehian
Dardashti
($)
2022
1,056,300
(4,792,428)
(3,736,128)
2021
2,013,300
(9,347,516)
(7,334,216)
Year
Average
Summary
Compensation
Table Total for
Non-PEO NEOs
($)
Average Exclusion
of Stock Awards
and Option
Awards for
Non-PEO NEOs
($)
Average Inclusion
of Equity Values for
Non-PEO NEOs
($)
Average
Compensation
Actually Paid to
Non-PEO NEOs
($)
2022
1,496,649
(532,912)
(6,486,499)
(5,522,762)
2021
1,620,939
(12,276,244)
(10,655,305)
The amounts in the Compensation Committee recommended toInclusion of Equity Values in the Board of Directors thattables above are derived from the Compensation Discussion and Analysis section be includedamounts set forth in this Proxy Statement.the following tables:
THE COMPENSATION COMMITTEE
Year
Year-End
Fair Value
of Equity
Awards
Granted
During
Year That
Remained
Unvested
as of Last
Day of
Year for
Soroush
Salehian
Dardashti
($)
Change in Fair
Value from
Last Day of
Prior Year to
Last Day of
Year of
Unvested
Equity Awards
for Soroush
Salehian
Dardashti
($)
Vesting-Date
Fair Value of
Equity Awards
Granted
During Year
that Vested
During Year
for Soroush
Salehian
Dardashti
($)
Change in Fair
Value from
Last Day of
Prior Year to
Vesting Date of
Unvested
Equity Awards
that Vested
During Year
for Soroush
Salehian
Dardashti
($)
Total -
Inclusion of
Equity Values
for PEO 1
($)
2022
(2,997,317)
(1,795,111)
(4,792,428)
2021
(6,575,075)
(2,772,441)
(9,347,516)
Shahin Farshchi, Committee Chair
32
Hrach Simonian
Ahmed Fattouh
37

TABLE OF CONTENTS

Year
Average
Year-End
Fair Value
of Equity
Awards
Granted
During
Year That
Remained
Unvested
as of Last
Day of
Year for
Non-PEO
NEOs
($)
Average
Change in
Fair Value
from Last
Day of Prior
Year to Last
Day of Year
of Unvested
Equity
Awards for
Non-PEO
NEOs
($)
Average
Vesting-
Date Fair
Value of
Equity
Awards
Granted
During
Year that
Vested
During
Year for
Non-
PEO
NEOs
($)
Average
Change in
Fair Value
from Last
Day of Prior
Year to
Vesting
Date of
Unvested
Equity
Awards that
Vested
During
Year for
Non-PEO
NEOs
($)
Total - Average Inclusion
of Equity Values for Non-
PEO NEOs
($)
2022
134,187
(4,460,626)
104,645
(2,264,705)
(6,486,499)
2021
(8,977,360)
(3,298,884)
(12,276,244)
4.
The Company TSR assumes $100 was invested in the Company for the period starting December 31, 2020 through the end of the listed year. Historical stock performance is not necessarily indicative of future stock performance.
Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”)
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company’s cumulative TSR over the two most recently completed fiscal years.

33

TABLE OF CONTENTS

Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Net Income during the two most recently completed fiscal years.

34

TABLE OF CONTENTS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth information regarding the beneficial ownership of our common stock as of September 1, 2022October 19, 2023 by:
each person who is the beneficial owner of more than 5% of the outstanding shares of common stock;
each of the Company’s named executive officers and directors; and
all of the Company’s executive officers and directors as a group.
Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, which includes the power to dispose of or to direct the disposition of the security or has the right to acquire such powers within 60 days. In computing the number of shares of the Company’s common stock beneficially owned by a person or entity and the percentage ownership, the Company deemed outstanding shares of its common stock subject to options, warrants, and warrantsrestricted stock units held by that person or entity that are currently exercisable or exercisable, or will vest, as applicable, within 60 days of September 1, 2022.October 19, 2023. The Company did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person or entity.
Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the Company believes that the persons and entities named in the table have sole voting and investment power with respect to their beneficially owned common stock.
Unless otherwise noted, the address of each beneficial owner is c/o Aeva Technologies, Inc., 555 Ellis Street, Mountain View, California 94043.
We have based our calculation of the percentage of beneficial ownership on 217,993,803223,309,007 shares of our common stock outstanding as of September 1, 2022.October 19, 2023. The information provided below does not give effect to the Common Stock Financing Transactions, which occurred after October 19, 2023.
Name and Address of Beneficial Owners
Number of
Shares of
Common
Stock
Beneficially
Owned
Percentage of
Outstanding
Common Stock
5% Stockholders:
 
 
Entities affiliated with Sylebra Capital LTD(1)
27,101,533
12.4%
Canaan Partners XI LLC(2)
18,485,197
8.5%
Entities affiliated with Lux Ventures IV, L.P.(3)
16,651,687
7.6%
 
 
 
Directors and Named Executive Officers:
 
 
Soroush Salehian Dardashti(4)
27,440,307
12.4%
Mina Rezk(5)
51,017,737
22.8%
Saurabh Sinha(6)
465,940
*
Shahin Farshchi
19,407
*
Hrach Simonian
Erin Polek
Christopher Eberle
Stephen Zadesky
Ahmed Fattouh
Directors and executive officers as a group (9 individuals)
78,943,391
34.7%
Name and Address of Beneficial Owners
Number of
Shares of
Common
Stock
Beneficially
Owned
Percentage of
Outstanding
Common Stock
5% Stockholders:
 
 
Entities affiliated with Sylebra Capital LTD(1)
27,101,533
12.1%
Canaan Partners XI LLC(2)
18,485,196
8.3%
Entities affiliated with Lux Ventures IV, L.P.(3)
16,651,687
7.5%
The Vanguard Group(4)
11,394,956
5.1%
 
 
 
Directors and Named Executive Officers:
 
 
Soroush Salehian Dardashti(5)
27,866,172
12.3%
Mina Rezk(6)
52,188,212
22.7%
Saurabh Sinha(7)
761,954
*
Shahin Farshchi(8)
106,616
*
Hrach Simonian(9)
87,209
*
Stefan Sommer
Erin Polek(10)
87,209
*
Christopher Eberle(11)
87,209
*
Stephen Zadesky(12)
99,709
*
Directors and executive officers as a group (9 individuals)
81,284,290
34.6%
*
Indicates less than 1%
1)(1)
Solely based on information in a Form 13F13D/A jointly filed with the SEC on August 16, 2022June 22, 2023 by Sylebra, Sylebra Capital LTDManagement, Daniel Patrick Gibson and Sylebra Capital LLC, indicating itthey had soleshared voting and dispositive power for 27,101,533 shares of our common stock. Sylebra and Sylebra Capital LLC are the investment sub-advisers to certain advisory clients that directly hold shares of our common stock and Sylebra Capital Management is the investment manager and parent of Sylebra. Sylebra Capital Management owns 100% of the shares of Sylebra, and Mr. Gibson owns 100% of the Class A shares of Sylebra Capital Management and 100% of the share capital of Sylebra
35

TABLE OF CONTENTS

Capital LLC. Mr. Gibson is a founder and Chief Investment Officer of Sylebra Capital Management. The address for these beneficial owners is 20th Floor, 28 Hennessy Road, Wan Chai, Hong Kong. The amount shown does not reflect (i) 24,795,027 shares of common stock acquired by the Sylebra Purchasers from the Company on November 9, 2023 pursuant to the Subscription Agreement or (ii) any shares of common stock underlying shares of Facility Preferred Stock or the Sylebra Warrants that may be issued to the Sylebra Purchasers in the future pursuant to the Facility Agreement dated November 8, 2023. See “Certain Relationships and Related Transactions—Common Stock Financing Transactions” for more information.
2)(2)
Solely based on information in a Form 13F13D/A filed with the SEC on August 10, 2022December 20, 2021 by Canaan Partners XI LLC and Canaan Partners XI LLC, indicating it had sole voting and dispositive power for 18,485,19718,485,196 shares of our common stock.
3)(3)
Solely based on information in a Schedule 13D filed with the SEC on August 5,15, 2022 by Lux Venture Partners IV, LLC; Lux Ventures IV, L.P.; Lux Co-Invest Partners, LLC; and Lux Co-Invest Opportunities, L.P., The Schedule 13D indicates that asshared voting and dispositive power of August 1, 2022, Lux Ventures IV, L.P. directly owns 14,692,316 shares of our common stock and Lux Co-Invest Opportunities, L.P. directly ownshas shared and dispositive power of 1,959,371 shares of our common stock. The Schedule 13D indicates that Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC (the “Individual Lux Managers”). The Schedule 13D indicates that each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. The address for these entities and individuals is c/o Lux Capital Management, 920 Broadway, 11th Floor, New York, NY 10010.
38

TABLE OF CONTENTS

1,959,371 shares of our common stock. The Schedule 13D indicates that Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC (the “Individual Lux Managers”). The Schedule 13D indicates that each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. The address for these entities and individuals is c/o Lux Capital Management, 920 Broadway, 11th Floor, New York, NY 10010.
4)(4)
Solely based on information in a Schedule 13G filed with the SEC on February 9, 2023 by The Vanguard Group indicating it beneficially owned, with shared voting power of 72,374 shares, sole dispositive power of 11,248,710 shares and shared dispositive power of 146,246 shares. The address for The Vanguard Group is 100 Vanguard Blvd., Malvern PA 19355.
(5)
Interests shown consist of (a) 24,275,34023,824,040 shares of our common stock held by a trust for which Mr. Salehian serves as the trustee and (b) 3,164,9674,042,132 shares subject to optionsawards exercisable or vesting within 60 days of September 1, 2022.October 19, 2023.
5)(6)
Interests shown consist of (a) 45,133,34427,333,334 shares of our common stock held by a trust for which Mr. Rezk serves as the trustee, (b) 17,800,000 shares of our common stock are held by EAD Group, LLC, of which Mr. Rezk is the sole member and (b) 5,884,393(c) 7,054,878 shares subject to optionsawards exercisable or vesting within 60 days of September 1, 2022.October 19, 2023. All shares held by EAD Group, LLC have been pledged by Mr. Rezk.
6)(7)
Interests shown consist of (a) 183,191409,767 shares of our common stock held directly by Mr. Sinha and (b) 153,125352,187 shares subject to optionsawards exercisable or vesting within 60 days of September 1, 2022October 19, 2023.
(8)
Interests shown consist of (a) 19,407 shares of our common stock held directly by Mr. Shahin and (c) 129,624(b) 87,209 shares of our common stock underlying restricted stock units held directly by Mr. Shahin that will vest within 60 days of September 1, 2022.October 19, 2023.
(9)
Interests shown consist of 87,209 shares of our common stock underlying restricted stock units held directly by Mr. Simonian that will vest within 60 days of October 19, 2023.
(10)
Interests shown consist of 87,209 shares of our common stock underlying restricted stock units held directly by Ms. Polek that will vest within 60 days of October 19, 2023.
(11)
Interests shown consist of 87,209 shares of our common stock underlying restricted stock units held directly by Mr. Eberle that will vest within 60 days of October 19, 2023. These securities are held by Mr. Eberle for the benefit of Sylebra and/or one or more of certain of the affiliates of Sylebra. Mr. Eberle is obligated to transfer the underlying shares upon vesting and settlement of these restricted stock units or any proceeds from the sale thereof as directed by Sylebra and, therefore, Sylebra may be deemed to beneficially own these securities. Mr. Eberle is the Global Head of Semiconductor and Hardware Investments at Sylebra. Mr. Eberle disclaims beneficial ownership of the securities beneficially owned by Sylebra and its affiliated entities, including the restricted stock units discussed in this footnote (11) and those discussed in footnote (1) above.
(12)
Interests shown consist of (a) 12,500 shares of our common stock held directly by Mr. Zadesky and (b) 87,209 shares of our common stock underlying restricted stock units held directly by Mr. Zadesky that will vest within 60 days of October 19, 2023.
3936

TABLE OF CONTENTS

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Certain RelationshipsThe following is a description of the transactions and Relatedseries of similar transactions, since January 1, 2022, that we were a participant or will be a participant in, which:
the amount involved exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years; and
any of our directors, executive officers, holders of more than 5% of our capital stock or any member of their immediate family had or will have a direct or indirect material interest, other than compensation arrangements with directors and executive officers.
Common Stock Financing Transactions
On November 8, 2023 we entered into a series of transactions with certain entities affiliated with Sylebra, a significant stockholder of the Company, as described below. We refer to these transactions collectively as the “Common Stock Financing Transactions.” The Common Stock Financing Transactions, and each agreement in connection therewith was approved by our Audit Committee, in accordance with our Related Person Transaction Policy.
Subscription Agreement
We entered into a subscription agreement (the “Subscription Agreement”) providing for the purchase of an aggregate of 24,795,027 shares of common stock by entities affiliated with Sylebra, a significant stockholder of the Company (the “Sylebra Purchasers”), at a price of $0.58 per share, or a total purchase price of approximately $14.4 million. We also entered into a substantially similar subscription agreement with Adage Capital Management, which prior to such transaction was not a significant stockholder of the Company, to purchase 12,007,272 shares of common stock for a total purchase price of approximately $7 million.
Facility Agreement and Facility Preferred Stock
We entered into a Standby Equity Purchase Agreement (the “Facility Agreement”) with the Sylebra Purchasers. Pursuant to the Facility Agreement, we have the right, but not the obligation, to sell to the Sylebra Purchasers up to $125.0 million worth of shares of our preferred stock (the “Facility Preferred Stock”), at our request until November 8, 2026, upon the satisfaction of certain conditions described below. Each sale we request under the Facility Agreement (each, an “Advance” and collectively, the “Advances”) may be for a number of shares of Facility Preferred Stock with an aggregate value of at least $25.0 million but not more than $50.0 million (except with the consent of the Sylebra Purchasers).
The rights, preferences and privileges of the Facility Preferred Stock will be set out in a certificate of designation. When and if issued, the Facility Preferred Stock will be issued at a price per share of $10,000. Holders of Facility Preferred Stock will be entitled to a quarterly dividend at the rate of 7.0% per annum payable in cash or in kind at our option. The Facility Preferred Stock will have an initial liquidation preference of 120% of the issuance price, plus accrued dividends. The Facility Preferred Stock will have no voting rights as a class or series except in such instances as required by Delaware law or certain matters enumerated in the certificate of designations related to the protection of the Facility Preferred Stock.
The Facility Preferred Stock will be convertible at the option of the holders into a number of shares of common stock equal to $10,000 divided by the then-applicable conversion price, which will be equal to the lesser of (i) the average five day closing price from the date of Advance, or (ii) the closing price per share of common stock on the date of each Advance subject to certain customary anti-dilution adjustments. At any time after the two year anniversary of any issuance of any series of Facility Preferred Stock, we will have the option to convert all (but not less than all) of any series of then-outstanding Facility Preferred Stock by paying a make-whole payment, in either stock or cash, equal to three years of dividends, provided that the closing price of the common stock exceeds 250% of the then-applicable conversion price for at least 20 out of 30 consecutive trading days prior to the date of conversion. To the extent, if any, a conversion would result any the holder thereof becoming the beneficial owner of more than 19.9% of the outstanding common stock, we will issue such investor a warrant (the “Pre-Funded Warrant”). The Facility Preferred Stock will be subject to customary pre-emptive rights.
Our right to request Advances is conditioned upon our achieving a minimum of one new passenger auto-OEM or commercial OEM program award with at least a 50,000 unit volume, the trading price of the common stock being
37

TABLE OF CONTENTS

below $3.00 at the time of the Advance request and other customary conditions. Prior to any Advance, we will assess our capital needs and other factors, including the impact of an Advance on any outstanding executive pledge arrangements.
Pursuant to the Facility Agreement, we agreed to pay Sylebra a facility fee in the amount of $2.5 million, an origination fee in the amount of $0.63 million and an administrative fee in the amount of $0.3 million and to reimburse Sylebra for its reasonable fees and expenses in connection with the Facility Agreement in an amount not to exceed $0.4 million. In addition, upon receipt of stockholder approval, we are required to issue to the Sylebra Purchasers a Series A Warrant to purchase 15,000,000 shares of common stock at an exercise price of $1.00 per share.
Registration Rights Agreement
We entered into a registration rights agreement with the Sylebra Purchasers that provides for certain customary registration rights with respect to the Facility Preferred Stock, the Series A Warrant, the Pre-Funded Warrant and the shares of common stock issued upon any future conversion thereof.
Sylebra Stockholders Agreement
We entered into a shareholder agreement (the “Sylebra Stockholders Agreement”) with Sylebra, whereby for as long as Sylebra and its affiliates beneficially own at least (i) 9.0% of our outstanding common stock (on an as converted basis), Sylebra will have the right to nominate one director, who will initially be Christopher Eberle, Global Head of Semiconductor and Hardware Investments at Sylebra, and (ii) 14.0% of our outstanding common stock (on an as converted basis), Sylebra will have the right to nominate an additional director, who shall be an automotive executive or relevant industry expert. Sylebra has waived its right to designate such additional director until the election of the Class I directors in 2025.
Letter Agreement with Sylebra
On September 27, 2022, we entered into a letter agreement (the “Sylebra Letter Agreement”) with Sylebra. Among other things, the Sylebra Letter Agreement provides that: (i) Mr. Eberle be appointed as a Class III director with a term expiring at the Company’s 2024 Annual Meeting and (ii) Sylebra and its Associates (as defined in Rule 12b-2 promulgated under the Exchange Act) will abide by certain customary standstill provisions, until such time as Sylebra owns less than 9.0% of our outstanding common stock and we request that Mr. Eberle resign from the Board of Directors (the “Restricted Period”). During the Restricted Period, no member of the Sylebra Group will, and Sylebra will cause the Representatives (as defined in the Sylebra Letter Agreement) of each member of the Sylebra Group not to, in any way, directly or indirectly without the prior consent of the Board:
(a)
with respect to Company or the Voting Securities (as defined below), (i) initiate, make participate in or encourage any “solicitation” (as such term is used in Regulation 14A (the “Proxy Rules”) promulgated under the Exchange Act) of proxies or consents with respect to the election or removal of directors or any other matter or proposal; (ii) become a “participant” (as such term is used in the Proxy Rules) in any such solicitation of proxies or consents with respect to any stockholder meeting of Company; or (iii) seek to advise, encourage or influence any Person with respect to the voting or disposition of any Voting Securities;
(b)
initiate, propose or otherwise “solicit” (as such term is used in the Proxy Rules) Company’s stockholders to approve any shareholder proposal, whether made pursuant to Rule 14a-4 or Rule 14a-8 of the Proxy Rules or otherwise, or cause or encourage any Person to initiate or submit any such shareholder proposal;
(c)
(i) seek, alone or in concert with others, election or appointment to, or representation on, the Board; (ii) nominate or propose the nomination of, or recommend the nomination of, or encourage any Person to nominate or propose the nomination of or recommend the nomination of, any candidate to the Board; or (iii) seek, alone or in concert with others, or encourage any Person to seek, the removal of any member of the Board;
(d)
other than solely with other members of the Sylebra Group with respect to Voting Securities now or subsequently owned by them, (i) form, join (whether or not in writing), encourage, influence, advise or participate in a partnership, limited partnership, syndicate or other group, including a “group” as defined pursuant to Section 13(d) of the Exchange Act, with respect to any Voting Securities; (ii) deposit any Voting Securities into a voting trust, arrangement or agreement; (iii) subject any Voting Securities to any voting trust, arrangement or agreement; and (iv) acquire, directly or indirectly, beneficial ownership of Voting Securities equal to or greater than 15.0% of the Company’s total outstanding shares of common stock.
38

TABLE OF CONTENTS

(e)
(i) make any unsolicited offer or proposal (with or without conditions) with respect to any merger, acquisition, recapitalization, restructuring, disposition or other business combination involving any member of the Sylebra Group and Company; or (ii) solicit a third party to, on an unsolicited basis, make an offer or proposal (with or without conditions) with respect to any merger, acquisition, recapitalization, restructuring, disposition or other business combination involving Company, or publicly encourage, initiate or support any third party in making such an unsolicited offer or proposal; or
(f)
other than with any other member of the Sylebra Group, enter into any agreements, understandings or arrangements (whether written or oral) with, or advise, finance, assist or encourage, any Person in connection with any of the foregoing.
In connection with Sylebra common stock financing transactions described above, on November 6, 2023, notwithstanding the terms of the Sylebra Letter Agreement, the Board consented to the beneficial ownership or acquisition by Sylebra of Voting Securities up to 19.9% of the Company’s total outstanding shares of common stock.
For purposes of the Sylebra Letter Agreement, “Voting Securities” means the shares of common stock and any other securities of the Company entitled to vote in the election of directors, or securities convertible into, or exercisable or exchangeable for, such shares or other securities.
2021 Stockholders Agreement
On March 12, 2021, Aeva, Inc. consummated (the “Closing”) a business combination with InterPrivate Acquisition Corp. (the Company’s predecessor, which was originally incorporated in Delaware as a special purpose acquisition company (“InterPrivate”)). In connection with the Closing, InterPrivate, InterPrivate Acquisition Management LLC and certain stockholders of the Company entered into a Stockholders Agreement, dated March 12, 2021 (the “2021 Stockholders Agreement”), to provide for certain governance matters relating to the Company.
Pursuant to the terms of the 2021 Stockholders Agreement, the size of the Board of Directors was set at seven members and initially consisted of five directors, with two vacancies. The 2021 Stockholders Agreement provides Messrs. Dardashti and Rezk with the right to appoint an Audit Committee Qualified Director whom will be subject to the approval of the remaining members of the Board of Directors.
Subject to the rules of the NYSE, from and after March 12, 2021, each of Mr. Rezk and Mr. Dardashti is entitled to nominate himself to continue to serve on the Board of Directors until such time as he holds less than 5% of our outstanding common stock (or his earlier death or incapacity), and we will include such nominees in our Proxy Materials for each applicable meeting of stockholders and, subject to applicable law and the exercise of fiduciary duties, recommend to our stockholders that each such nominee be elected at such meeting. Mr. Rezk will serve as Chairman of the Board of Directors for so long as he is a director. In the event Mr. Rezk is no longer a director, then Mr. Salehian will serve as the Chairman of the Board of Directors so long as he is a director.
Advisory Agreement
Prior to his appointment on the Board, Mr. Zadesky served on the Company’s Board of Advisors. For his service on the Board of Advisors, the Company granted Mr. Zadesky an equity award of 100,000 RSUs.
Amended and Restated Registration Rights Agreement
On March 12, 2021, the Company, certain of our stockholders affiliated with InterPrivate LLC (the “Sponsor Holders”), of InterPrivate and certain stockholders of Legacy Aeva (together with the Sponsor Holders, the “Holders”) entered into an Amended and Restated Registration Rights Agreement (the “Registration Rights and Lock-Up Agreement”).
Pursuant to the terms of the Registration Rights and Lock-Up Agreement, we are obligated to file a registration statement to register the resale of certain of our securities held by the Holders. In addition, subject to certain requirements and customary conditions, including with regard to the number of demand rights that may be exercised, the Holders may demand at any time or from time to time, to sell all or any portion of their registrable securities in an underwritten offering so long as the total offering price is reasonably expected to exceed $30 million. The Registration Rights and Lock-Up Agreement also provides the Holders with “piggy-back” registration rights, subject to certain requirements and customary conditions.
Stockholders Agreement
InterPrivate Acquisition Corp., InterPrivate Acquisition Management LLC and certain stockholders of the Company entered into a Stockholders Agreement, dated March 12, 2021 (the “Stockholders Agreement”), to provide for certain governance matters relating to the Company.
Pursuant to the terms of the Stockholders Agreement, the initial size of the Board of Directors was set at seven members and initially consisted of five directors, with two vacancies. We refer to this as the “Initial Board.” At least three of the independent directors met the independence requirements under Rule 10A-3 promulgated under the Exchange Act with respect to service on the Audit Committee of the Board of Directors. We refer to each of these directors as an “Audit Committee Qualified Director.” The Initial Board consisted of: (i) the Audit Committee Qualified Director designated by the InterPrivate Acquisition Management LLC (the “IPV Director”), Ahmed M. Fattouh, designated a Class I director; (ii) the independent director designated by Lux (the “Lux Director”), Shahin Farshchi and (iii) the Audit Committee Qualified Director designated by Canaan (the “Canaan Director”), Hrach Simonian, designated the Class II directors; and (iv) Mr. Dardashti and (v) Mr. Rezk, designated Class III directors.
Subject to the rules of the NYSE, from and after March 12, 2021, each of Soroush Salehian Dardashti and Mina Rezk is entitled to nominate himself to continue to serve on the Board until such time as he holds less than 5% of our outstanding common stock (or his earlier death or incapacity), and we will include such nominees in our proxy materials for each applicable meeting of stockholders and, subject to applicable law and the exercise of fiduciary duties, recommend to our stockholders that each such nominee be elected at such meeting. Mr. Rezk will serve as Chairman of the Board of Directors for so long as he is a director. In the event Mr. Rezk is no longer a director, then Mr. Salehian will serve as the Chairman of the Board of Directors so long as he is a director.
Sylebra Letter Agreement
On September 27, 2022, we entered into a letter agreement (the “Sylebra Letter Agreement”) with Sylebra HK Company Limited (“Sylebra”), one of our significant stockholders, and Mr. Eberle. Among other things, in connection with the Sylebra Letter Agreement, (i) we increased the size of the Board from seven directors to nine directors, and (ii) we appointed Mr. Eberle to serve as a director with a term expiring at our 2024 annual meeting of stockholders. The Sylebra Letter Agreement further provides that Sylebra and its Associates (as defined in Rule 12b-2 promulgated under the Exchange Act) will abide by certain customary standstill provisions, lasting from the date of the Sylebra Letter Agreement until the termination of the Sylebra Letter Agreement. Other than as described herein, there are no arrangements or understandings between Mr. Eberle, on the one hand, and us or any other persons, on the other hand, pursuant to which Mr. Eberle was selected as a director.
Indemnification Agreements
The Company has entered into separate indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in the Second Amended and Restatedour Certificate of Incorporation and the Amended and Restated By-laws. These agreements, among other things, will require the Company to indemnify
4039

TABLE OF CONTENTS

These agreements, among other things, will require the Company to indemnify our directors and executive officers for certain expenses, including attorneys; fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of the Company’s directors or executive officers or as a director or executive officer of any other company or enterprise to which the person provides services at the Company’s request. The Company believes that these charter provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.
The limitation of liability and indemnification provisions in the Second Amended and Restatedour Certificate of Incorporation and the Amended and Restated By-laws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit the Company and its stockholders. A stockholder’s investment may decline in value to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
Advisory Agreement
Prior to his appointment on the Board, Mr. Zadesky served on the Company’s Board of Advisors. For his service on the Board of Advisors, the Company granted Mr. Zadesky an equity award of 100,000 RSUs.
Related Person Transaction Policy
The Board of Directors of the Company has adopted a written Related Person Transaction Policy that sets forth the policies and procedures regarding the identification, review, consideration and oversight of “related person transactions.” A “related person transaction” is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which Aeva or any of its subsidiaries are participants involving an amount that exceeds $120,000, in which any “related person” has a material interest.
Transactions involving compensation for services provided to the Company as an employee, consultant or director will not be considered related person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than 5% of any class of the Company’s voting securities, including any of their immediate family members and affiliates, including entities owned or controlled by such persons.
Under the policy, the related person in question or, in the case of transactions with a holder of more than 5% of any class of the Company’s voting securities, an officer with knowledge of a proposed transaction, must present information regarding the proposed related person transaction to the Company’s Audit Committee (or, where review by the Company’s Audit Committee would be inappropriate, to another independent body of the Board of Directors) for review. To identify related person transactions in advance, the Company will rely on information supplied by the Company’s executive officers, directors and certain significant stockholders. In considering related person transactions, the Company’s Audit Committee will take into account the relevant available facts and circumstances, which may include, but are not limited to:
the risks, costs, and benefits to the Company;
the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;
the terms of the transaction;
the availability of other sources for comparable services or products; and
the terms available to or from, as the case may be, unrelated third parties.
The Company’s Audit Committee will approve only those transactions that it determines are fair to us and in Company’s best interests. All of the transactions described above were entered into prior to the adoption of such policy.
4140

TABLE OF CONTENTS

GENERAL INFORMATION ABOUT THE ANNUAL MEETING
AND FREQUENTLY ASKED QUESTIONS
Voting Instructions and Information
How do I attend the Annual Meeting?
We will be hosting the 20222023 Annual Meeting live via the internet on NovemberDecember 18, 20222023 at 10:00 a.m. (Pacific time). You will be able to attend the 20222023 Annual Meeting, vote your shares electronically and submit your questions during the meeting via live webcast by visiting www.virtualshareholdermeeting.com/AEVA2022AEVA2023. You will be able to attend the 20222023 Annual Meeting from any location with internet connectivity. You will not be able to attend the 20222023 Annual Meeting in person.
Appointing a proxy in response to this solicitation will not affect your right to attend the 20222023 Annual Meeting and to vote during the 20222023 Annual Meeting. Please note that if you hold your common stock in “street name” (that is, through a broker, bank or other nominee), you will receive instructions from your broker, bank or other nominee that you must follow in order to have your shares of common stock voted.
Stockholders may submit questions and comments before and during the meeting. During the meeting, we will spend up to 15 minutes answering stockholder questions that comply with the meeting rules of procedure. The rules of procedure will be posted on the virtual meeting web portal. To the extent time doesn’t allow us to answer all of the appropriately submitted questions, we will answer them in writing on the Investor Relationsinvestor relations page on our website at https://investors.aeva.com/overview/default.aspx, soon after the meeting. If we receive substantially similar questions, we will group such questions together and provide a single response to avoid repetition.
The Annual Meeting webcast will begin promptly at 10:00 a.m. (Pacific time). We encourage you to access the meeting webcast prior to the start time. Online check-in will begin, and stockholders may begin submitting written questions, at 9:45 a.m. (Pacific time), and you should allow ample time for the check-in procedures.
What matters will be presented?
We are not aware of any matters to be presented at the Annual Meeting other than those described in this Proxy Statement. If any matters not described in this Proxy Statement are properly presented at the meeting, then proxies will use their own judgment to determine how to vote your shares. If the meeting is adjourned or postponed, then proxies can vote your shares at the adjournment or postponement as well.
Are all of the Company’s directors standing for election at the 20222023 Annual Meeting?
No, only the Board-nominated Class I director isII directors are standing for election at this time. Our Class II directors will stand for election at the 2023 Annual Meeting and our Class III directors will stand for election at the 2024 Annual Meeting.
Why is the 2022 Annual Meeting being held online?
Due to the ongoing public health impact of the COVID-19 pandemic, and to support the health and well-being of our stockholders and other participantsClass I director(s) will stand for election at the 2025 Annual Meeting, this year the Annual Meeting will be a virtual meeting of stockholders held via a live webcast. The virtual meeting will provide the same rights and advantages of a physical meeting. Stockholders will be able to present questions online during the meeting, providing our stockholders with the opportunity for meaningful engagement with the Company.Meeting.
How do stockholders participate in the virtual meeting?
To participate in the meeting, you must have the 16-digit number that is shown on your Notice of Internet Availability of Proxy Materials or on your proxy card if you elected to receive proxy materials by mail.or voter instruction form. You may access the Annual Meeting by visiting www.virtualshareholdermeeting.com/AEVA2022AEVA2023. We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual meeting or submitting questions. If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the virtual meeting log in page.
Will stockholders be able to participate in the virtual meeting on the same basis stockholders would be able to participate in an in-person annual meeting?
The virtual meeting format for the Annual Meeting will enable full and equal participation by all our stockholders from any place in the world that has internet connection at little to no cost, while protecting the health and well-being of our stockholders and other participants at the Annual Meeting.
4241

TABLE OF CONTENTS

We designed the format of the virtual meeting to ensure that stockholders who attend our Annual Meeting will be afforded the same rights and opportunities to participate as they would at an in-person meeting and to enhance shareholder access, participation and communication through online tools. We will take the following steps to ensure such an experience:
providing stockholders with the ability to submit appropriate questions in advance of the meeting to ensure thoughtful responses from management and the Board;
providing stockholders with the ability to submit appropriate questions real-time via the meeting website; and
answering as many questions submitted in accordance with the meeting rules of conduct as possible in the time allotted for the meeting without discrimination.
What stockholders are entitled to vote?
You may vote if you owned shares of our common stock as of September 26, 2022,October 19, 2023, which is the record date for the Annual Meeting. You are entitled to one vote on each matter presented at the Annual Meeting for each share of common stock that you owned on that date. As of September 1, 2022,October 19, 2023, we had 217,993,803223,309,007 shares of common stock outstanding.
What is the difference between holding shares as a stockholder of record and as a beneficial owner?
As summarized below, there are some distinctions between shares held of record and those owned beneficially.
Stockholder of Record. If your shares are registered directly in your name with our transfer agent, Continental Stock Transfer & Trust Company, you are considered to be the stockholder of record with respect to those shares, and we have sent the Notice of Internet AvailabilityProxy Materials directly to you. As a stockholder of record, you have the right to grant your voting proxy directly to us or to vote during the live webcast of the Annual Meeting.
Beneficial Owner Stockholders. If your shares are held in a stock brokerage account or by a bank or other intermediary, you are considered to be the beneficial owner of shares held in “street name,” and the Notice of Internet Availability has beenProxy Materials will be forwarded to you by your bank, broker, or intermediary (which is considered to be the stockholder of record with respect to those shares). As a beneficial owner, you have the right to direct your bank, broker, or intermediary on how to vote. Your bank, broker, or intermediary has sent you a voting instruction card for you to use in directing the bank, broker, or intermediary regarding how to vote your shares. However, since you are not the stockholder of record, you may not vote these shares during the live webcast of the Annual Meeting.
Who will tabulate the votes?
Broadridge Financial Solutions will tabulate the votes and an independent third party will serve as Inspector of Elections.
How do I vote?
If you plan to attend the Annual Meeting, you may vote and submit questions while attending the meeting via live webcast. You will need the 16-digit number included on your Notice of Availability or your proxy card (if you received a printed copy of the proxy materials)or voter instruction form in order to be able to enter the meeting. Shares held in your name as the stockholder of record may be voted by you, while the polls remain open, at www.virtualshareholdermeeting.com/AEVA2022AEVA2023 during the meeting.
If your common stock is held in your name, there are three ways for you to vote by proxy:
If you received a paper copy of the proxy materialsProxy Materials by mail, mail the completed proxy card in the enclosed return envelope;
Call 1 800-690-6903; or
Log on to the internet at www.proxyvote.com and follow the instructions at that site. The website address for internet voting is also provided on your Notice of Availability.proxy card.
43

TABLE OF CONTENTS

Telephone and internet proxy voting will close at 11:59 p.m. (Eastern time) on NovemberDecember 17, 20222023 (although you may also vote live at the Annual Meeting). Proxies submitted by mail must be received prior to the meeting. Unless you indicate otherwise on your proxy card, the persons named as your proxies will vote your common stock:
FORstock in accordance with the nominee for director named in this Proxy Statement; andrecommendations of the Board.
FOR the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for 2022.42

TABLE OF CONTENTS

If your common stock is held in the name of your broker, bank or other nominee, then you should receive separate instructions from the holder of your common stock describing how to vote your common stock.
Even if you plan to attend the Annual Meeting via live webcast, we recommend that you vote your common stock in advance as described above so that your vote will be counted if you later decide not to participate in the virtual Annual Meeting.
What happens if I do not vote? What is the effect of broker non-votes?
If you are a stockholder of record, then your shares will not be voted if you do not provide your proxy, unless you attend the live webcast and vote online during the Annual Meeting.
If (i) you are the beneficial owner of shares held in the name of a broker, trustee or other nominee, (ii) you do not provide that broker, trustee or other nominee with voting instructions, (iii) such person does not have discretionary authority to vote on such proposal, and (iv) you do not attend the live webcast and vote online during the Annual Meeting, then a “broker non-vote” will occur. Under the rules governing banks and brokers who submit a proxy card with respect to shares held in street name, such banks and brokers have the discretion to vote on routine matters, but not on non-routine matters. OurWe expect each of Proposal 2 (ratify the appointment of our independent registered public accounting firm for 2022) is2023) and Proposal 3 (approve an amendment to our Certificate of Incorporation to effect the only proposal in this Proxy Statement that isReverse Stock Split) will be considered a routine matter. Thematter under NYSE rules. We expect the other proposals arewill not be considered routine matters under NYSE rules, and without your instructions, your broker cannot vote your shares. For all other proposals,Proposal 1 (election of Class II directors), broker non-votes are not considered “present,” and as such, broker non-votes will not affect the outcome of any such other proposals.proposal. Broker non-votes will have the same effect as votes “AGAINST” Proposal 4 (approval of certain security issuances for purposes of complying with NYSE rules).
How is a quorum determined?
Holders of a majority in voting power of the stock entitled to vote at the Annual Meeting must be present or represented by proxy to constitute a quorum for the transaction of business at the Annual Meeting. Shares that vote with respect to at least one proposal to be considered at the Annual Meeting, votes to “WITHHOLD” authority on the election of directors, and votes to “ABSTAIN,” broker votes and broker non-votes (only when accompanied by broker votes with respect to at least one matter at the meeting) are counted as present and entitled to vote for purposes of determining a meeting quorum. No business may be conducted at the Annual Meeting if a quorum is not present. Stockholders attending the Annual Meeting through the live webcast will be considered present for the purposes of determining a meeting quorum. If a quorum is not present by attendance at the Annual Meeting or represented by proxy, the stockholders present by attendance at the meeting or by proxy may adjourn the meeting, until a quorum is present. If a new record date is fixed for the adjourned meeting, we will provide notice of the adjourned meeting to each stockholder of record entitled to vote at the meeting.
What vote levels are required to pass an item of business?
Proposal
 
Vote Required
Broker
Discretionary
Voting
Allowed
Proposal 1
Election of Class I DirectorII Directors
Plurality of Votes Cast for
each Director Nominee
No
Proposal 2
Ratification of Appointment of Independent Registered Public Accounting Firm
Majority of Votes Cast
Yes
Proposal 3
Approval theof Reverse Stock Split Amendment to our 2021 Incentive Award PlanCertificate of Incorporation to Provide the Board of Directors with Discretion to Effect a Reverse Stock Split
Majority of Votes CastEntitled to Vote Thereon
NoYes
Proposal 4
Approval our Employee Stock Purchase Planof Certain Security Issuances for Purposes of Complying with NYSE Rules
Majority of Votes Cast
No
4443

TABLE OF CONTENTS

Proposal
Vote Required
Broker
Discretionary
Voting
Allowed
Proposal 5
Advisory (non-binding) vote to approve the compensation of our named executive officers;
Majority of Votes Cast
No
Proposal 6
Advisory (non-binding) vote on the frequency of future advisory votes on executive compensation;
Majority of Votes Cast
No
With respect to Proposal 1, you may vote “FOR” or “WITHHOLD”.“WITHHOLD.” Only votes cast “FOR“FOR” will be counted in the election of directors. Votes cast to “WITHHOLD” will result in the nomineenominees receiving fewer votes but will not count as a vote against the nominee. Thenominees. A maximum of two directors will be elected at the meeting and, therefore, the two individuals who receive the largest number of votes arewill be elected as directors up to the maximum number of directors to be elected at the meeting.directors. This means that the nomineetwo nominees receiving the highest number of votes at the Annual Meeting will be elected, even if these votes do not constitute a majority of the votes cast.
With respect to Proposals 2-62, 3 and 4 you may vote “FOR,” “AGAINST” or “ABSTAIN.”
If you abstain from voting on this matter, your shares will be counted as present and entitled to vote on that matter for purposes of establishing a quorum, but will not be counted for purposes of determining the number of votes cast.
We expect each of Proposal 2 (ratify the appointment of our independent registered public accounting firm for 2022) is2023) and Proposal 3 (approve an amendment to our Certificate of Incorporation to provide the only proposal on whichBoard of Directors with discretion to effect the Reverse Stock Split) will be considered a routine matter under NYSE rules. We expect the other proposals will not be considered routine matters under NYSE rules, and without your instructions, your broker is entitled tocannot vote your sharesshares. The Board reserves the right to withdraw Proposal No. 4 and, if no instructions are received from you.such proposal is withdrawn, all references in this Proxy Statement and any related proxy materials to voting for Proposal No. 4 should be disregarded.
What are the Board'sBoard’s voting recommendations?
FOR election of our Board-nominated slate of directors (see Proposal 1);
FOR the ratification of the appointment of Deloitte & Touche LLP, an independent registered public accounting firm, to be the auditors of our annual financial statements for the fiscal year ending December 31, 20222023 (see Proposal 2).;
FORthe approval of the amendmentReverse Stock Split Amendment to our 2021 Incentive Award PlanCertificate of Incorporation to provide the Board of Directors with the right to decide at its discretion to effect the Reverse Stock Split with the exact ratio and effective time of the Reverse Stock Split, if any, to be determined by our Board of Directors at any time within one year of the date of the 2023 Annual Meeting (see Proposal 3); and
FORthe approval our Employeeof certain security issuances for purposes of complying with New York Stock Purchase PlanExchange rules (see Proposal 4);
FOR the approval of the advisory (non-binding) vote to approve the compensation of our named executive officers (see Proposal 5);
FOR the frequency of the advisory (non-binding) vote to approve the compensation of our named executive officers by held every three years (see Proposal 6).
Unless you give other instructions on your proxy card, the persons named as proxies on the proxy card will vote in accordance with the recommendations of the Board.
Where can I find the voting results?
Preliminary voting results will be announced at the 20222023 Annual Meeting, and final voting results will be reported in a Current Report on Form 8-K, which we will file with the SEC within four business days following the Annual Meeting.
How can I revoke my proxy?
You can revoke your proxy if your common stock is held in your name by:
Filing written notice of revocation before our Annual Meeting with our Vice Presidenthead of Legallegal at 555 Ellis Street, Mountain View, California 94043;
Signing a proxy bearing a later date and delivering it before our Annual Meeting; or
Attending the live webcast and voting online during the Annual Meeting.
If your common stock is held in the name of your broker, bank or other nominee, please follow the voting instructions provided by the holder of your common stock regarding how to revoke your proxy.
45

TABLE OF CONTENTS

What are the costs of proxy solicitations?
Our Board solicits proxies on our behalf, and we will bear the expense of preparing, printing and mailing this Proxy Statement and the proxies we solicit. Proxies may be solicited by mail, telephone, personal contact and electronic means and may also be solicited by directors and officers in person, by the internet, by telephone or by facsimile transmission, without additional remuneration.
44

TABLE OF CONTENTS

We will also request brokerage firms, banks, nominees, custodians and fiduciaries to forward proxy materialsProxy Materials to the beneficial owners of shares of our stock as of the record date and will reimburse them for the cost of forwarding the proxy materialsProxy Materials in accordance with customary practice. Your cooperation in promptly voting your shares and submitting your proxy by the internet or telephone, or by completing and returning the enclosed proxy card (if you received your proxy materialsProxy Materials in the mail), will help to avoid additional expense.
Where you can find our corporate governance materials?
Current copies of our Board’s Corporate Governance Guidelines, Code of Business Conduct and Ethics, and the charters for the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee are published in the Governance Documents section of the Investor Relationsinvestor relations page on our website at https://investors.aeva.com/governance/governance-documents/default.aspx. We are not, however, including the other information contained on or available through our website as a part of, or incorporating such information by reference into, this Proxy Statement.
Additional Information
On November 27, 2023, a complaint was filed in the Delaware Court of Chancery by a purported stockholder against the Company and its directors, captioned Wallace v. Salehian et al., C.A. No. 2023-1187 (Del. Ch.). The complaint asserts claims including breach of fiduciary duty with respect to Proposal 4 and demands further disclosure with respect to Proposal 4. The complaint seeks to, among other things, enjoin the stockholder vote on Proposal 4 pending further disclosure.
Elimination of Paper and Duplicative Materials
Internet availability
Pursuant to rules adopted by the SEC, we are providing access to our proxy materials over the internet. Accordingly, we sent a Notice of Internet Availability of Proxy Materials (the “Notice”) to our stockholders. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice.
Important Notice: Our 2022 Proxy Statement and Annual Report on Form 10-K for the fiscal year ended December 31, 2021 are available free of charge on our investor relations website at https://investors.aeva.com/. We will provide by mail, without charge, a copy of our Annual Report on Form 10-K at your request. Please direct all inquiries to our Investor Relations Department at Aeva Technologies, Inc., at 555 Ellis Street, Mountain View, California 94043, or by email at investors@aeva.ai.
Householding
Householding permits us to mail a single set of proxy materialsProxy Materials to any household in which two or more different stockholders reside and are members of the same household or in which one stockholder has multiple accounts. If we household materials for future meetings, then only one copy of our Annual Report on Form 10-K and Proxy Statementproxy statement will be sent to multiple stockholders who share the same address and last name, unless we have received contrary instructions from one or more of those stockholders. In addition, we have been notified that certain intermediaries (i.e., brokers, banks or other nominees) will household proxy materialsProxy Materials for the Annual Meeting. If you wish to receive a separate copy of the Annual Report on Form 10-K and Proxy Statementproxy statement or of future annual reports and proxy statements, then you may contact our Investor Relations Departmentinvestor relations department by (i) mail at Aeva Technologies, Inc., Attention: Investor Relations, 555 Ellis Street, Mountain View, California 94043, or (ii) e-mail at investors@aeva.ai. You can also contact your broker, bank or other nominee to make a similar request. If we did not household your proxy materialsProxy Materials for the 20222023 Annual Meeting but you would like us to do so in the future, please contact our Investor Relations Departmentinvestor relations department by mail, telephone or email as listed above.
Incorporation by Reference
The Audit Committee Report and the disclosure under the heading of “Pay versus Performance Information” contained herein shall not be deemed to be “soliciting material” or “filed” with the SEC, nor shall such information be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference therein. In addition, we are not including any information contained on or available through our corporate website or any other website that we may maintain as part of, or incorporating such information by reference into, this Proxy Statement.
46

TABLE OF CONTENTS

Transfer Agent Information
Continental Stock Transfer & Trust Company (CST) is the transfer agent for the common stock of Aeva Technologies, Inc. CST can be reached at 917.262.2373 or via email at proxy@continentalstock.com. You should contact CST if you are a registered stockholder and have a question about your account or if you would like to report a change in your name or address. CST can also be contacted as follows:
Regular, Registered or Overnight Mail
Continental Stock Transfer & Trust Company
One State Street Plaza, 30th Floor
New York, New York 10004
4745

TABLE OF CONTENTS

Annex A
Amendment No. 1 to CERTIFICATE OF AMENDMENT
TO THE
SECOND AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF

AEVA TECHNOLOGIES, INC.
* * * * *
Aeva Technologies, Inc. 2021 Incentive Award Plan
This Amendment No. 1, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), pursuant to the Aeva Technologies, Inc. 2021 Incentive Award Plan (thisGeneral Corporation Law of the State of Delaware (theAmendmentDGCL”) was approved, does hereby certify as follows:
1. That Article IV of the Seconded Amended and Restated Certificate of Incorporation of the Corporation is hereby amended by adding the following paragraph at the end of Article IV as a new Paragraph D of Article IV:
D. Upon the effectiveness of the Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation adding this Section D. (the “Effective Time”), each 5 to 50 shares of the Corporation’s Common Stock, par value $0.0001 per share, issued and outstanding immediately prior to the Effective Time shall automatically be combined into one (1) validly issued, fully paid and non-assessable share of Common Stock, par value $0.0001 per share, without any further action by the Corporation or the holder thereof, the exact ratio within the 5 to 50 range to be determined by the Board of Directors of Aeva Technologies, Inc. on September 26, 2022,the Corporation prior to the Effective Time and publicly announced by the Corporation, subject to stockholder approvalthe treatment of fractional share interests as described below (such combination, the “Reverse Stock Split”). No fractional shares shall be issued at the Aeva Technologies, Inc. 2022 Annual Meeting of Stockholders. Capitalized terms used but not definedEffective Time and, in this Amendment havelieu thereof, the meanings ascribed toCorporation’s transfer agent shall aggregate all fractional shares and sell them inas soon as practicable after the Aeva Technologies, Inc. 2021 Incentive Award Plan (the “Plan”).
1. Section 4.1 ofEffective Time at the Plan (Number of Shares) is amended and restated in its entirety to read as follows:
“4.1. Number of Shares. Subject to adjustment under Article VIII and the terms of Article IV, Awards may be made under the Plan covering up to the Overall Share Limit; provided, however, that the Overall Share Limit shall be increasedthen-prevailing prices on the first dayopen market, on behalf of each calendar year beginning with calendar year 2023those stockholders who would otherwise be entitled to receive a fractional share, and after the transfer agent’s completion of such sale, stockholders shall receive a cash payment (without interest or deduction) from the transfer agent in an amount equal to the least of (x) 5%their respective pro rata shares of the total net proceeds of that sale and, where shares are held in certificated form, upon the surrender of the stockholder’s Old Certificates (as defined below). Each certificate that immediately prior to the Effective Time represented shares of Common Stock (“Old Certificates”) shall thereafter represent that number of Shares outstanding onwhole shares of Common Stock into which the last dayshares of the immediately preceding calendar year, and (y) a lower number of Shares as determinedCommon Stock represented by the Board. As of the Effective Date, the Company ceased granting awards under the Prior Plan; however, Prior Plan Awards will remainOld Certificate shall have been combined, subject to the termstreatment of fractional share interests as described above.”
2. On [], the Board of Directors of the Prior Plan. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares.”
2. Section 4.3Corporation determined that each [](1) shares of the Plan (IncentiveCorporation's Common Stock, Option Limitations) is amended by replacingpar value $0.0001 per share, issued and outstanding immediately prior to the reference to “12,738,379” with “39,063,679”Effective Time shall automatically be combined into one (1) validly issued, fully paid and non-assessable share of Common Stock, par value $0.001 per share. The Corporation publicly announced this ratio on [].
3. This amendment has been duly adopted in accordance with Section 11.25242 of the Plan (“Overall Share Limit”) is amended and restated in its entirety to read as follows:
“11.25 “Overall Share Limit” means the sum of (i) 39,063,679 Shares subject to adjustment pursuant to Section 4.1 and (ii) any Shares that are subject to Prior Plan Awards that become available for issuance under the Plan pursuant to Article IV.”DGCL.
4. All references in the PlanThis Certificate of Amendment shall become effective at [] Eastern time on [].
IN WITNESS WHEREOF, this Certificate of Amendment to the “Plan” shall mean the Plan as amendedSecond Amended and Restated Certificate of Incorporation has been executed by this amendment.
5. Except as specifically set forth herein, alla duly authorized officer of the terms, conditions and all other provisionsCorporation on this [] day of the Plan remain in full force and effect.[].
Name:
Title:
(1)
To be based on a reverse stock split ratio of between 1:5 and 1:50, as determined by the Board of Directors.
A-1

TABLE OF CONTENTS

Annex B
CERTIFICATE OF DESIGNATIONS OF

SERIES [] CONVERTIBLE PREFERRED STOCK,

OF

AEVA TECHNOLOGIES, INC.
2022 EMPLOYEE STOCK PURCHASE PLAN
1. Purpose. The purposePursuant to Section 151 of the Plan is to provide Eligible Employees with an opportunity to purchase shares of Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a Code Section 423 Component (“423 Component”) and a non-Code Section 423 Component (“Non-423 Component”). The Company intends to have the 423 Component of the Plan qualify as an “employee stock purchase plan” under Section 423 of the Code. The provisions of the 423 Component, accordingly, will be construed so as to extend and limit Plan participation in a uniform and nondiscriminatory basis consistent with the requirements of Section 423 of the Code. In addition, the Plan authorizes the grant of an option to purchase shares of Common Stock under the Non-423 Component that does not qualify as an “employee stock purchase plan” under Section 423 of the Code; such an option will be granted pursuant to rules, procedures or sub-plans adopted by the Administrator designed to achieve tax, securities laws or other objectives for Eligible Employees and the Company. Except as otherwise provided herein, the Non-423 Component will operate and be administered in the same manner as the 423 Component.
2. Definitions.
(a) “423 Component” is defined in Section 1 of the Plan.
(b) “Administrator” means the Committee or the Board, or, subject to the rules and interpretive determinations promulgated by the Committee, any officer(s) or employee(s) of the Company to whom the Committee has delegated the authority to handle the operation and administration of the Plan. The Administrator also shall include any third-party vendor or broker/administrator hired by the Committee to assist with the day-to-day operation and administration of the Plan.
(c) “Affiliate” means any entity, other than a Subsidiary, that is an “affiliate” within the meaning of Rule 12b-2 promulgated under Section 12 of the Exchange Act.
(d) “Applicable Laws” means the requirements relating to the administration of equity-based awards and the related issuance of shares of Common Stock under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable securities and exchange control laws of any foreign country or jurisdiction where options are, or will be, granted under the Plan.
(e) “Board” means the Board of Directors of the Company.
(f) “Change in Control” shall have the meaning given such term in the Aeva Technologies Inc. 2021 Incentive Award Plan or any successor plan thereto, in each case, asDelaware General Corporation Law (as amended, and/supplemented or restated from time to time.
(g)time, theCodeDGCL means), AEVA TECHNOLOGIES, INC., a corporation organized and existing under the U.S. Internal Revenue Code of 1986, as amended. References to a specific Sectionlaws of the CodeState of Delaware (the “Company”), in accordance with the provisions of Section 103 of the DGCL, DOES HEREBY CERTIFY:
That the Second Amended and Restated Certificate of Incorporation of the Company (as amended from time to time, the “Certificate of Incorporation”), authorizes the issuance of 432,000,000 shares of capital stock, consisting of 422,000,000 shares of common stock, par value $0.0001 per share (“Common Stock”), and 10,000,000 shares of preferred stock, par value $0.0001 per share (“Preferred Stock”);
That, pursuant to the provisions of the Certificate of Incorporation, the board of directors of the Company (the “Board”) is authorized to fix by resolution or U.S. Treasury Regulation thereunder will include such Section or regulation,resolutions the designations and the powers, including voting powers, if any, valid regulationpreferences and relative, participating, optional or other official applicable guidance promulgated under such Section,special rights, if any, and any comparable provisionthe qualifications, limitations or restrictions thereof, of any future legislation or regulation amending, supplementing or supersedingseries of Preferred Stock, and to fix the number of shares constituting any such Section or regulation.series; and
(h) “Committee” meansThat, pursuant to the Compensation Committee ofauthority conferred upon the Board and any successor committee thereto or such other committeeby the Certificate of Incorporation, the Board adopted the following resolution designating a new series of Preferred Stock as may be designated by“Series [] Convertible Preferred Stock”:
RESOLVED, that, pursuant to the Board to administer the Planauthority vested in whole or in part, including any subcommittee of the Board as designated by the Board in accordance with the provisions of Article IV of the Certificate of Incorporation and the provisions of Section 14 hereof.
(i) “Common151 of the DGCL, a series of Preferred Stock” means the common stock of the Company $0.0001 par value per share (and any stockis hereby authorized, and the number of shares to be included in such series, and the powers (including voting powers), designations, preferences and relative, participating, optional or other securities into whichspecial rights, and the qualifications, limitations and restrictions of the shares of Preferred Stock included in such Commonseries, shall be as follows:
SECTION 1. Designation and Number of Shares. The shares of such series of Preferred Stock shall be designated as “Series [] Convertible Preferred Stock” (the “Series [ ] Preferred Stock”). The number of authorized shares constituting the Series [] Preferred Stock shall be []. That number from time to time may be convertedincreased or into which it may be exchanged).
(j) “Company” means Aeva Technologies, Inc.,decreased by further resolution duly adopted by the Board, or any duly authorized committee thereof and by the filing of a Delaware corporation, and any successor thereto.
(k) “Compensation” means an Eligible Employee’s base salary or hourly wages. The Administrator, in its discretion, may, on a uniform and nondiscriminatory basis, establish a different definition of Compensation for a subsequent Offering Period.
(l) “Contributions” means the payroll deductions and other additional payments that the Company may permit to be made by a Participant to fund the exercise of options grantedcertificate pursuant to the Plan.provisions of the DGCL stating that such increase or decrease, as applicable, has been so authorized. The Company shall not have the authority to issue fractional shares of Series [] Preferred Stock.
SECTION 2. Ranking. The Series [] Preferred Stock will rank, with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company:
(a) on a parity basis with each other class or series of Capital Stock of the Company now existing or hereafter authorized, the terms of which expressly provide that such class or series ranks on a parity basis with the Series [] Preferred Stock as to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company (such Capital Stock, “Parity Stock”);
(b) junior to each other class or series of Capital Stock of the Company now existing or hereafter authorized, the terms of which expressly provide that such class or series ranks senior to the Series [] Preferred Stock as to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company (such Capital Stock, “Senior Stock”); and
(c) senior to the Common Stock and each other class or series of Capital Stock of the Company (other than the Parity Stock) now existing or hereafter authorized, the terms of which do not expressly provide that such class or series ranks on a parity basis with or senior to the Series [] Preferred Stock as to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company (such Capital Stock, “Junior Stock”).
B-1

TABLE OF CONTENTS

(m) SECTION 3. Definitions. As used herein with respect to Series [] Preferred Stock:
Designated CompanyAccrued Dividends” means, as of any Subsidiarydate, with respect to any share of Series  [] Preferred Stock, all Dividends that have accrued on such share pursuant to Section 4(b), whether or not declared.
Affiliate” means, as to any Person, any other Person that, has been designateddirectly or indirectly, controls, or is controlled by, the Administrator from time to time in its sole discretion as eligible to participate in the Plan. For purposes of the 423 Component, onlyor is under common control with, such Person; provided, however, (i) that the Company and its Subsidiaries may be Designated Companies; provided, that at any given time, a Subsidiary that is a Designated Company under the 423 Component shall not be a Designated Company underdeemed to be Affiliates of any Investor or any of its Affiliates, (ii) portfolio companies (as such term is customarily used among institutional investors) in which the Non-423 Component.
(n) “Eligible Employee” meansInvestor or any individual who is a common law employee providing services to the Companyof its Affiliates has an investment (whether as debt or a Designated Company and has completed at least five (5) consecutive calendar months of service since his or her last hire date (or such lesser period of time as mayequity) shall not be determined by the Administrator in its discretion). For purposesdeemed an Affiliate of the Plan,Investor and (iii) if any direct or indirect limited partner of a Person that is an investment fund (a “Fund”) owns a majority of the employment relationship will be treated as continuing intact while the individual is on sick leaveeconomic interest of such Fund, such direct or other leave of absence that the Employer approves or is legally protected under applicable laws. Where the period of leave exceeds three (3) months and the individual’s right to reemployment isindirect limited partner shall not guaranteed either by statute or by contract, the employment relationship will be deemed to have terminated three (3) months and one (1) day following the commencementbe an “Affiliate” of such leave. The Administrator,Fund without other mechanisms of exerting “control” over such Fund in addition to such limited partner’s ownership of economic interests in such Fund. For this purpose, “control” (including, with its discretion, from timecorrelative meanings, “controlled by” and “under common control with”) shall mean the possession, directly or indirectly, of the power to time may, priordirect or cause the direction of management or policies of a Person, whether through the ownership of securities or partnership or other ownership interests, by contract or otherwise.
Any Person shall be deemed, for purposes of this Certificate of Designations, to an Enrollment Date for all optionsbeneficially own”, to have “beneficial ownership” of, or to be granted onbeneficially owning” any securities (which securities shall also be deemed “beneficially owned” by such Enrollment Date in an Offering, determine (for each Offering under the 423 Component, on a uniform and nondiscriminatory basis or as otherwise permitted by Treasury Regulation Section 1.423-2)Person) that the definition of Eligible Employee will or will not include an individual if he or she: (i)such Person is a highly compensated employeedeemed to “beneficially own” within the meaning of Section 414(q) of the Code, or (ii) is a highly compensated employee within the meaning of Section 414(q) of the Code with compensation above a certain level or is an officer or subject to the disclosure requirements of Section 16(a) ofRules 13d-3 and 13d-5 under the Exchange Act; provided, that any Person shall be deemed to beneficially own any securities that such Person has the exclusionright to acquire, whether or not such right is appliedexercisable within sixty (60) days or thereafter (including assuming conversion of all Series [] Preferred Stock, if any, owned by such Person to Common Stock).
Board” has the meaning set forth in the recitals above.
Business Day” means any weekday that is not a day on which banking institutions in New York, New York are authorized or required by law, regulation or executive order to be closed.
Bylaws” means the Amended and Restated Bylaws of the Company, as may be amended from time to time.
Capital Stock” means, with respect to each Offering underany Person, any and all shares of, interests in, rights to purchase, warrants to purchase, options for, participations in or other equivalents of or interests in (however designated) stock issued by such Person.
Certificate of Designations” means this Certificate of Designations relating to the 423 ComponentSeries [] Preferred Stock, as it may be amended from time to time.
Certificate of Incorporation” has the meaning set forth in an identical manner to all highly compensated employeesthe recitals above.
Change of Control” means whether in a single transaction or a series of related transactions, the merger or consolidation of the Employer whose employees are participating in that Offering. Each exclusion shall be appliedCompany with respect to an Offering underor into another Person or the merger of another Person with or into the Company, or the sale, transfer or lease of all or substantially all of the assets of the Company (determined on a 423 Componentconsolidated basis), whether in a manner complying with U.S. Treasury Regulation Section 1.423-2(e)(2)(ii). Such exclusions may be applied with respectsingle transaction or a series of related transactions, to an Offering under the Non-423 Component without regard to the limitationsanother Person, or any recapitalization, reclassification or other transaction in which all or substantially all of Treasury Regulation Section 1.423-2.
(o) “Employer” means the employer of the applicable Eligible Employee(s).
(p) “Enrollment Date” means the first Trading Day of each Offering Period.
(q) “Enrollment Window” is defined in Section 5(a) of the Plan.
(r) “Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.
(s) “Exercise Date” means the last Trading Day of each Purchase Period.
(t) “Fair Market Value” means, on a given date: (i) if the Common Stock is listed onor is entitled to be exchanged for or converted into cash, securities or other property, other than (1) a nationalmerger or consolidation transaction following which holders of securities exchange,that represented 100% of the closing sales priceVoting Stock of the Company immediately prior to such transaction own directly or indirectly (in substantially the same proportion to each other as immediately prior to such transaction, other than changes in proportionality as a result of any cash/stock election provided under the terms of the definitive agreement regarding such transaction) at least a majority of the voting power of the Voting Stock of the surviving Person in such merger or consolidation transaction immediately after such transaction, and (2) a sale, transfer or lease of all or substantially all of the assets of the Company to a Subsidiary or a Person that becomes a Subsidiary of the Company.
close of business” means 5:00 p.m. (New York City time).
Closing Price of the Common Stock on any date of determination means the closing sale price or, if no closing sale price is reported, on the primary exchange on whichlast reported sale price, of the shares of the Common Stock is listed and traded on such date, or, if there are no such sales on that date, then on the last preceding dateNYSE on which such sales were reported; (ii) if the Common Stock is not listed on any national securities exchange but is quoted in an inter-dealer quotation system on a last-sale basis, the average between the closing bid price and ask price reported on such date, or, if there is no such sale on that date, then on the last preceding date on which a sale was reported; or (iii) if the Common Stock is not listed on a national securities exchange or quoted in an inter-dealer quotation system on a last-sale basis, the amount determined by the Board in good faith to be the fair market value of the Common Stock.
(u) “Fiscal Year” means the fiscal year of the Company.
(v) “New Exercise Date” means a new Exercise Date if the Administrator shortens any Offering Period then in progress.
(w) “Non-423 Component” is defined in Section 1 of the Plan.
(x) “Offering” means an offer under the Plan of an option that may be exercised during an Offering Period as further described in Section 4 of the Plan. For purposes of the Plan, the Administrator may designate separate Offerings under the Plan (the terms of which need not be identical) in which Eligible Employees of one or more Employers will participate, even if the dates of the applicable Offering Periods of each such Offering
B-2

TABLE OF CONTENTS

are identical andsuch date. If the provisionsCommon Stock is not traded on the NYSE on any date of determination, the Closing Price of the Plan will separately apply to each Offering. ToCommon Stock on such date of determination means the extent permittedclosing sale price as reported in the composite transactions for the principal United States securities exchange or automated quotation system on which the Common Stock is so listed or quoted, or, if no closing sale price is reported, the last reported sale price on the principal United States securities exchange or automated quotation system on which the Common Stock is so listed or quoted, or if the Common Stock is not so listed or quoted on a United States securities exchange or automated quotation system, the last quoted bid price for the Common Stock in the over-the-counter market as reported by U.S. Treasury Regulation Section 1.423-2(a)(1),OTC Markets Group Inc. or any similar organization, or, if that bid price is not available, the terms of each Offering need not be identical; provided, that the termsmarket price of the PlanCommon Stock on that date as determined by an Independent Financial Advisor retained by the Company for such purpose.
Common Securities” means (i) for any issuance of shares of Common Stock below the Stock Issuance Cap, Common Stock and an Offering together satisfy U.S. Treasury Regulation (ii) for any issuance of shares of Common Stock that would exceed the Stock Issuance Cap, a Warrant exercisable for such number of shares of Common Stock by which such issuance would cause such Holder to be deemed to exceed the Stock Issuance Cap.
Common Stock” has the meaning set forth in the recitals above.
Common Stock Price” is $[].1
Company” has the meaning set forth in the recitals above.
Company Redemption Right” has the meaning set forth in Section 1.423-2(a)(2) and (a)(3)8(a)(i).
(y) Offering PeriodsConversion Agent” means the periodsTransfer Agent acting in its capacity as conversion agent for the Series [] Preferred Stock, and its successors and assigns.
Conversion Date” means the date on which a Holder complies with the conversion procedures set forth in Section 7 of approximately six (6) months or such other period or periodsthis Agreement.
Conversion Notice” has the meaning set byforth in Section 7(a).
Conversion Price” shall have the Administrator during which an option may be granted pursuant to the Plan and may be exercised, as determined under meaning set forth in Section 4 of the Plan. The duration and timing of Offering Periods may be changed pursuant to Sections 4 and 20 of the Plan.6(a).
(z) ParentConversion Rate” means, a “parent corporation,rate calculated by dividing the Issuance Price by the Common Stock Price, subject to adjustment as set forth herein.
Current Market Pricewhether now or hereafter existing,per share of Common Stock, as defined in Section 424(e)of any date of determination, means the arithmetic average of the Code.closing price per share of Common Stock for each of the five (5) consecutive full Trading Days ending on, and including, the Trading Day immediately preceding such day, appropriately adjusted to take into account the occurrence during such period of any event described in Section 9.
(aa) ParticipantDGCLmeans an Eligible Employee that participateshas the meaning set forth in the Plan.recitals above.
(bb) PersonDividend Conversion Pricemeans an individual, entity or group.
(cc) “Plan” means this Aeva Technologies, Inc. 2022 Employee Stock Purchase Plan.
(dd) “Purchase Period” means, unless changed by the Administrator,lesser of (a) the approximately six (6) month period commencing after one Exercise Date and ending with the next Exercise Date. Unless otherwise determined by the Administrator, the Purchase Period will have the same duration and coincide with the length of the Offering Period.
(ee) “Purchaseaverage Closing Price” means an amount equal to eighty-five percent (85%) of the Fair Market Value of a per share of Common Stock on the EnrollmentNYSE for the five (5) consecutive Trading Days immediately preceding a Dividend Payment Date or (b) the last Closing Price per share of Common Stock on the Exercise Date, whichever is lower; provided, thatNYSE on the Purchase Price may be determined for subsequent Offering Periods byTrading Day immediately preceding the Administrator subject to compliance with Dividend Payment Date.
Distributed Property” has the meaning set forth in Section 4239(a)(iv).
Distribution Transaction” means any distribution of equity securities of a Subsidiary or a business unit of the Code (or any successor rule or provision or any other Applicable Law, regulation or stock exchange rule) or pursuantCompany to Section 20holders of the Plan.
(ff) “Subsidiary” means a “subsidiary corporation,” whether now or hereafter existing, as defined in Section 424(f) of the Code.
(gg) “Trading Day” means a day on which the national stock exchange upon which the Common Stock, is listed is open for trading.whether by means of a spin-off, split-off, redemption, reclassification, exchange, stock dividend, share distribution, rights offering or similar transaction.
(hh) U.S. Treasury RegulationsDividend Payment Date” means the Treasury regulationsfirst day of the Code. References toeach of January, April, July and October of each year; provided that if any such Dividend Payment Date is not a specific Treasury Regulation or Section of the Code shall include such Treasury Regulation or Section, any valid regulation promulgated under such Section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such Section or regulation.
3. Eligibility.
(a) First Offering Period. Any individual who is an Eligible Employee immediately prior to the first Offering Period will be automatically enrolled in the first Offering Period, subject to the provisions of Section 5 of the Plan.
(b) Subsequent Offering Periods. Any Eligible Employee on a given Enrollment Date following the first Offering Period will be eligible to participate in the Plan, subject to the requirements of Section 5 of the Plan.
(c) Non-U.S. Employees. Eligible Employees who are citizens or residents of a non-U.S. jurisdiction (without regard to whether they also are citizens or residents of the United States or resident aliens (within the meaning of Section 7701(b)(1)(A) of the Code)) may be excluded from participation in the Plan or an Offering if the participation of such Eligible Employees is prohibited under the laws ofBusiness Day, then the applicable jurisdiction or if complying withDividend shall be payable on the laws of the applicable jurisdiction would cause the Plan or an Offering to violate Section 423 of the Code. In the case of the Non-423 Component, an Eligible Employee may be excluded from participation in the Plan or an Offering if the Administrator has determined that participation ofnext Business Day immediately following such Eligible Employee is not advisable or practicable.Dividend Payment Date, without any interest.
(d) Limitations. Any provisions of the Plan to the contrary notwithstanding, no Eligible Employee will be granted an option under the Plan (i) to the extent that, immediately after the grant, such Eligible Employee (or any other Person whose stock would be attributed to such Eligible Employee pursuant to Section 424(d) of the Code) would own capital stock of the Company or any Parent or Subsidiary of the Company and/or hold outstanding options to purchase such stock possessing five percent (5%) or more of the total combined voting
1
Price to be inserted at the Advance Date and will be the lesser of (i) the average Closing Price per share of Common Stock on the NYSE for the five (5) consecutive Trading Days immediately preceding the Issuance Date, a Dividend Payment Date, a Conversion Date or a relevant calculation date, as applicable, or (ii) the last Closing Price per share of Common Stock on the NYSE on the Trading Day immediately preceding the Issuance Date, a Dividend Payment Date, a Conversion Date, or a relevant calculation date, as applicable.
B-3

TABLE OF CONTENTS

powerDividend Payment Period” means in respect of any share of Series [] Preferred Stock the period from and including the Issuance Date of such share to, but excluding, the first Dividend Payment Date following the applicable Issuance Date and, subsequently, in each case the period from and including any Dividend Payment Date to, but excluding, the next Dividend Payment Date.
Dividend Rate” means 7.0% per annum of the Issuance Price per share, calculated on the basis of a 360-day year consisting of twelve 30-day months.
Dividend Record Date” has the meaning set forth in Section 4(d).
Dividends” has the meaning set forth in Section 4(a).
Exchange Act” means the Securities Exchange Act of 1934, as amended.
Expiration Date” the date any tender offer or exchange offer by the Company expires.
Fair Market Value” means, with respect to any security or other property, the fair market value of all classes ofsuch security or other property as reasonably determined in good faith by the capital stock of the CompanyBoard, or ofan authorized committee thereof, (i) after consultation with an Independent Financial Advisor, as to any Parentsecurity or Subsidiary of the Company, or (ii) to the extent that his or her rights to purchase stock under all employee stock purchase plans (as defined in Section 423 of the Code) of the Company or any Parent or Subsidiary of the Company accrues atother property with a rate that exceeds twenty-five thousand dollars ($25,000) worth of stock (determined at the Fair Market Value of less than $100,000,000, or (ii) otherwise using an Independent Financial Advisor to provide a valuation opinion; provided that for any publicly traded security listed on a national securities exchange, the stock atCurrent Market Price (substituting for this purpose only a reference to such security for all references to Common Stock in the time such option is granted)definition of Current Market Price) for each calendar yearthe applicable date shall constitute the Fair Market Value.
Holder” means a Person in which such option is outstanding at any time, as determined in accordance with Section 423whose name the shares of the CodeSeries [] Preferred Stock are registered, which Person shall be treated by the Company, the Transfer Agent, the Registrar, the paying agent and the regulations thereunder.
4. Offering Periods.
(a) Conversion Agent as the absolute owner of the shares of Series [Frequency] Preferred Stock for the purpose of making payment and Durationsettling conversions and for all other purposes; provided. The Administrator may establish Offering Periods that, to the fullest extent permitted by law, no Person that has received shares of Series [] Preferred Stock in violation of the Standby Equity Purchase Agreement shall be a Holder, the Transfer Agent, the Registrar, the paying agent and the Conversion Agent, in each case as applicable, shall not, unless directed otherwise by the Company, recognize any such Person as a Holder, and the Person in whose name the shares of the Series [] Preferred Stock were registered immediately prior to such transfer shall remain the Holder of such frequency and duration as it may from time to time determine as appropriate.shares.
(b) First Offering PeriodIndependent Financial Advisor. The first Offering Period under” means an accounting, appraisal, investment banking firm or consultant of nationally recognized standing that does not have a material relationship with the Plan shall commence onCompany.
Investor” has the date determined by the Administrator and shall end on the last Trading Day on or immediately preceding the August 31st or the February 28th/29th that next occurs after the commencement of the first Offering Period.
(c) Successive Offering Periods. Unless the Administrator determines otherwise, following the completion of the first Offering Period, a new Offering Period shall commence on the first Trading Day on or following March 1 and September 1 of each calendar year and end on or following the last Trading Day on or immediately preceding August 31 and February 28, respectively, approximately six (6) months later.
(d) Additional Offering Periods. At the discretion of the Administrator, additional Offering Periods may be conducted under the Plan. Such additional Offering Periods may, but need not, qualify under Section 423 of the Code. The Administrator shall determine the commencement and duration of each additional Offering Period, and additional Offering Periods may be consecutive or overlapping. The other terms and conditions of each additional Offering Period shall be thosemeaning set forth in the Plan document, with such changes or additional features as the Administrator determines necessary to comply with Section 423 of the Code (or any successor rule or provision or any other Applicable Law, regulation or stock exchange rule). The Administrator shall have the power to change the duration of Offering Periods (including the commencement dates thereof)Standby Equity Purchase Agreement.
Issuance Date” means, with respect to future Offerings without stockholder approval.any share of Series [] Preferred Stock, the date of issuance of such share.
(e) Offering Period LimitIssuance Price. No Offering Period may last more than twenty-seven (27) months.
(f) Applicable Offering Period. For purposes” means the price for each share of calculating the Purchase Price, the applicable Offering PeriodSeries [] Preferred Stock, which shall be determined as follows: Once a Participant is enrolled in$10,000.
Junior Stock” has the Plan for an Offering Period, such Offering Period shall continue to apply to him or her until the earliest of (x) the end of such Offering Period, or (y) the end of his or her participation under Section 10 of the Plan.
5. Participation.
(a) First Offering Period. An Eligible Employee will be entitled to continue to participate in the first Offering Period pursuant to Section 3(a) of the Plan only if such individual submits a subscription agreement authorizing Contributions in a form determined by the Administrator to the Company’s designated third-party broker/plan administrator (i) no earlier than the effective date of the Form S-8 registration statement that registers the offer and sale of Common Stock under the Plan and (ii) no later than ten (10) business days following the effective date of such S-8 registration statement or such other period of time as the Administrator may determine (the “Enrollment Window”).
(b) Subsequent Offering Periods. Once an Eligible Employee begins participation in an Offering Period, then such Eligible Employee will automatically participate in each subsequent Offering Period unless the Eligible Employee withdraws or is deemed to withdraw from this Plan or terminates further participation in an Offering Period asmeaning set forth in Section 10 below. An Eligible Employee who is continuing participation pursuant2(b).
Liquidation Preference” means an amount equal to the immediately preceding sentence is not required to file any additional subscription agreement in order to continue participation in this Plan; during each subsequent Offering Period an Eligible Employee who is not continuing participation pursuant to the immediately preceding sentence is required to file a subscription agreement prior to the commencement120% of the Offering Period (or such earlier date asIssuance Price.
Notice of Company Redemption” has the Administrator may determine)meaning set forth in Section 8(a)(ii).
NYSE” means The New York Stock Exchange.
Officer’s Certificate” means a certificate signed by the Chief Executive Officer, the Chief Financial Officer, the Secretary, or any President or Vice President of the Company.
Optional Conversion” has the meaning set forth in Section 6(a).
Parent Entity” means, with respect to any Person, any other Person of which such agreement relatesfirst Person is a direct or indirect wholly owned Subsidiary.
Parity Stock” has the meaning set forth in order to participateSection 2(c).
Permitted Transferee” has the meaning set forth in such Offering Period.the Standby Equity Purchase Agreement.
B-4

TABLE OF CONTENTS

6. Contributions.Person” means any individual, corporation, estate, partnership, joint venture, association, joint-stock company, limited liability company, trust, unincorporated organization or any other entity.
(a) AtPIK Securities” means (i) Common Stock for any dividend payment in shares of Common Stock below the timeStock Issuance Cap and (ii) a Participant enrollsWarrant for any dividend payment in the Plan pursuant to Section 5shares of Common Stock in excess of the Plan, he or she will elect to have Contributions (inStock Issuance Cap.
Preferred Stock” has the form of payroll deductions or otherwise, to the extent permitted by the Administrator) made on each pay day during the Offering Period in an amount not exceeding fifteen percent (15%) of the Compensation, which he or she receives on each pay day during the Offering Period (for illustrative purposes, should a pay day occur on an Exercise Date, a Participant will have any payroll deductions made on such day applied to his or her account under the then-current Purchase Period or Offering Period). The Administrator, in its sole discretion, may permit all Participants in a specified Offering to contribute amounts to the Plan through payment by cash, check or other meansmeaning set forth in the subscription agreement priorrecitals above.
Principal Market” means the NYSE; provided, however, that in the event shares of the Company’s Common Stock are ever listed or traded on the NYSE American, the Nasdaq Global Market, the Nasdaq Global Select Market, or the Nasdaq Capital Market, then the “Principal Market” shall mean such other market or exchange on which shares of the Company’s Common Stock are then listed or traded.
Record Date” means, with respect to any dividend, distribution or other transaction or event in which holders of Common Stock have the right to receive any cash, securities or other property or in which Common Stock is exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of holders of Common Stock entitled to receive such cash, securities or other property (whether such date is fixed by the Board or by statute, contract or otherwise).
Redemption Date” means, with respect to each Exercise Dateshare of Series [] Preferred Stock, the date on which the Company makes the payment in full of the Redemption Price for each Purchase Period. A Participant’s subscription agreement will remainsuch share either to the Holder of such share or to the Transfer Agent, irrevocably, for the benefit of such Holder.
Redemption Price” has the meaning set forth in effectSection 8(a)(i).
Registrar” means the Transfer Agent acting in its capacity as registrar for successive Offering Periods unless terminatedthe Series [] Preferred Stock, and its successors and assigns.
Registration Rights Agreement” means the Registration Rights Agreement dated as provided in Section 10 hereof.of [], 202[] among the Company, the Holders (as defined therein) party thereto and the other parties thereto.
(b) InRequired Regulatory Approvals” has the event Contributions are mademeaning set forth for such term in the form of payroll deductions, such payroll deductions for a Participant will commence onStandby Equity Purchase Agreement.
Senior Stock” has the first day ofmeaning set forth in Section 2(a).
Series [ ] Preferred Stock” has the payroll cycle following the Enrollment Date and will end on the last pay day prior to the Exercise Date of such Offering Period to which such authorization is applicable, unless sooner terminated by the Participant as providedmeaning set forth in Section 10 hereof or suspended by the Participant as provided in Section 6(d) hereof; provided, that for the first Offering Period, payroll deductions will commence on the first day of the payroll cycle following the end of the Enrollment Window.1.
(c) All Contributions made for a Participant will be credited to his or her account under the Plan, and Contributions will be made in whole percentages of Compensation only. A Participant may not make any additional payments into such account.
(d) A Participant may discontinue his or her participation in the Plan as provided in Section 10 of the Plan. If permitted by the Administrator, as determined in its sole discretion, a Participant may, on a single occasion, either reduce his or her rate of Contribution during, or suspend his or her Contributions for the remainder of, an on-going Offering Period by filing with the Company’s designated third-party broker/plan administrator a new authorization for payroll deductions, with the new rate of Contribution, or suspension of Contributions, to become effective as soon as reasonably practicable and continuing for the remainder of the Offering Period. If a Participant suspends his or her ContributionsShelf Registration Statement” means, at any time during an Offering Period, such Participant’s cumulative Contributions prior to such suspension shall be used to purchase shares on the next occurring Exercise Date unless such Participant discontinues his or her participation in the Plan as provided in Section 10of determination, a registration statement of the Plan priorCompany filed with the Securities and Exchange Commission on Form S-3 (or any successor form) or on Form S-1 (or any successor form) for an offering to such Exercise Date.
(e) Tobe made on a continuous basis pursuant to Rule 415 under the extent necessary to comply with Section 423(b)(8)Securities Act of the Code and Section 3(d) hereof, a Participant’s Contributions1933, as amended (or any similar rule that may be decreased to zero percent (0%) at any time during a Purchase Period. Subject to Section 423(b)(8) of the Code and Section 3(d) hereof, Contributions will recommence at the rate originally electedadopted by the ParticipantSecurities and Exchange Commission) that is then effective, as of the beginning of the first Purchase Period scheduled to end in the following calendar year, unless terminated by the Participant as provided in Section 10 of the Plan.
(f) Notwithstanding any provisionsis available to the contraryHolder as a selling shareholder pursuant to any registration rights agreement then in effect and to which the Plan,Company and the Administrator may allow Eligible Employees to participate in the Plan via cash contributions instead of payroll deductions if (i) payroll deductionsHolder are not permitted under applicable local law, (ii) the Administrator determines that cash contributions are permissible under Section 423 of the Code or (iii) for Participants participating in the Non-423 Component.
(g) At the time the option is exercised, in whole or in part, or at the time some or all ofparty, and covers the Common Stock issued underinto which the PlanSeries [] Preferred Stock is disposedconvertible.
Standby Equity Purchase Agreement” means that certain Standby Equity Purchase Agreement among the Company and the Investor dated as of (or any otherOctober [3], 2023, as it may be amended, supplemented or otherwise modified from time thatto time.
Stock Issuance Cap” means a taxable event related toHolder may not become the Plan occurs), the Participant must make adequate provision forbeneficial owner of more than 19.9% of the Company’s or the Employer’s federal, state, local or any other tax liability payable to any authority including taxes imposed by jurisdictions outside of the U.S., national insurance, social security or other tax withholding obligations, if any, which arise upon the exercise of the option or the disposition of the Common Stock (or any other time that a taxable event related to the Plan occurs). At any time, the Company or the Employer may, but will not be obligated to, withhold from the Participant’s compensation the amount necessary for the Company or the Employer to meet applicable withholding obligations, including any withholding required to make available to the Company or the Employer any tax deductions or benefits attributable to sale or early disposition of Common Stock by the Eligible Employee. In addition, the Company or the Employer may, but will not be obligated to, withhold from the proceeds of the sale ofoutstanding Common Stock, or in a “20% issuance” at a price less than the “Minimum Price”, within the meaning of NYSE Rules 312.03 and 312.04.
Subsidiary”, when used with respect to any Person, means any corporation, limited liability company, partnership, association, trust or other methodentity of withholdingwhich (i) securities or other ownership interests representing more than 50% of the Companyordinary voting power (or, in the case of a partnership, more than 50% of the general partnership interests) or (ii) sufficient voting rights to elect at least a majority of the Employer deems appropriate toboard of directors or other governing body are, as of such date, owned by such Person or one or more Subsidiaries of such Person or by such Person and one or more Subsidiaries of such Person.
Trading Day” means any day during which the extent permitted by U.S. Treasury Regulation Section 1.423-2(f).Principal Market shall be open for business.
B-5

TABLE OF CONTENTS

7. GrantTransfer Agent” means the Person acting as Transfer Agent, Registrar and paying agent and Conversion Agent for the Series [] Preferred Stock, and its successors and assigns. The Transfer Agent initially shall be [].
Trigger Event” has the meaning set forth in Section 9(a)(viii).
Warrant” means a pre-funded warrant in the form attached as Exhibit E to the Standby Equity Purchase Agreement that shall (a) expire on the fourth (4th) anniversary of Option. On the Enrollment Date of an applicable Offering Period, each Eligible Employee participating inits issuance, (b) be exercisable for such Offering Period will be granted an option to purchase on each Exercise Date during such Offering Period (at the applicable Purchase Price) up to a number of shares of Common Stock determined by dividing such Eligible Employee’s Contributions accumulated prior to such Exercise Date and retained in the Eligible Employee’s account as would have been purchasable upon conversion or redemption of the Exercise Date bySeries [] Preferred Stock, but for the applicable Purchase Price; provided, that in no event will an Eligible Employee be permitted to purchase during each Purchase Period shares of Common Stock with a value greater than $12,500, or during any one year period, shares of Common Stock with a value greater than $25,000; provided, further, that such purchase willIssuance Cap, and (c) be subject to the limitationsanti-dilution adjustments (in accordance with Section 9 set forth in Sections 3(d) and 13herein). No additional consideration shall be required to be paid by the holder of the Plan. The Eligible Employee may accept the grantwarrant to effect any exercise of such option (i)warrant.
Voting Stock” means (a) with respect to the Company, the Common Stock and any other Capital Stock of the Company having the right to vote generally in any election of directors of the Board and (b) with respect to any other Person, all Capital Stock of such Person having the right to vote generally in any election of directors of the board of directors of such Person or other similar governing body.
VWAP” per share of Common Stock on any Trading Day means the per share volume-weighted average price as displayed under the heading Bloomberg VWAP on Bloomberg (or, if Bloomberg ceases to publish such price, any successor service reasonably chosen by the Company) page “BHG<equity>AQR” (or its equivalent successor if such page is not available) in respect of the period from the open of trading on the relevant Trading Day until the close of trading on such Trading Day (or if such volume-weighted average price is unavailable, the market price of one share of Common Stock on such Trading Day determined, using a volume-weighted average method, by an Independent Financial Advisor retained for such purpose by the Company).
SECTION 4. Dividends.
(a) Holders shall be entitled to receive dividends of the type and in the amount determined as set forth in this Section 4 (such dividends, “Dividends”).
(b) Accrual of Dividends. Dividends on each share of Series [] Preferred Stock (i) shall accrue on a daily basis from and including the Issuance Date of such share, whether or not declared and whether or not the Company has assets legally available to make payment thereof, at a rate equal to the Dividend Rate as further specified below and (ii) shall be payable quarterly in arrears on each Dividend Payment Date, commencing on the first OfferingDividend Payment Date following the Issuance Date of such share. The amount of Dividends accrued with respect to any share of Series [] Preferred Stock for any Dividend Payment Period by submitting a properly completed subscription agreementshall equal the sum of the daily Dividend amounts accrued in accordance with the requirementsprior sentence of this Section 5 of the Plan on or before the last day of the Enrollment Window, and (ii)4(b) with respect to such share during such Dividend Payment Period. For the avoidance of doubt, for any subsequent Offeringshare of Series [] Preferred Stock with an Issuance Date that is not a Dividend Payment Date, the amount of Dividends payable with respect to the initial Dividend Payment Period underfor such share shall equal the Plan, by continuing to (or electing to,product of (A) the daily accrual determined as applicable) participatespecified in the Planprior sentence, assuming a full Dividend Payment Period in accordance with the requirementsdefinition of Section 5such term, and (B) the number of days from and including such Issuance Date to but excluding the next Dividend Payment Date.
(c) Payment of Dividend. With respect to any Dividend Payment Date, the Company will pay, to the extent permitted by applicable law, Dividends on each share of Series [] Preferred Stock in kind by the issuance of Common Securities with an aggregate value (at the time of such payment) equal to the amount of the Plan.dividend to have been paid divided by the Dividend Conversion Price (a “PIK Securities”); provided that any Dividend payments shall be aggregated per Holder and shall be made to the nearest cent (with $0.005 being rounded upward). Notwithstanding any other provision of this Certificate of Designation or the Series [] Preferred Stock, any dividend that is paid in the form of PIK Securities shall be considered paid or duly provided for, for all purposes of this Certificate of Designation and the Series [] Preferred Stock, and shall not be considered overdue. The AdministratorBoard may for future Offering Periods, increaseat its sole discretion elect to pay the Dividends in whole or decrease,part in its absolute discretion, the maximum number of sharescash in lieu of Common Stock that an Eligible Employee may purchase during each Purchase PeriodSecurities.
(d) Record Date. Each Dividend shall be paid pro rata to the Holders entitled thereto. The record date for payment of an Offering Period or duringDividends on any one-year period. Exerciserelevant Dividend Payment Date will be the close of the option will occur as provided in Section 8, unless the Participant has withdrawn pursuant to Section 10 of the Plan. To the extent not otherwise exercised in full, the option will expirebusiness on the lastfifteenth (15th) day of the Offering Period.
8. Exercise of Option.
(a) Unlesscalendar month preceding the relevant Dividend Payment Date (each, a Participant withdraws from the Plan as provided in Section 10 of the Plan, hisDividend Record Date”), whether or her option for the purchase of shares of Common Stock will be exercised automatically on the Exercise Date, and the maximum number of full shares subject to the option will be purchased fornot such Participant at the applicable Purchase Price with the accumulated Contributions from his or her account. No fractional shares of Common Stock will be purchased; any Contributions accumulated inday is a Participant’s account, which are not sufficient to purchase a full share will be retained in the Participant’s account for the subsequent Purchase Period or Offering Period, subject to earlier withdrawal by the Participant. Any other funds left over in a Participant’s account after the Exercise Date will also be retained in the Participant’s account for the subsequent Purchase Period or Offering Period, subject to earlier withdrawal by the Participant. During a Participant’s lifetime, a Participant’s option to purchase shares hereunder is exercisable only by him or her.
(b) If the Administrator determines that, on a given Exercise Date, the number of shares of Common Stock with respect to which options are to be exercised may exceed (i) the number of shares of Common Stock that were available for sale under the Plan on the Enrollment Date of the applicable Offering Period, or (ii) the number of shares of Common Stock available for sale under the Plan on such Exercise Date, the Administrator may in its sole discretion (x) provide that the Company will make a pro rata allocation of the shares of Common Stock available for purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform a manner as will be practicable and as it will determine in its sole discretion to be equitable among all Participants exercising options to purchase Common Stock on such Exercise Date, and continue all Offering Periods then in effect or (y) provide that the Company will make a pro rata allocation of the shares available for purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform a manner as will be practicable and as it will determine in its sole discretion to be equitable among all Participants exercising options to purchase Common Stock on such Exercise Date, and terminate any or all Offering Periods then in effect pursuant to Section 20 of the Plan. The Company may make a pro rata allocation of the shares available on the Enrollment Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional shares for issuance under the Plan by the Company’s stockholders subsequent to such Enrollment Date.
9. Delivery. As soon as reasonably practicable after each Exercise Date on which a purchase of shares of Common Stock occurs, the Company will arrange the delivery to each Participant of the shares purchased upon exercise of his or her option in a form determined by the Administrator (in its sole discretion) and pursuant to rules established by the Administrator. The Company may permit or require that shares be deposited directly with a broker designated by the Company or to a designated agent of the Company, and the Company may utilize electronic or automated methods of share transfer. The Company may require that shares be retained with such broker or agent for a designated period of time and/or may establish other procedures to permit tracking of disqualifying dispositions of such shares. No Participant will have any voting, dividend, or other stockholder rights with respect to shares of Common Stock subject to any option granted under the Plan until such shares have been purchased and delivered to the Participant as provided in this Section 9.Business Day.
B-6

TABLE OF CONTENTS

10. Withdrawal.
(a) A Participant may withdraw all but not less than all the Contributions credited to his or her account and not yet used to exercise his or her option under the Plan at(e) Priority of Dividends. So long as any time prior to the last thirty (30) days of the applicable Offering Period by (i) submitting to the Company’s stock administration office (or its designee) a written notice of withdrawal in the form determined by the Administrator for such purpose, or (ii) following an electronic or other withdrawal procedure determined by the Administrator; provided, that a Participant may not withdraw during any blackout period applicable to such Participant. All of the Participant’s Contributions credited to his or her account will be paid to such Participant promptly and as soon as administratively feasible after receipt of notice of withdrawal by the Company’s stock administration office (or its designee) and such Participant’s option for the Offering Period will be automatically terminated, and no further Contributions for the purchase of shares will be made for such Offering Period. If a Participant withdraws from an Offering Period, Contributions will not resume at the beginning of the succeeding Offering Period, unless the Participant re-enrolls in the Plan by submitting a subscription agreement to the Company’s designated third-party broker/plan administrator prior to the commencement of such succeeding Offering Period.
(b) A Participant’s withdrawal from an Offering Period will not have any effect upon his or her eligibility to participate in any similar plan that may hereafter be adopted by the Company or in succeeding Offering Periods that commence after the termination of the Offering Period from which the Participant withdraws.
11. Termination of Employment. Upon a Participant’s ceasing to be an Eligible Employee, for any reason, he or she will be deemed to have elected to withdraw from the Plan and the Contributions credited to such Participant’s account during the Offering Period but not yet used to purchase shares of CommonSeries [_] Preferred Stock under the Plan will be returned to such Participant or, in the case of his or her death, to the Person or Persons entitled thereto under Section 15 of the Plan, and such Participant’s option will be automatically terminated. Unless determined otherwise by the Administrator in a manner that, with respect to an Offering under the 423 Component, is permitted by, and compliant with, Section 423 of the Code, a Participant whose employment transfers between entities through a termination with an immediate rehire (with no break in service) by the Company or a Designated Company shall not be treated as terminated under the Plan; provided, however, that no Participant shall be deemed to switch from an Offering under the Non-423 Component to an Offering under the 423 Component or vice versaremain outstanding, unless (and then only to the extent) such switch would not cause the 423 Component or any Option thereunder to fail to comply with Section 423 of the Code.
12. Interest. No interest will accruefull Dividends on the Contributions of a Participant in the Plan, except as may be required by Applicable Law, as determined by the Company, and if so required by the laws of a particular jurisdiction, shall, with respect to Offerings under the 423 Component, apply to all Participants in the relevant Offering, except to the extent otherwise permitted by U.S. Treasury Regulation Section 1.423-2(f).
13. Stock.
(a) Subject to adjustment upon changes in capitalization of the Company as provided in Section 19 hereof, the aggregate number ofoutstanding shares of CommonSeries [_] Preferred Stock available forthat have accrued from and including the issuancelater of shares pursuant to(x) the Plan shall be no more than 1,831,812 shares, which number shall be automatically increased onIssuance Date or (y) the first day of each Fiscal Year following the Fiscal Yearcurrent Dividend Payment Period in whichrespect of such shares of Series [] Preferred Stock have been declared and paid in cash or in kind, or have been or contemporaneously are declared, and a sum of cash or Common Stock sufficient for the Effective Date falls in an amount equal topayment of those Dividends has been, or is, set aside or issued for the lesser of (x) 5%benefit of the total number of all classes of CommonHolders for the current Dividend Payment Period, the Company may not declare any dividend on, or make any cash distributions relating to, Junior Stock outstanding on the last day of the immediately preceding Fiscal Year and (y)or Parity Stock, or redeem, purchase, acquire (either directly or through any Subsidiary), or make a lower numberliquidation payment relating to, any Junior Stock or Parity Stock, other than:
(i) purchases, redemptions or other acquisitions of shares of CommonJunior Stock as determined byin connection with any employment contract, benefit plan or other similar arrangement with or for the Board. Notwithstanding anything in this Section 13(a) tobenefit of current or former employees, officers, directors or consultants;
(ii) purchases of Junior Stock through the contrary,use of the numberproceeds of a substantially contemporaneous sale of other shares of CommonJunior Stock;
(iii) as a result of an exchange or conversion of any class or series of Parity Stock that may be issued or transferredJunior Stock for any other class or series of Parity Stock (in the case of Parity Stock) or Junior Stock (in the case of Parity Stock or Junior Stock);
(iv) purchases of fractional interests in shares of Parity Stock or Junior Stock pursuant to the rights granted underconversion or exchange provisions of such Parity Stock or Junior Stock or the 423 Componentsecurity being converted or exchanged;
(v) payment of any dividends in respect of Junior Stock where the dividend is in the form of the Plansame stock or rights to purchase the same stock as that on which the dividend is being paid (subject to the restrictions set forth in Section 4(e)); or
(vi) distributions of Junior Stock or rights to purchase Junior Stock.
Notwithstanding the foregoing, for so long as any shares of Series [] Preferred Stock remain outstanding, if dividends are not declared and paid in full upon such shares of Series [] Preferred Stock and any Parity Stock, all dividends declared upon such shares of Series [] Preferred Stock and any Parity Stock will be declared on a proportional basis so that the amount of dividends declared per share will bear to each other the same ratio that all accrued and unpaid dividends as of the end of the most recent Dividend Payment Period per share of Series [] Preferred Stock and accrued and unpaid dividends as of the end of the most recent dividend period per share of any Parity Stock bear to each other.
Subject to the provisions of this Section 4, dividends may be declared by the Board, or any duly authorized committee thereof, and paid by the Company, on any Junior Stock and Parity Stock from time to time and the Holders will not be entitled to participate in those dividends (other than pursuant to adjustments otherwise provided under Section 9(a)).
(f) Conversion Following a Record Date. If the Conversion Date for any shares of Series [] Preferred Stock is prior to the close of business on a Dividend Record Date, the Holder of such shares will not be entitled to any dividend in respect of such Dividend Record Date, other than through the inclusion of Accrued Dividends in the Liquidation Preference as of the Conversion Date in the calculation under Section 5(a). If the Conversion Date for any shares of Series [] Preferred Stock is after the close of business on a Dividend Record Date but prior to the corresponding payment date for such dividend, the Holder of such shares as of such Dividend Record Date, shall be entitled to receive such dividend, notwithstanding the conversion of such shares prior to the applicable Dividend Payment Date; provided that the amount of such Dividend with respect to the then current Dividend Payment Period shall not exceed an aggregatebe included for the purpose of 36,636,240 shares, subject to determining the amount of Accrued Dividends or Liquidation Preference under Section 19.
(b) Until the shares of Common Stock are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company)5(a), a Participant will only have the rights of an unsecured creditor with respect to such Conversion Date.
SECTION 5. Liquidation Rights. (a)Liquidation. In the event of any Change of Control, the Holders of shares of Series [] Preferred Stock shall be entitled, out of assets legally available therefor, before any distribution or payment out of the assets of the Company may be made to or set aside for the holders of any Junior Stock, and no rightsubject to votethe rights of the holders of any Senior Stock or Parity Stock and the rights of the Company’s existing and future creditors, to receive dividends or any other rights asin full a stockholder will exist with respect to such shares.
(c) Shares of Common Stock to be delivered to a Participant under the Plan will be registeredliquidating distribution in cash and in the nameamount per share of the Participant or in the name of the Participant and his or her spouse.Series [] Preferred Stock
B-7

TABLE OF CONTENTS

14. Administration. The Planequal to the sum of (i) the Liquidation Preference plus (ii) the Accrued Dividends with respect to such share of Series [] Preferred Stock as of the date of such voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders shall not be entitled to any further payments in the event of any such voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company other than what is expressly provided for in this Section 5 and will have no right or claim to any of the Company’s remaining assets.
(b) Partial Payment. If in connection with any distribution described in Section 5(a), the assets of the Company or proceeds therefrom are not sufficient to pay in full the aggregate liquidating distributions required to be administeredpaid pursuant to Section 5(a) to all Holders of shares of Series [] Preferred Stock and the liquidating distributions payable to all holders of any Parity Stock, the amounts distributed to such Holders and to the holders of all such Parity Stock shall be paid pro rata in accordance with the respective aggregate liquidating distributions to which they would otherwise be entitled if all amounts payable thereon were paid in full.
SECTION 6. Right of the Holders to Convert.
(a) At any time prior to the occurrence of a Change of Control, each Holder shall have the right, at such Holder’s option, subject to the conversion procedures set forth in Section 7, to convert each share of such Holder’s Series [] Preferred Stock at such time (including following the delivery of any Notice of Company Redemption) into the number of Common Securities equal to the quotient of the Issuance Price divided by the BoardConversion Price (as defined below) in effect at the time of conversion (an “Optional Conversion”). The “Conversion Price” applicable to the Series [] Preferred Stock shall initially be equal to the Common Stock Price. Such initial Conversion Price, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below. The right of conversion may be exercised as to all or a Committee appointed by the Board, which Committee will be constituted to comply with Applicable Laws. To the extent not prohibited by Applicable Laws, the Committee may,any portion of such Holder’s Series [] Preferred Stock from time to time delegate some orin accordance with this Section 6; provided that, in each case, no right of conversion may be exercised by a Holder in respect of fewer than 10 shares of Series [] Preferred Stock (unless such conversion relates to all shares of Series [] Preferred Stock held by such Holder).
(b) The Company shall at all times reserve and keep available out of its authority underauthorized and unissued Common Stock, solely for issuance upon the Plan to the Administrator as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the timeconversion of the delegation. For purposesSeries [] Preferred Stock, such number of the Plan, all references to the Committee will be deemed to refer to the Administrator to whom the Committee delegates authority pursuant to this Section 14. The Administrator will have full and exclusive discretionary authority to construe, interpret and apply the terms of the Plan, to designate separate Offerings under the Plan, to designate Subsidiaries and Affiliates as participating in the 423 Component or Non-423 Component, to determine eligibility, to adjudicate all disputed claims filed under the Plan and to establish such procedures that it deems necessary for the administration of the Plan (including, without limitation, to adopt such procedures and sub-plans as are necessary or appropriate to permit the participation in the Plan by employees who are foreign nationals or employed outside the U.S., the terms of which sub-plans may take precedence over other provisions of the Plan, with the exception of Section 13(a) hereof, but unless otherwise superseded by the terms of such sub-plan, the provisions of the Plan shall govern the operation of such sub-plan). Unless otherwise determined by the Administrator, the employees eligible to participate in each sub-plan will participate in a separate Offering and will be in the Non-423 Component, unless such designation would cause the 423 Component to violate the requirements of Section 423 of the Code. Without limiting the generality of the foregoing, the Administrator is specifically authorized to adopt rules and procedures regarding eligibility to participate, the definition of Compensation, handling of Contributions, making of Contributions to the Plan (including, without limitation, in forms other than payroll deductions), establishment of bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures and handling of stock certificates that vary with applicable local requirements. The Administrator also is authorized to determine that, to the extent permitted by U.S. Treasury Regulation Section 1.423-2(f), the terms of an option granted under the Plan or an Offering to citizens or residents of a non-U.S. jurisdiction will be less favorable than the terms of options granted under the Plan or the same Offering to employees resident solely in the U.S. Every finding, decision and determination made by the Administrator will, to the full extent permitted by law, be final and binding upon all parties.
15. Designation of Beneficiary.
(a) If permitted by the Administrator, a Participant may file a designation of a beneficiary who is to receive any shares of Common Stock as shall from time to time be issuable upon the conversion of all the shares of Series [] Preferred Stock then outstanding. Any shares of Common Stock issued upon conversion of Series [] Preferred Stock shall be duly authorized, validly issued, fully paid and cash, if any, from the Participant’s account under the Plan in the eventnon-assessable.
SECTION 7. Mechanics of Optional Conversion.
(a) In order for a Holder to effect an Optional Conversion, such Participant’s death subsequent to an Exercise Date on which the option is exercised but prior to delivery to such Participant of such shares and cash. In addition, if permitted by the Administrator, a Participant may file a designation of a beneficiary who is to receive any cash from the Participant’s account under the Plan in the event of such Participant’s death prior to exercise of the option. If a Participant is married and the designated beneficiary is not the spouse, spousal consent will be required for such designation to be effective.
(b) Such designation of beneficiary may be changed by the Participant at any time byholder shall (i) provide written notice to the Company’s stock administrationTransfer Agent (“Conversion Notice”) that such Holder elects to convert all or any number of such holder’s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (ii) if such Holder’s shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock at the office (or its designee)of the Transfer Agent. The Conversion Notice shall state such Holder’s name or the names of the nominees in which such Holder wishes the Common Securities to be issued. If required by the Company or the Transfer Agent, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in a form determinedreasonably satisfactory to the Company, duly executed by the Administrator. Inregistered holder or his, her or its attorney duly authorized in writing. The close of business on the eventdate of receipt by the Transfer Agent of the death of a ParticipantConversion Notice and, in the absence of a beneficiary validly designated under the Plan who is living atif applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the “Conversion Time”), and the Common Securities issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such Participant’s death,date. The Company shall, as soon as practicable after the Company willConversion Time (i) issue and deliver to such Holder, or to his, her or its nominees, a notice of issuance for the number of Common Securities in accordance with the provisions hereof and a notice of issuance for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, and (ii) pay all Accrued Dividends on the shares of Preferred Stock converted.
(b) Effect of Conversion. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares and/or cash toshall immediately cease and terminate at the executor or administratorConversion Time, except only the right of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares and/or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other Person as the Company may designate.
(c) All beneficiary designations will be in such form and manner as the Administrator may designate from time to time. Notwithstanding Sections 15(a) and (b) above, the Company and/or the Administrator may decide not to permit such designations by Participants in non-U.S. jurisdictions to the extent permitted by U.S. Treasury Regulation Section 1.423-2(f).
16. Transferability. Neither Contributions credited to a Participant’s account nor any rights with regard to the exercise of an option orholders thereof to receive shares of Common Stock under the Plan may be assigned, transferred, pledged or otherwise disposeda Warrant in exchange therefor and to receive payment of in any way (other than by will, the laws of descent and distribution or as provided in Section 15 hereof) by the Participant. Any such attempt at assignment, transfer, pledge or other disposition will be without effect, except that the Company may treat such act as an election to withdraw funds from an Offering Period in accordance with Section 10 hereof.Accrued Dividends.
B-8

TABLE OF CONTENTS

17. UseAny shares of Funds. ThePreferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Company may use all Contributions received or held by it underthereafter take such appropriate action (without the Planneed for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.
(c) No Further Adjustment. Upon any such conversion, no adjustment to the Conversion Price shall be made for any corporate purpose,declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.
SECTION 8. Redemption. (a) Redemption at the Option of the Company.
(i) At any time on or after the two (2)-year anniversary of the Issuance Date, the Company shall have the right (the “Company Redemption Right”) to redeem, in whole but not in part, the shares of Series [] Preferred Stock of any Holder outstanding at such time at a redemption price equal to [] per share2 (such price, the “Redemption Price”); provided, that (A) the Closing Price of a share of Common Stock exceeds 250% of the then-applicable Conversion Price per share for at least 20 out of 30 consecutive Trading Days prior to the Redemption Date and (B) a Shelf Registration Statement that is required to be effective pursuant to the Registration Rights Agreement on such date shall be effective on such date with respect to the applicable Holder (a “Company Redemption”). The Redemption Price shall be payable in cash or Common Securities. The number of Common Securities issuable upon such Company Redemption shall be equal to the Redemption Price divided by the Conversion Price then in effect. Notwithstanding the foregoing, the Company will not be obligatedexercise the Company Redemption Right, or otherwise send a Notice of Company Redemption in respect of the redemption of, any Series [] Preferred Stock pursuant to segregate such Contributions except under Offeringsthis Section 8 unless the Company has sufficient funds or Common Stock legally available to fully pay the Redemption Price in respect of all shares of Series [] Preferred Stock called for Participants inredemption.
(ii) To exercise the Non-423 Component for which Applicable Laws require that ContributionsCompany Redemption Right pursuant to this Section 8(a), the Company shall deliver written notice thereof (a “Notice of Company Redemption”) to the Plan by Participants be segregated fromHolders and the Company’s general corporate funds and/or deposited with an independent third party.
18. Reports. Individual accounts will be maintained for each Participant in the Plan. Statements of account will be given to participating Eligible EmployeesTransfer Agent at least annually, which statementsfive days prior to the Redemption Date designated therein for such redemption. The Notice of Company Redemption shall contain instructions whereby Holders will surrender to the Transfer Agent all shares of Series [] Preferred Stock. The Company shall deliver or cause to be delivered to each Holder that has complied with the instructions set forth in such Notice of Company Redemption, either: (A) in cash by wire transfer, or (B) Common Securities on a book-entry basis, through the amountsfacilities of Contributions,The Depository Trust Company, or by mailing certificates evidencing the Purchaseshares to such Holders, in an amount equal to the Redemption Price of the number of shares of CommonSeries [] Preferred Stock purchasedin respect of which such Holder has complied with such instructions in accordance herewith.
(b) Effect of Redemption. With respect to any share of Series [] Preferred Stock which has not been converted by a Holder prior to the Redemption Date and the remaining cash balance, if any.
19. Adjustments, Dissolution, Liquidation, Merger or Change in Control.
(a) Adjustments. In the event that any subdivision or consolidation of outstanding shares of Common Stock, declaration of a dividend payable in shares of Common Stock or other stock split, other recapitalization or capital reorganization of the Company, any consolidation or merger of the Company with another corporation or entity, the adoptionhas been specified to be redeemed by the Company of any plan of exchange affecting the Common Stock or any distribution to holders of Common Stock of securities or property (other than normal cash dividends or dividends payable in Common Stock), the Committee, in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will, in such manner as it may deem equitable, adjust the number and class of Common Stock that may be delivered under the Plan, the Purchase Price per share and the number of shares of Common Stock covered by each option under the Plan that has not yet been exercised, and the numerical limits of Sections 7 and 13 of the Plan. For the avoidance of doubt, the Committee may not delegate its authority to make adjustments pursuant to this Section 19(a).
(b) Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company any Offering Period thenRedemption Right and which has been redeemed in progress will be shortened by setting a New Exercise Date, and will terminate immediately prioraccordance with the provisions of this Section 8, or for which the Company has irrevocably deposited an amount equal to the consummationRedemption Price in respect of such proposed dissolution or liquidation, unless provided otherwise byshare with the Administrator. The New Exercise Date willTransfer Agent, then (i) Dividends shall cease to accrue on such share, (ii) such share shall no longer be before the date of the Company’s proposed dissolution or liquidation. The Company’s stock administration office (or its designee) will notify each Participant in writing or electronically, prior to the New Exercise Date, that the Exercise Date for the Participant’s option has been changed to the New Exercise Datedeemed outstanding and that the Participant’s option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in Section 10 hereof.
(c) Merger or Change in Control. In the event of a merger or Change in Control, each outstanding option will be assumed or an equivalent option substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. In the event that the successor corporation refuses to assume or substitute for the option, the Offering Period(iii) all rights with respect to which such option relates will be shortened by setting a New Exercise Date on which such Offering Periodshare shall end. The New Exercise Date will occur before the date of the Company’s proposed merger or Change in Control. The Company’s stock administration office (or its designee) will notify each Participant in writing or electronically prior to the New Exercise Date, that the Exercise Date for the Participant’s option has been changed to the New Exercise Datecease and that the Participant’s option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in Section 10 hereof.terminate.
20. Amendment or Termination.
(a) The Board or the Administrator, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time and for any reason. If the Plan is terminated, the Board or the Administrator, in its discretion, may elect to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of shares of Common Stock on the next Exercise Date (which may be sooner than originally scheduled, if determined by the Administrator in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to Section 19 hereof). If the Offering Periods are terminated prior to expiration, all amounts then credited to Participants’ accounts that have not been used to purchase shares of Common Stock will be returned to the Participants (without interest thereon, except as otherwise required under Applicable Laws, as further set forth in Section 12 hereof) as soon as administratively practicable.
2
Amount to equal Issuance Price plus three (3) years of Dividend payment
B-9

TABLE OF CONTENTS

(b) Without stockholder consent and without limiting Section 20(a) hereof, the AdministratorSECTION 9. Anti-Dilution Adjustments. (a) Adjustments. The Conversion Rate will be entitledsubject to changeadjustment, without duplication, upon the Offering Periods or Purchase Periods, designate separate Offerings, limit the frequency and/or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit Contributions in excessoccurrence of the amount designated by a Participant in orderfollowing events, except that the Company shall not make any adjustment to adjust for delays or mistakes in the Company’s processingConversion Rate if Holders of properly completed Contribution elections, establish reasonable waitingthe Series [] Preferred Stock participate, at the same time and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied towardupon the purchasesame terms as holders of Common Stock for each Participant properly correspond with Contribution amounts, and establishsolely as a result of holding shares of Series [] Preferred Stock, in any transaction described in this Section 9(a), without having to convert their Series [] Preferred Stock, as if the respective Holders held such other limitations or procedures as the Administrator determines in its sole discretion advisable that are consistent with the Plan.
(c) In the event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, in its discretion and, to the extent necessary or desirable, modify, amend or terminate the Plan to reduce or eliminate such accounting consequence including, but not limited to:
(i) amending the Plan to conform with the safe harbor definition under the Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto), including with respect to an Offering Period underway at the time;
(ii) altering the Purchase Price for any Offering Period or Purchase Period including an Offering Period or Purchase Period underway at the time of the change in Purchase Price;
(iii) shortening any Offering Period or Purchase Period by setting a New Exercise Date, including an Offering Period or Purchase Period underway at the time of the Administrator action;
(iv) reducing the maximum percentage of Compensation a Participant may elect to set aside as Contributions; and
(v) reducing the maximum number of shares of Common Stock into which the number of shares of Series [] Preferred Stock held by such Holders are then convertible pursuant to Section 6(a) (without regard to any limitations on convertibility contained therein):
(i) The issuance of Common Stock as a Participant may purchase during any Offering Perioddividend or Purchase Period.
Such modificationsdistribution to all or amendments will not require stockholder approvalsubstantially all holders of Common Stock, or a subdivision or combination of Common Stock or a reclassification of Common Stock into a greater or lesser number of shares of Common Stock, in which event the Conversion Rate shall be adjusted based on the following formula:
CR1
=
CR0 x (OS1 / OS0)
CR0
=
the Conversion Rate in effect immediately prior to the close of business on (i) the Record Date for such dividend or distribution, or (ii) the effective date of such subdivision, combination or reclassification
CR1
=
the new Conversion Rate in effect immediately after the close of business on (i) the Record Date for such dividend or distribution, or (ii) the effective date of such subdivision, combination or reclassification
OS0
=
the number of shares of Common Stock outstanding immediately prior to the close of business on (i) the Record Date for such dividend or distribution or (ii) the effective date of such subdivision, combination or reclassification
OS1
=
the number of shares of Common Stock that would be outstanding immediately after, and solely as a result of, the completion of such event
Any adjustment made pursuant to this clause (i) shall be effective immediately after the close of business on the Record Date for such dividend or distribution, or the consenteffective date of such subdivision, combination or reclassification. If any Plan Participants.such event is announced or declared but does not occur, the Conversion Rate shall be readjusted, effective as of the date the Board announces that such event shall not occur, to the Conversion Rate that would then be in effect if such event had not been declared.
21. Notices. All notices(ii) The dividend, distribution or other communications by a Participantissuance to the Company underall or substantially all holders of Common Stock of rights (other than rights, options or warrants distributed in connection with a stockholder rights plan (in which event the Plan will be deemedprovisions of Section 9(a)(viii) shall apply)), options or warrants entitling them, for a period of not more than forty-five (45) calendar days after the date such dividend, distribution or issuance is first announced, to have been duly given when received by the Company’s stock administration office (or its designee) in the form and manner specified by the Company’s stock administration office (or its designee)at the location,subscribe for or by the Person, designated by the Company’s stock administration office (or its designee) for the receipt thereof.
22. Conditions Upon Issuance of Shares.
(a) Sharespurchase shares of Common Stock, will not be issued with respect to an option unlessat a price per share that is less than the exerciseCurrent Market Price as of the Record Date for such option andissuance, in which event the issuance and delivery of such shares pursuant thereto will comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act of 1933, as amended, the Exchange Act, the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the shares may then be listed, andConversion Rate will be further subject toincreased based on the approval of counsel for the Company with respect to such compliance.following formula:
(b) As a condition to the exercise of an option, the Company may require the Person exercising such option to represent and warrant at the time of any such exercise that the shares are being purchased only for investment and without any present intention to sell or distribute such shares if, in the opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions of law.
23. Data Protection. By participating in the Plan or accepting any rights granted under it, each Participant consents to the collection and processing of personal data relating to the Participant so that the Company and its Affiliates can fulfill their obligations and exercise their rights under the Plan and generally administer and manage the Plan. This data will include, but may not be limited to, data about participation in the Plan and shares offered or received, purchased, or sold under the Plan from time to time and other appropriate financial and other data about the Participant and the Participant’s participation in the Plan.
CR1
=
CR0 x [(OS0+X) / (OS0+Y)]
CR0
=
the Conversion Rate in effect immediately prior to the close of business on the Record Date for such dividend, distribution or issuance
CR1
=
the new Conversion Rate in effect immediately following the close of business on the Record Date for such dividend, distribution or issuance
OS0
=
the number of shares of Common Stock outstanding immediately prior to the close of business on the Record Date for such dividend, distribution or issuance
B-10

TABLE OF CONTENTS

X
=
the total number of shares of Common Stock issuable pursuant to such rights, options or warrants
Y
=
the number of shares of Common Stock equal to the aggregate price payable to exercise such rights, options or warrants divided by the Current Market Price as of the Record Date for such dividend, distribution or issuance.
24. Code Section 409A. The 423 ComponentFor purposes of this clause (ii), in determining whether any rights, options or warrants entitle the holders to purchase the Common Stock at a price per share that is less than the Current Market Price as of the Plan is exempt fromRecord Date for such dividend, distribution or issuance, there shall be taken into account any consideration the application of Code Section 409ACompany receives for such rights, options or warrants, and any ambiguities herein will be interpreted to so be exempt from Code Section 409A. In furtheranceamount payable on exercise thereof, with the value of the foregoing and notwithstanding any provision in the Plan to the contrary,such consideration, if the Administrator determines that an option granted under the Plan may be subject to Code Section 409A or that any provision in the Plan would cause an option under the Planother than cash, to be subjectthe Fair Market Value thereof.
Any adjustment made pursuant to Code Section 409A,this clause (ii) shall become effective immediately following the Administrator may amendclose of business on the terms ofRecord Date for such dividend, distribution or issuance. In the Plan and/event that such rights, options or of an outstanding option granted under the Plan, or take such other action the Administrator determines is necessary or appropriate, in each case, without the Participant’s consent, to exempt any outstanding option or future option that may be granted under the Plan from or to allow any such options to comply with Code Section 409A, but only to the extent any such amendments or action by the Administrator would not violate Code Section 409A. Notwithstanding the foregoing, the Company shall have no liability to a Participant or any other party if the option to purchase Common Stock under the Plan that is intended to be exempt from or compliant with Code Section 409A iswarrants are not so exempt or compliant or for any action taken byissued, the Administrator with respect thereto. The Company makes no representation that the option to purchase Common Stock under the Plan is compliant with Code Section 409A.
25. TermConversion Rate shall be readjusted, effective as of Plan. The Plan will become effective upon the earlier to occur of its adoption by the Board or its approval by the stockholders of the Company (the “Effective Date”). It will continue in effect for a term of ten (10) years, unless sooner terminated under Section 20 of the Plan.
26. Stockholder Approval. The Plan will be subject to approval by the stockholders of the Company within twelve (12) months before or after the date the Plan is adopted by the Board. Such stockholder approval will be obtained in the manner andBoard publicly announces its decision not to issue such rights, options or warrants, to the degree required under Applicable Laws.
27. Governing Law. The PlanConversion Rate that would then be in effect if such dividend, distribution or issuance had not been declared. To the extent that such rights, options or warrants are not exercised prior to their expiration or shares of Common Stock are otherwise not delivered pursuant to such rights, options or warrants upon the exercise of such rights, options or warrants, the Conversion Rate shall be governed by, and construedreadjusted to the Conversion Rate that would then be in accordance with,effect had the lawsadjustments made upon the dividend, distribution or issuance of such rights, options or warrants been made on the basis of the Statedelivery of Delaware (exceptonly the number of shares of Common Stock actually delivered.
(iii) The Company or one or more of its choice-of-law provisions).
28. No RightSubsidiaries purchases Common Stock pursuant to Employment. Participation in the Plana tender offer or exchange offer (other than an exchange offer that constitutes a Distribution Transaction subject to Section 9(a)(v)) by a Participant shall not be construed as giving a Participant the right to be retained as an employee of the Company or a Subsidiary or Affiliate, as applicable. Furthermore,of the Employer may dismiss a Participant from employment at any time, free from any liabilityCompany for all or any claimportion of the Common Stock, or otherwise acquires Common Stock (except (1) in an open market purchase in compliance with Rule 10b-18 promulgated under the Plan.
29. Severability. IfExchange Act, (2) through an “accelerated share repurchase” on customary terms if the cash and value of any provisionother consideration included in the payment per share of Common Stock validly tendered, exchanged or otherwise acquired through a Covered Repurchase exceeds the arithmetic average of the Plan is or becomes or is deemed to be invalid, illegal, or unenforceableVWAP per share of Common Stock for any reason in any jurisdiction or as to any Participant, such invalidity, illegality or unenforceability shall not affect the remaining partseach of the Plan,ten (10) consecutive full Trading Days commencing on, and including, the PlanTrading Day next succeeding the last day on which tenders or exchanges may be made pursuant to such tender or exchange offer (as it may be amended) or shares of Common Stock are otherwise acquired through a Covered Repurchase or (3) in connection with tax withholding upon vesting or settlement of options, restricted stock units, performance share units or other similar equity awards or upon forfeiture or cashless exercise of options or other equity awards) (a “Covered Repurchase”), in which event the Conversion Rate shall be construed and enforced as to such jurisdiction or Participant as ifincreased based on the invalid, illegal or unenforceable provision had not been included.following formula:
30. Compliance with Applicable Laws. The terms of the Plan are intended to comply with all Applicable Laws and will be construed accordingly.
31. Jurisdiction; Waiver of Jury Trial. The Plan shall be governed by and construed in accordance with the internal laws of the State of Delaware applicable to contracts made and performed wholly within the State of Delaware, without giving effect to the conflict of laws provisions thereof. EACH PARTICIPANT IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY SUIT, ACTION, OR OTHER PROCEEDING INSTITUTED BY OR AGAINST SUCH PARTICIPANT IN RESPECT OF THE PARTICIPANT’S RIGHTS OR OBLIGATIONS HEREUNDER.
CR1
=
CR0 x [(FMV + (SP1 x OS1)) / (SP1 x OS0)]
CR0
=
the Conversion Rate in effect immediately prior to the close of business on the Expiration Date
CR1
=
the new Conversion Rate in effect immediately after the close of business on the Expiration Date
FMV
=
the Fair Market Value, on the Expiration Date, of all cash and any other consideration paid or payable for all shares validly tendered or exchanged and not withdrawn, or otherwise acquired through a Covered Repurchase, as of the Expiration Date
OS0
=
the number of shares of Common Stock outstanding immediately prior to the last time tenders or exchanges may be made pursuant to such tender or exchange offer (including the shares to be purchased in such tender or exchange offer) or shares are otherwise acquired through a Covered Repurchase
B-11

TABLE OF CONTENTS

OS1
=
the number of shares of Common Stock outstanding immediately after the last time tenders or exchanges may be made pursuant to such tender or exchange offer (after giving effect to the purchase of shares in such tender or exchange offer) or shares are otherwise acquired through a Covered Repurchase
SP1
=
the arithmetic average of the VWAP per share of Common Stock for each of the ten (10) consecutive full Trading Days commencing on, and including, the Trading Day next succeeding the Expiration Date
Such adjustment shall become effective immediately after the close of business on the Expiration Date. If an adjustment to the Conversion Rate is required under this Section 9(a)(iii), delivery of any additional shares of Common Stock that may be deliverable upon conversion as a result of an adjustment required under this Section 9(a)(iii) shall be delayed to the extent necessary in order to complete the calculations provided for in this Section 9(a)(iii).
In the event that the Company or any of its Subsidiaries is obligated to purchase Common Stock pursuant to any such tender offer, exchange offer or other commitment to acquire shares of Common Stock other than through a Covered Repurchase but is permanently prevented by applicable law from effecting any such purchases, or all such purchases are rescinded, then the Conversion Rate shall be readjusted to be the Conversion Rate that would have been then in effect if such tender offer, exchange offer or Covered Repurchase had not been made.
(iv) The Company shall, by dividend or otherwise, distribute to all or substantially all holders of its Common Stock (other than for cash in lieu of fractional shares), shares of any class of its Capital Stock, evidences of its indebtedness, assets, other property or securities, but excluding (A) dividends or distributions referred to in Section 9(a)(i) or Section 9(a)(ii), (B) Distribution Transactions as to which Section 9(a)(v) shall apply, (C) dividends or distributions paid exclusively in cash as to which Section 9(a)(vi) shall apply and (D) rights, options or warrants distributed in connection with a stockholder rights plan as to which Section 9(a)(viii) shall apply (any of such shares of its Capital Stock, indebtedness, assets or property that are not so excluded are hereinafter called the “Distributed Property”), then, in each such case the Conversion Rate shall be increased based on the following formula:
CR1
=
CR0 x [SP0 / (SP0 - FMV)]
CR0
=
the Conversion Rate in effect immediately prior to the close of business on the Record Date for such dividend or distribution
CR1
=
the new Conversion Rate in effect immediately after the close of business on the Record Date for such dividend or distribution
SP0
=
the Current Market Price as of the Record Date for such dividend or distribution
FMV
=
the Fair Market Value of the portion of Distributed Property distributed with respect to each outstanding share of Common Stock on the Record Date for such dividend or distribution; provided that, if FMV is equal or greater than SP0, then in lieu of the foregoing adjustment, the Company shall distribute to each holder of Series [] Preferred Stock on the date the applicable Distributed Property is distributed to holders of Common Stock, but without requiring such holder to convert its shares of Series [] Preferred Stock, in respect of each share of Series [] Preferred Stock held by such holder, the amount of Distributed Property such holder would have received had such holder owned a number of shares of Common Stock equal to the Conversion Rate on the Record Date for such dividend or distribution
Any adjustment made pursuant to this clause (iv) shall be effective immediately after the close of business on the Record Date for such dividend or distribution. If any such dividend or distribution is declared but does not occur, the Conversion Rate shall be readjusted, effective as of the date the Board announces that such dividend or distribution shall not occur, to the Conversion Rate that would then be in effect if such dividend or distribution had not been declared.
B-12

TABLE OF CONTENTS

(v) The Company effects a Distribution Transaction, in which case the Conversion Rate in effect immediately prior to the effective date of the Distribution Transaction shall be increased based on the following formula:
CR1
=
CR0 x [(FMV + MP0) / MP0]
CR0
=
the Conversion Rate in effect immediately prior to the close of business on the effective date of the Distribution Transaction
CR1
=
the new Conversion Rate in effect immediately after the close of business on the effective date of the Distribution Transaction
FMV
=
the product of (x) the number of shares or units of Capital Stock or equity interests distributed per share of Common Stock in the Distribution Transaction and (y) the arithmetic average of the volume-weighted average prices for a share or unit of such Capital Stock or equity interest distributed to holders of Common Stock on the principal United States securities exchange or automated quotation system on which such capital stock or other interest trades, as reported by Bloomberg (or, if Bloomberg ceases to publish such price, any successor service chosen by the Company) in respect of the period from the open of trading on the relevant Trading Day until the close of trading on such Trading Day (or if such volume-weighted average price is unavailable, the market price of one share of such capital stock or other interest on such Trading Day determined, using a volume-weighted average method, by an Independent Financial Advisor retained for such purpose by the Company), for each of the ten (10) consecutive full Trading Days commencing with, and including, the first Trading Day following the effective date of the Distribution Transaction
MP0
=
the arithmetic average of the VWAP per share of Common Stock for each of the ten (10) consecutive full Trading Days commencing on, and including, the first Trading Day following the effective date of the Distribution Transaction
Such adjustment shall become effective immediately following the close of business on the effective date of the Distribution Transaction. If an adjustment to the Conversion Rate is required under this Section 9(a)(v), delivery of any additional shares of Common Stock that may be deliverable upon conversion as a result of an adjustment required under this Section 9(a)(v) shall be delayed to the extent necessary in order to complete the calculations provided for in this Section 9(a)(v).
(vi) The Company makes a cash dividend or distribution to all or substantially all holders of the Common Stock, the Conversion Rate shall be increased based on the following formula:
CR1
=
CR0 x [SP0 / (SP0 – C)]
CR0
=
the Conversion Rate in effect immediately prior to the close of business on the Record Date for such dividend or distribution
CR1
=
the new Conversion Rate in effect immediately after the close of business on the Record Date for such dividend or distribution
SP0
=
the Current Market Price as of the Record Date for such dividend or distribution
C
=
the amount in cash per share of Common Stock the Company distributes to all or substantially all holders of its Common Stock; provided that, if C is equal or greater than SP0, then in lieu of the foregoing adjustment, the Company shall pay to each holder of Series [] Preferred Stock on the date the applicable cash dividend or distribution is made to holders of Common Stock, but without requiring such holder
B-13

TABLE OF CONTENTS

to convert its shares of Series [] Preferred Stock, in respect of each share of Series [] Preferred Stock held by such holder, the amount of cash such holder would have received had such holder owned a number of shares of Common Stock equal to the Conversion Rate on the Record Date for such dividend or distribution
Any adjustment made pursuant to this clause (vi) shall be effective immediately after the close of business on the Record Date for such dividend or distribution. If any dividend or distribution is declared but not paid, the Conversion Rate shall be readjusted, effective as of the date the Board announces that such dividend or distribution will not be paid, to the Conversion Rate that would then be in effect if such had dividend or distribution not been declared.
(vii) The Company issues shares of Common Stock or any other security convertible into, exercisable or exchangeable for Common Stock (such Common Stock or other security, “Equity-Linked Securities”) (other than in Excluded Issuances (as defined below) or a transaction to which Section 9(a)(i), Section 9(a)(ii), Section 9(a)(iv) or Section 9(a)(v) applies), for a consideration per share of Common Stock (or conversion, exercise or exchange price per share of Common Stock) less than the then-applicable Conversion Price on the date the Company fixes the offering price (or conversion, exercise or exchange price) of Equity-Linked Securities, the Conversion Rate shall be increased based on the following formula:
CR1
=
CR0 x [(OS0 + A) / (OS0 + B)]
CR0
=
the Conversion Rate in effect immediately prior to the issuance of such Equity-Linked Securities
CR1
=
the new Conversion Rate in effect immediately after the issuance of such Equity-Linked Securities
OS0
=
the number of shares of Common Stock outstanding immediately prior to the issuance of such Equity-Linked Securities (treating for this purpose as outstanding all shares of Common Stock issuable upon (i) conversion of all convertible securities of the Company and (ii) exercise or vesting of any equity awards of the Company, including options and restricted stock units (using the treasury stock method as determined by the Company))
A
=
the maximum number of additional shares of Common Stock issued (or into which Equity-Linked Securities may be converted)
B
=
the number of shares of Common Stock (or into which such Equity-Linked Securities may be converted) that would have been issued assuming such additional shares of Common Stock had been issued or deemed issued at a price per share of Common Stock equal to the Conversion Price (such amount determined by dividing the aggregate consideration receivable by the Company for the total number of shares of Common Stock to be issued (or into which such Equity-Linked Securities may be converted) by the Conversion Price immediately prior to the execution of the definitive agreement on pricing such shares (or such Equity-Linked Securities))
For purposes of this Section 9(a)(vii), the aggregate consideration receivable by the Company in connection with the issuance of such shares of Common Stock or Equity-Linked Securities shall be deemed to be equal to the sum of (x) the purchase price payable solely in cash of all such securities plus (y) the minimum aggregate amount, if any, payable upon conversion, exercise or exchange of any such Equity-Linked Securities into or for shares of Common Stock plus (z) the Fair Market Value of any consideration that consists all or in part of property other than cash; and “Excluded Issuances” means issuances of Common Stock or Equity-Linked Securities (i) as consideration for an acquisition of businesses and/or related assets, (ii) pursuant to employee benefit plans and compensation related arrangements approved by the Board, (iii) pursuant to any issuance, exercise or conversion of securities or rights issued pursuant to a distribution in which shares of the Series [] Preferred Stock participate or in connection with
B-14

TABLE OF CONTENTS

a stockholder rights plan, or (iv) in connection with the conversion, exercise or exchange of any Equity-Linked Security pursuant to its terms. Any adjustment made pursuant to this Section 9(a)(vii) shall become effective immediately upon the date of such issuance of such Common Stock or Equity-Linked Securities, as applicable.
Upon the expiration or termination of any unconverted, unexercised or unexchanged Equity-Linked Security which resulted in an adjustment to the Conversion Rate pursuant to this Section 9(a)(vii), the Conversion Rate shall be adjusted to such Conversion Rate that would be in effect if such Equity-Linked Security had never been issued.
(viii) If the Company has a stockholder rights plan in effect with respect to the Common Stock on any Conversion Date, upon conversion of any shares of the Series [] Preferred Stock, Holders of such shares will receive, in addition to the applicable number of shares of Common Stock, the rights under such rights plan relating to such Common Stock, unless, prior to such Conversion Date, the rights have (i) become exercisable or (ii) separated from the shares of Common Stock (the first of such events to occur, a “Trigger Event”), in which case, the Conversion Rate will be adjusted, effective automatically at the time of such Trigger Event, as if the Company had made a distribution of such rights to all holders of Common Stock as described in Section 9(a)(ii) (without giving effect to the forty-five (45) calendar day limit on exercisability of rights, options or warrants ordinarily subject to such Section 9(a)(ii)), subject to appropriate readjustment in the event of the expiration, termination or redemption of such rights prior to the exercise, deemed exercise or exchange thereof. Notwithstanding the foregoing, to the extent any such stockholder rights are exchanged by the Company for shares of Common Stock or other property or securities, the Conversion Rate shall be appropriately readjusted as if such stockholder rights had not been issued, but the Company had instead issued such shares of Common Stock or other property or securities as a dividend or distribution of shares of Common Stock pursuant to Section 9(a)(i) or Section 9(a)(iv), as applicable.
To the extent that such rights are not exercised prior to their expiration, termination or redemption, the Conversion Rate shall be readjusted to the Conversion Rate that would then be in effect had the adjustments made upon the occurrence of the Trigger Event been made on the basis of the issuance of, and the receipt of the exercise price with respect to, only the number of shares of Common Stock actually issued pursuant to such rights.
Notwithstanding anything to the contrary in this Section 9(a)(viii), no adjustment shall be required to be made to the Conversion Rate with respect to any Holder which is, or is an “affiliate” or “associate” of, an “acquiring person” under such stockholder rights plan or with respect to any direct or indirect transferee of such Holder who receives Series [] Preferred Stock in such transfer after the time such Holder becomes, or its affiliate or associate becomes, such an “acquiring person”.
(b) Calculation of Adjustments. All adjustments to the Conversion Rate shall be calculated by the Company to the nearest 1/10,000th of one share of Common Stock (or if there is not a nearest 1/10,000th of a share, to the next lower 1/10,000th of a share). No adjustment to the Conversion Rate will be required unless such adjustment would require an increase or decrease of at least one percent of the Conversion Rate; provided, however, that any such adjustment that is not required to be made will be carried forward and taken into account in any subsequent adjustment; provided, further that any such adjustment of less than one percent that has not been made will be made upon any Conversion Date or redemption or repurchase date.
(c) When No Adjustment Required. (i) Except as otherwise provided in this Section 9, the Conversion Rate will not be adjusted for the issuance of Common Stock or any securities convertible into or exchangeable for Common Stock or carrying the right to purchase any of the foregoing, or for the repurchase of Common Stock.
(ii) Except as otherwise provided in this Section 9, the Conversion Rate will not be adjusted as a result of the issuance of, the distribution of separate certificates representing, the exercise or redemption of, or the termination or invalidation of, rights pursuant to any stockholder rights plans.
(iii) No adjustment to the Conversion Rate will be made:
(A) upon the issuance of any shares of Common Stock pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on securities of the Company and the
B-15

TABLE OF CONTENTS

investment of additional optional amounts in Common Stock under any plan in which purchases are made at market prices on the date or dates of purchase, without discount, and whether or not the Company bears the ordinary costs of administration and operation of the plan, including brokerage commissions;
(B) upon the issuance of any shares of Common Stock or options or rights to purchase such shares pursuant to any present or future employee, director or consultant benefit plan or program of or assumed by the Company or any of its Subsidiaries or of any employee agreements or arrangements or programs;
(C) except as expressly provided in Section 9, upon the issuance of any shares of Common Stock pursuant to any option, warrant, right, or exercisable, exchangeable or convertible security, including the Series [] Preferred Stock;
(D) for a change in the par value of the Common Stock;
(E) pursuant to any merger, joint venture, partnership, share exchange, business combination or similar transaction or any other direct or indirect acquisition by the Company with parties that are not Affiliates, whereby the Common Stock comprises, in whole or in part, the consideration paid by the Company in such transaction, provided such transaction was (1) approved by the holders of the Voting Stock or (2) approved by the Board; or
(F) upon the issuance of any shares of Common Stock or warrants to acquire only shares of Common Stock issued to non-Affiliate banks, equipment lessors or other lending institutions, or to non-Affiliate real property lessors, in each case, in connection with a debt financing, equipment leasing or real property leasing transaction, provided such transaction was approved by the Board.
(d) Successive Adjustments. After an adjustment to the Conversion Rate under this Section 9, any subsequent event requiring an adjustment under this Section 9 shall cause an adjustment to each such Conversion Rate as so adjusted.
(e) Multiple Adjustments. For the avoidance of doubt, if an event occurs that would trigger an adjustment to the Conversion Rate pursuant to this Section 9 under more than one subsection hereof, such event, to the extent fully taken into account in a single adjustment, shall not result in multiple adjustments hereunder; provided, however, that if more than one subsection of this Section 9 is applicable to a single event, the subsection shall be applied that produces the largest adjustment.
(f) Notice of Adjustments. Whenever the Conversion Rate is adjusted as provided under this Section 9, the Company shall as soon as reasonably practicable following the occurrence of an event that requires such adjustment (or if the Company is not aware of such occurrence, as soon as reasonably practicable after becoming so aware):
(i) compute the adjusted applicable Conversion Rate in accordance with this Section 9 and prepare and transmit to the Conversion Agent an Officer’s Certificate setting forth the applicable Conversion Rate, the method of calculation thereof, and the facts requiring such adjustment and upon which such adjustment is based; and
(ii) provide a written notice to the Holders of the occurrence of such event and a statement in reasonable detail setting forth the method by which the adjustment to the applicable Conversion Rate was determined and setting forth the adjusted applicable Conversion Rate.
(g) Conversion Agent. The Conversion Agent shall not at any time be under any duty or responsibility to any Holder to determine whether any facts exist that may require any adjustment of the Conversion Rate or with respect to the nature or extent or calculation of any such adjustment when made, or with respect to the method employed in making the same. The Conversion Agent shall be fully authorized and protected in relying on any Officer’s Certificate delivered pursuant to this Section 9(g) and any adjustment contained therein and the Conversion Agent shall not be deemed to have knowledge of any adjustment unless and until it has received such certificate. The Conversion Agent shall not be accountable with respect to the validity or value (or the kind or amount) of any shares of Common Stock, or of any securities or property, that may at the time be issued or delivered with respect to any Series [] Preferred Stock and the Conversion Agent makes no representation
B-16

TABLE OF CONTENTS

with respect thereto. The Conversion Agent shall not be responsible for any failure of the Company to issue, transfer or deliver any shares of Common Stock pursuant to the conversion of Series [] Preferred Stock or to comply with any of the duties, responsibilities or covenants of the Company contained in this Section 9.
(h) Fractional Shares. No fractional shares of Common Stock will be delivered to the Holders upon conversion. In lieu of fractional shares otherwise issuable, the Holders will be entitled to receive, at the Company’s sole discretion, an amount in cash equal to the fraction of a share of Common Stock multiplied by the Closing Price of the Common Stock on the Trading Day immediately preceding the applicable Conversion Date. In order to determine whether the number of shares of Common Stock to be delivered to a Holder upon the conversion of such Holder’s shares of Series [] Preferred Stock will include a fractional share, such determination shall be based on the aggregate number of shares of Series [] Preferred Stock of such Holder that are being converted and/or issued on any single Conversion Date.
SECTION 10. Reserved.
SECTION 11. Voting Rights.
(a) General. The Holders have no voting rights except as expressly set forth herein or as otherwise provided by the DGCL. The Holders of shares of Series [] Preferred Stock shall be entitled to vote with the other holders of Preferred Stock, voting together as a single class, with respect to (i) changes to the legal or tax form of the Company, (ii) changes to the authorized number of shares of Preferred Stock or any series of Preferred Stock, (iii) the issuance of additional Preferred Stock other than in connection with the Standby Equity Purchase Agreement on the Issuance Date, (iv) amendments to the Company’s Certificate of Incorporation or Bylaws which may alter or change the privileges, preferences or rights of the Preferred Stock, or the qualifications, limitations or restrictions thereof, or change the authorized number of shares of the Preferred Stock or any series thereof below the amount issued and outstanding, or (v) the incurrence of any indebtedness or the provision of any guaranty by the Company that is junior to the most senior indebtedness of the Company in right of payment or lien priority, the incurrence of any indebtedness by any Subsidiary and the provision of any guaranty or the imposition of any lien on any assets or equity securities of the Company or any Subsidiary. On such matters on which the Holders are entitled to vote, each Holder shall be entitled to the number of votes, equal to the number of shares of Series [] Preferred Stock held by such Holder. The Holders shall be entitled to notice of any meeting of holders of Preferred Stock in accordance with the Certificate of Incorporation and Bylaws of the Company.
(b) Each Holder of Series [] Preferred Stock will have one (1) vote per share on any matter on which Holders of Series [] Preferred Stock are entitled to vote as a single class, whether at a meeting or by written consent.
SECTION 12. Preemptive Rights. Each of the Holders of Series [] Preferred Stock shall have preemptive rights to purchase issuances of securities offered by the Company on a pro-rata basis among all series of Preferred Stock up to an amount equal to such Holder’s beneficial ownership interest in the Common Stock of the Company and without regard to the Stock Issuance Cap for purposes of calculating shares issuable pursuant to the preemptive rights. However, in the event of a Holder’s exercise of its preemptive rights, where such Holder’s ownership of Common Stock exceeds the Stock Issuance Cap, the Company shall issue to the relevant Holder a Warrant exercisable for Common Stock at such time that the Holder’s ownership of Common Stock is below the Stock Issuance Cap.
SECTION 13. Term. Except as expressly provided in this Certificate of Designations, the shares of Series [] Preferred Stock shall be perpetual.
SECTION 14. Creation of Capital Stock. The Board, or any duly authorized committee thereof, without the vote of the Holders, may authorize and issue additional shares of Capital Stock of the Company.
SECTION 15. No Sinking Fund. Shares of Series [] Preferred Stock shall not be subject to or entitled to the operation of a retirement or sinking fund.
SECTION 16. Transfer Agent, Conversion Agent, Registrar and Paying Agent. The duly appointed Transfer Agent, Conversion Agent, Registrar and paying agent for the Series [] Preferred Stock shall be []. The Company
B-17

TABLE OF CONTENTS

may, in its sole discretion, appoint any other Person to serve as Transfer Agent, Conversion Agent, Registrar or paying agent for the Series [] Preferred Stock and thereafter may remove or replace such other Person at any time. Upon any such appointment or removal, the Company shall send notice thereof to the Holders.
SECTION 17. Replacement Certificates. (a) Mutilated, Destroyed, Stolen and Lost Certificates. If physical certificates evidencing the Series [] Preferred Stock are issued, the Company shall replace any mutilated certificate at the Holder’s expense upon surrender of that certificate to the Transfer Agent. The Company shall replace certificates that become destroyed, stolen or lost at the Holder’s expense upon delivery to the Company and the Transfer Agent of satisfactory evidence that the certificate has been destroyed, stolen or lost, together with any indemnity that may be required by the Transfer Agent and the Company. Any such replacement shall be done in accordance with the Bylaws of the Company.
(b) Certificates Following Conversion. If physical certificates representing the Series [] Preferred Stock are issued, the Company shall not be required to issue replacement certificates representing shares of Series [] Preferred Stock on or after the Conversion Date applicable to such shares (except if any certificate for shares of Series [] Preferred Stock shall be surrendered for partial conversion, the Company shall, at its expense, execute and deliver to or upon the written order of the Holder of the certificate so surrendered a new certificate for the shares of Series [] Preferred Stock not converted). In place of the delivery of a replacement certificate following the applicable Conversion Date, the Transfer Agent, upon receipt of the satisfactory evidence and indemnity described in clause (a) above, shall deliver the shares of Common Stock issuable upon conversion of such shares of Series [] Preferred Stock formerly evidenced by the physical certificate.
SECTION 18. Taxes. (a) Transfer Taxes. The Company shall pay any and all stock transfer, documentary, stamp and similar taxes that may be payable in respect of any issuance or delivery of shares of Series [] Preferred Stock or shares of Common Stock or other securities issued on account of Series [] Preferred Stock pursuant hereto or certificates representing such shares or securities. However, in the case of conversion of Series [] Preferred Stock, the Company shall not be required to pay any such tax that may be payable in respect of any transfer involved in the issuance or delivery of shares of Common Stock or other securities to a beneficial owner other than the beneficial owner of the Series [] Preferred Stock immediately prior to such conversion, and shall not be required to make any such issuance, delivery or payment unless and until the Person otherwise entitled to such issuance, delivery or payment has paid to the Company the amount of any such tax or has established, to the satisfaction of the Company, that such tax has been paid or is not payable.
(b) Withholding. All payments and distributions (or deemed distributions) on the shares of Series [] Preferred Stock (and on the shares of Common Stock received upon their conversion) shall be subject to withholding and backup withholding of taxes to the extent required by law, subject to applicable exemptions, and amounts withheld, if any, shall be treated as received by the Holders.
(c) Ownership Restriction. The Series [] Preferred Stock may only be held by, and may only be transferred to, a Holder that delivers to the Company (i) an IRS Form W-9, (ii) an IRS Form W-8BEN-E certifying its status as a “withholding foreign partnership,” (iii) an IRS Form W-8BEN-E or W-8EXP certifying entitlement to a complete exemption from dividend withholding tax under an applicable income tax treaty for which the Holder qualifies for benefits or under Section 892 of the Code. Any purported Transfer to a Person not described in the immediately preceding sentence shall be void ab initio.
SECTION 19. Notices. All notices referred to herein shall be in writing and, unless otherwise specified herein, all notices hereunder shall be deemed to have been given upon the earlier of receipt thereof or three (3) Business Days after the mailing thereof if sent by registered or certified mail with postage prepaid, or by private courier service addressed: (i) if to the Company, to its office at Aeva Technologies, Inc., 555 Ellis Street, Mountain View, CA 94043 (Attention: Soroush Salehian) (with a copy to (which shall not constitute notice or delivery of process) Simpson Thacher & Bartlett LLP, 2475 Hanover Street, Palo Alto, CA 94304 (Attention: Heidi E. Mayon)), (ii) if to any Holder, to such Holder at the address of such Holder as listed in the stock record books of the Company (which may include the records of the Transfer Agent) or (iii) to such other address as the Company or any such Holder, as the case may be, shall have designated by notice similarly given.
SECTION 20. Facts Ascertainable. When the terms of this Certificate of Designations refers to a specific agreement or other document to determine the meaning or operation of a provision hereof, the Secretary of the Company shall maintain a copy of such agreement or document at the principal executive offices of the Company
B-18

TABLE OF CONTENTS

and a copy thereof shall be provided free of charge to any Holder who makes a request therefor. The Secretary of the Company shall also maintain a written record of the Issuance Date, the number of shares of Series [] Preferred Stock issued to a Holder and the date of each such issuance, and shall furnish such written record free of charge to any Holder who makes a request therefor.
SECTION 21. Waiver. Except as otherwise set forth in this Certificate of Designations, notwithstanding any provision in this Certificate of Designations to the contrary, any provision contained herein and any right of the Holders of Series [] Preferred Stock granted hereunder may be waived as to all shares of Series [] Preferred Stock (and the Holders thereof) upon the vote or written consent of the Holders of a majority of the shares of Series [] Preferred Stock then outstanding.
SECTION 22. Severability. If any term of the Series [] Preferred Stock set forth herein is invalid, unlawful or incapable of being enforced by reason of any rule of law or public policy, all other terms set forth herein which can be given effect without the invalid, unlawful or unenforceable term will, nevertheless, remain in full force and effect, and no term herein set forth will be deemed dependent upon any other such term unless so expressed herein.
[Signature Page Follows]
B-19

TABLE OF CONTENTS

IN WITNESS WHEREOF, the Company has caused this Certificate of Designations to be executed this []th day of [], 20[].
AEVA TECHNOLOGIES, INC.
By:
Name:
Title:
B-20

TABLE OF CONTENTS

Annex C
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT UNDER ANY CIRCUMSTANCES BE OFFERED, TRANSFERRED SOLD OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE FEDERAL, STATE AND FOREIGN SECURITIES LAWS.
PRE-FUNDED WARRANT
AEVA TECHNOLOGIES, INC.
Warrant
Initial Exercise Date: [], 202[]
Shares:
This PRE-FUNDED WARRANT (this “Pre-Funded Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [], 202[] (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on [], 20[]1 (the “Termination Date”), but not thereafter, to subscribe for and purchase from AEVA TECHNOLOGIES, INC., a corporation organized and existing under the laws of the State of Delaware (the “Company”), up to 2 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock (as defined below). The purchase price of one share of Common Stock under this Pre-Funded Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Pre-Funded Warrant is issued pursuant to the terms under certain standby equity purchase agreement (the “Purchase Agreement”), effective on November 8, 2023, and entered into between the Company and the Holder.
Section 1Definitions. In addition to the terms defined elsewhere in this Pre-Funded Warrant, for all purposes of this Pre-Funded Warrant, the following terms have the meanings set forth in this Section 1.
Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Subscription Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.
Black Scholes Value” means the value of this Pre-Funded Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately
1
Note: To expire on the 7 year anniversary from the issue date of the Pre-Funded Warrant
2
Note: Each Pre-Funded Warrant will be exercisable for such number of shares of Common Stock as would have been purchasable upon conversion of the Preferred Stock.
C-1

TABLE OF CONTENTS

preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant to Section 3(d) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five business days of the Holder’s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Pre-Funded Warrant in accordance with Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Pre-Funded Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Pre-Funded Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Pre-Funded Warrant (without regard to any limitations on the exercise of this Pre-Funded Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Pre-Funded Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Pre-Funded Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Pre-Funded Warrant with the same effect as if such Successor Entity had been named as the Company herein.
Business Day” and “business day” mean a day other than Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by law to close.
Common Stock” means the Company’s common stock, par value $0.001 per share.
Common Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
Trading Day” means a day on which the principal Trading Market is open for trading.
Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).
VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Subscription Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.
Warrant Agent” shall be any duly appointed agent selected by the Company. The Warrant Agent shall initially be the Company.
C-2

TABLE OF CONTENTS

Section 2Exercise.
(a) Exercise of Pre-Funded Warrant.
(i) Exercise by Holder. Exercise of the rights represented by this Pre-Funded Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (with a copy to the Warrant Agent) of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
(ii) Exercise Procedures. Notwithstanding anything herein to the contrary, subject to Section 2(d)(ii), the Holder shall not be required to physically surrender this Pre-Funded Warrant to the Company until the Holder has exercised all of the Warrant Shares available hereunder and this Pre-Funded Warrant has been exercised in full, in which case, the Holder shall surrender this Pre-Funded Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company (with a copy to the Warrant Agent). Partial exercises of this Pre-Funded Warrant resulting in exercises of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares exercisable hereunder in an amount equal to the applicable number of Warrant Shares exercised. The Holder and the Company shall maintain records showing the number of Warrant Shares exercised and the date of such exercises. The Company shall deliver any objection to any Notice of Exercise within one (1) business day of receipt of such notice. The Holder and any assignee, by acceptance of this Pre-Funded Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the exercise of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for exercise hereunder at any given time may be less than the amount stated on the face hereof.
(iii) Maximum Percentage. The Holder may notify the Company in writing in the event it elects to be subject to the provisions contained in this Section 2(a)(iii); provided, however, no Holder shall be subject to this Section 2(a)(iii) unless he, she or it makes such election. If the election is made by the Holder, the Warrant Agent shall not effect the exercise of the Holder’s Pre-Funded Warrants, and such Holder shall not have the right to exercise such Pre-Funded Warrants, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the Warrant Agent’s actual knowledge, would beneficially own in excess of 19.9% (or such other amount as a Holder may specify) (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such person and its affiliates shall include the number of shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants with respect to which the determination of such sentence is being made, but shall exclude Common Stock that would be issuable upon (x) exercise of the remaining, unexercised portion of the Pre-Funded Warrants beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates (including, without limitation, any convertible notes or convertible preferred shares or warrants), subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended. For purposes of the Pre-Funded Warrants, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the U.S. Securities and Exchange Commission (the “Commission”) as the case may be, or (2) a more recent public announcement by the Company. For any reason at any time, upon the written request of the Holder of the Pre-Funded Warrants, the Company shall, within five (5) Business Days, confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding. By written notice to the Company, the Holder of the Pre-Funded Warrants may from time to time increase or decrease the Maximum Percentage applicable to such Holder to any other percentage specified in such notice; provided, however, that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company.
C-3

TABLE OF CONTENTS

(b) Exercise Price. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001 (the “Exercise Price”). (the “Exercise Price”).
(c) Cashless Exercise. If at any time after the Initial Exercise Date, there is no effective registration statement registering, or the prospectus contained therein is not available for, the resale of the Warrant Shares by the Holder, then this Pre-Funded Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:
(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, or (ii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;
(B) = the Exercise Price of this Series A Warrant, as adjusted hereunder; and
(X) = the number of Warrant Shares that would be issuable upon exercise of this Series A Warrant in accordance with the terms of this Series A Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.
If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of this Series A Warrant being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Series A Warrant. The Company agrees not to take any position contrary to this Section 2(c).
(d) Mechanics of Exercise.
(i) Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares exercised hereunder to be transmitted by the Company’s transfer agent (the “Transfer Agent”) to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of this Pre-Funded Warrant), and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) two (2) Trading Days after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Pre-Funded Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this
C-4

TABLE OF CONTENTS

Pre-Funded Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.
(ii) Delivery of New Pre-Funded Warrants Upon Exercise. If this Pre-Funded Warrant shall have been exercised in part, the Company shall, at the request of the Holder and upon surrender of this Pre-Funded Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Pre-Funded Warrant evidencing the rights of the Holder to exercise the unexercised Warrant Shares called for by this Pre-Funded Warrant, which new Pre-Funded Warrant shall in all other respects be identical with this Pre-Funded Warrant.
(iii) Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.
(iv) Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of this Series A Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of this Series A Warrant as required pursuant to the terms hereof.
(v) No Fractional Pre-Funded Warrant, Shares or Scrip. No fractional Pre-Funded Warrants, shares or scrip representing fractional shares shall be issued upon the exercise of this Pre-Funded Warrant. To the extent the Holder would be entitled to a fractional Pre-Funded Warrant, the Company shall round down to the nearest whole number of Pre-Funded Warrants to be issued to the Holder. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.
(vi) Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Pre-Funded Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
C-5

TABLE OF CONTENTS

The Company shall pay all reasonable Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to The Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.
(vii) Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Pre-Funded Warrant, pursuant to the terms hereof.
Section 3Certain Adjustments.
(a) Reserved.
(b) Subsequent Rights Offerings. If at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Pre-Funded Warrant (without regard to any limitations on exercise hereof) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.
(c) Pro Rata Distributions. During such time as this Pre-Funded Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Pre-Funded Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Pre-Funded Warrant (without regard to any limitations on exercise hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution.
(d) Fundamental Transaction. If, at any time while this Pre-Funded Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the consolidated assets of the Company in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another person or group of persons whereby such other person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other person or other persons making or party to, or associated or affiliated with the other persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Pre-Funded Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Pre-Funded Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Pre-Funded Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Pre-Funded Warrant). If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
C-6

TABLE OF CONTENTS

the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Pre-Funded Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), exercise this Pre-Funded Warrant from the Holder by paying to the Holder an amount equals to the Black Scholes Value (as defined below), in the form of cash, stock or any combination thereof (at the Company’s discretion), of the remaining unexercised portion of this Pre-Funded Warrant on or around the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company’s control, including not approved by the Company’s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Pre-Funded Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
(e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.
(f) Notice to Holder.
(i) Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.
(ii) Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Pre-Funded Warrant constitutes, or contains, material, non-public information regarding the Company, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Pre-Funded Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.
C-7

TABLE OF CONTENTS

(g) Voluntary Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Series A Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.
Section 4Reserved.
Section 5Transfer of Pre-Funded Warrant.
(a) Transferability. Subject to compliance with any applicable securities laws, this Pre-Funded Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Pre-Funded Warrant at the principal office of the Company or its designated Warrant Agent, which shall initially be the Company, together with a written assignment of this Pre-Funded Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Pre-Funded Warrant or Pre-Funded Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Pre-Funded Warrant evidencing the portion of this Pre-Funded Warrant not so assigned, and this Pre-Funded Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Pre-Funded Warrant to the Company unless the Holder has assigned this Pre-Funded Warrant in full, in which case, the Holder shall surrender this Pre-Funded Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Pre-Funded Warrant in full. The Pre-Funded Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Pre-Funded Warrant issued.
(b) Reserved.
(c) Pre-Funded Warrant Register. The Company shall register this Pre-Funded Warrant, upon records to be maintained by the Company for that purpose (the “Pre-Funded Warrant Register”), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat the registered Holder of this Pre-Funded Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. The Company has appointed the Warrant Agent to maintain the Pre-Funded Warrant Register, as the Company’s agent. The Company shall remain responsible for the contents of the Pre-Funded Warrant Register, notwithstanding the appointment of a Warrant Agent. The Company shall provide thirty (30) days’ prior written notice to the Holder of any appointment of or change in Warrant Agent and the new Warrant Agent’s contact information, including if the Company shall itself directly maintain the Pre-Funded Warrant Register after a third-party Warrant Agent has been appointed.
Section 6Miscellaneous.
(a) No Rights as Stockholder Until Exercise; No Settlement in Cash. This Pre-Funded Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof, except as expressly set forth in Section 3. Without limiting any rights of a Holder under this Pre-Funded Warrant, in no event shall the Company be required to net cash settle an exercise of this Pre-Funded Warrant.
(b) Loss, Theft, Destruction or Mutilation of Pre-Funded Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Pre-Funded Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Pre-Funded Warrant, shall not include the posting of any bond), and upon surrender and cancellation of this Warrant or stock certificate, if mutilated, the Company will make and deliver a new Pre-Funded Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Pre-Funded Warrant or stock certificate.
(c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a business day, then such action may be taken or such right may be exercised on the next succeeding business day.
C-8

TABLE OF CONTENTS

(d) Authorized Shares. The Company covenants that, during the period this Pre-Funded Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Pre-Funded Warrant. The Company further covenants that its issuance of this Pre-Funded Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Pre-Funded Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Pre-Funded Warrant will, upon exercise of the rights represented by this Pre-Funded Warrant in accordance herewith, be duly authorized, validly issued, fully paid and non-assessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).
Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Pre-Funded Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Pre-Funded Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Pre-Funded Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Pre-Funded Warrant.
Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Pre-Funded Warrant is exercisable, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.
(e) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Pre-Funded Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Pre-Funded Warrant (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Pre-Funded Warrant), and hereby irrevocably waives, and agrees not to assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Pre-Funded Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action or proceeding to enforce any provisions of this Pre-Funded Warrant, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
(f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Pre-Funded Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.
C-9

TABLE OF CONTENTS

(g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Pre-Funded Warrant, if the Company willfully and knowingly fails to comply with any provision of this Pre-Funded Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.
(h) Notices. Any notice or communication required or permitted hereunder shall be in writing and either delivered personally, emailed or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, and shall be deemed to be given and received (i) when so delivered personally, (ii) when sent, with no mail undeliverable or other rejection notice, if sent by email, or (iii) three (3) business days after the date of mailing to the address below or to such other address or addresses as such person may hereafter designate by notice given hereunder:
(i) if to a Holder, to its address and/or email address set forth on the register of Holders on file with the Company, with copies to such Holder’s representatives as set forth on such register, or to such other address, email address and/or to the attention of such other person as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such change;
(ii)
if to the Company, to:
Aeva Technologies, Inc.
555 Ellis Street
Mountain View, CA 94043
Attention:
E-mail:
with a required copy to (which copy shall not constitute notice):
Simpson Thacher & Bartlett LLP
2475 Hanover Street
Palo Alto, CA 94304
Attention: Heidi Mayon
E-mail: heidi.mayon@stblaw.com
(i) Successors and Assigns. Subject to applicable securities laws, this Pre-Funded Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Pre-Funded Warrant are intended to be for the benefit of the Company and any Holder from time to time of this Pre-Funded Warrant and shall be enforceable by the Company and/or Holder or holder of Warrant Shares.
(j) Amendment. This Pre-Funded Warrant may be amended by the Company without the consent of any of the holders of the Subscription Warrants for the purpose of (i) curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein, or making any other provisions with respect to matters or questions arising under this Pre-Funded Warrant that is not inconsistent with the provisions of this Pre-Funded Warrant, (ii) evidencing the succession of another corporation to the Company and the assumption by any such successor of the covenants of the Company contained in this Pre-Funded Warrant, (iii) evidencing and providing for the acceptance of appointment by a successor Warrant Agent with respect to the Subscription Warrants, and any provisions required in connection therewith, (iv) adding to the covenants of the Company for the benefit of the Holder or surrendering any right or power conferred upon the Company under this Pre-Funded Warrant, (v) to comply with the rules of the Depositary Trust Company (“DTC”), including to permit the deposit of Subscription Warrants with the DTC and settlement through the facilities thereof, if applicable; or (vi) amending this Pre-Funded Warrant in any manner that the Company may deem to be necessary or desirable and that will not adversely affect the interests of the Holder in any material respect. All other modifications or amendments to this Pre-Funded Warrant and the other Subscription Warrants, including any amendment to increase the
C-10

TABLE OF CONTENTS

Exercise Price or move the Termination Date, shall require the written consent of the holders of a majority of the then outstanding Subscription Warrants; provided that any material and adverse modification, waiver or termination of the economic terms of the transactions contemplated under this Pre-Funded Warrant shall require the prior written consent of the Holder of this Pre-Funded Warrant.
(k) Severability. Wherever possible, each provision of this Pre-Funded Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Pre-Funded Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Pre-Funded Warrant.
(l) Headings. The headings used in this Pre-Funded Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Pre-Funded Warrant.
********************
(Signature Page Follows)
C-11

TABLE OF CONTENTS

IN WITNESS WHEREOF, the Company has caused this Pre-Funded Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
AEVA TECHNOLOGIES, INC.
By:
Name:
Title:

TABLE OF CONTENTS

NOTICE OF EXERCISE
To: AEVA TECHNOLOGIES, INC.
CC: WARRANT AGENT
(1) The undersigned hereby elects to exercise Warrant Shares of the Company pursuant to the terms of the attached Pre-Funded Warrant (only if exercised in full).
(2) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:
The Warrant Shares shall be delivered to the following DWAC Account Number:
(3) Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.
Name of Investing Entity:
Signature of Authorized Signatory of Investing Entity:
Name of Authorized Signatory:
Title of Authorized Signatory:
Date:

TABLE OF CONTENTS

EXHIBIT B
ASSIGNMENT FORM
(To assign the foregoing Pre-Funded Warrant, execute this form and supply required
information. Do not use this form to purchase shares.)
FOR VALUE RECEIVED, the foregoing Pre-Funded Warrant and all rights evidenced thereby are hereby assigned to:
Name:
(Please Print)
Address:
(Please Print)
Phone Number:
Email Address:
Dated: , ,
Holder’s Signature:
Holder’s Address:

TABLE OF CONTENTS

Annex D
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT UNDER ANY CIRCUMSTANCES BE OFFERED, TRANSFERRED SOLD OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE FEDERAL, STATE AND FOREIGN SECURITIES LAWS.
SERIES A WARRANT
AEVA TECHNOLOGIES, INC.
Warrant
Initial Exercise Date: , 2023
Shares:
This SERIES A WARRANT (this “Series A Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2023 (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on , 2027 (the “Termination Date”), but not thereafter, to subscribe for and purchase from AEVA TECHNOLOGIES, INC., a corporation organized and existing under the laws of the State of Delaware (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock (as defined below). The purchase price of one share of Common Stock under this Series A Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Series A Warrant is issued pursuant to that certain Standby Equity Purchase Agreement, effective on October , 2023, and entered into between the Company and the Holder.
Section 1Definitions. In addition to the terms defined elsewhere in this Series A Warrant, for all purposes of this Series A Warrant, the following terms have the meanings set forth in this Section 1.
Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Series A Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.
Black Scholes Value” means the value of this Series A Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant to Section 3(d) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the
D-1

TABLE OF CONTENTS

Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five business days of the Holder’s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Series A Warrant in accordance with Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Series A Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Series A Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Series A Warrant (without regard to any limitations on the exercise of this Series A Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Series A Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Series A Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Series A Warrant with the same effect as if such Successor Entity had been named as the Company herein.
Business Day” and “business day” mean a day other than Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by law to close.
Common Stock” means the Company’s common stock, par value $0.001 per share.
Common Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
Trading Day” means a day on which the principal Trading Market is open for trading.
Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).
VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Series A Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.
Warrant Agent” shall be any duly appointed agent selected by the Company. The Warrant Agent shall initially be the Company.
D-2

TABLE OF CONTENTS

Section 2Exercise.
(a) Exercise of Series A Warrant.
(i) Exercise by Holder. Exercise of the purchase rights represented by this Series A Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (with a copy to the Warrant Agent) of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
(ii) Exercise Procedures. Notwithstanding anything herein to the contrary, subject to Section 2(d)(ii), the Holder shall not be required to physically surrender this Series A Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and this Series A Warrant has been exercised in full, in which case, the Holder shall surrender this Series A Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company (with a copy to the Warrant Agent). Partial exercises of this Series A Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) business day of receipt of such notice. The Holder and any assignee, by acceptance of this Series A Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.
(iii) Maximum Percentage. The Holder may notify the Company in writing in the event it elects to be subject to the provisions contained in this Section 2(a)(iii); provided, however, no Holder shall be subject to this Section 2(a)(iii) unless he, she or it makes such election. If the election is made by the Holder, the Warrant Agent shall not effect the exercise of this Series A Warrant, and such Holder shall not have the right to exercise this Series A Warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the Warrant Agent’s actual knowledge, would beneficially own in excess of 19.9% (or such other amount as a Holder may specify) (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such person and its affiliates shall include the number of shares of Common Stock issuable upon the exercise of the Series A Warrants with respect to which the determination of such sentence is being made, but shall exclude Common Stock that would be issuable upon (x) exercise of the remaining, unexercised portion of the Series A Warrants beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates (including, without limitation, any convertible notes or convertible preferred shares or warrants), subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended. For purposes of the Series A Warrants, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the U.S. Securities and Exchange Commission (the “Commission”) as the case may be, or (2) a more recent public announcement by the Company. For any reason at any time, upon the written request of the Holder of this Series A Warrant, the Company shall, within five (5) Business Days, confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.
D-3

TABLE OF CONTENTS

By written notice to the Company, the Holder of this Series A Warrant may from time to time increase or decrease the Maximum Percentage applicable to such Holder to any other percentage specified in such notice; provided, however, that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company.
(b) Exercise Price. The exercise price per share of Common Stock under this Series A Warrant shall be $1.00, subject to adjustment hereunder (the “Exercise Price”).
(c) Cashless Exercise. If at any time after the Initial Exercise Date, there is no effective registration statement registering, or the prospectus contained therein is not available for, the resale of the Warrant Shares by the Holder, then this Series A Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:
(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, or (ii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;
(B) = the Exercise Price of this Series A Warrant, as adjusted hereunder; and
(X) = the number of Warrant Shares that would be issuable upon exercise of this Series A Warrant in accordance with the terms of this Series A Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.
If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of this Series A Warrant being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Series A Warrant. The Company agrees not to take any position contrary to this Section 2(c).
(d) Mechanics of Exercise.
(i) Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Company’s transfer agent (the “Transfer Agent”) to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of this Series A Warrant), and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) two (2) Trading Days after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Series A Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this
D-4

TABLE OF CONTENTS

Series A Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.
(ii) Delivery of New Series A Warrants Upon Exercise. If this Series A Warrant shall have been exercised in part, the Company shall, at the request of the Holder and upon surrender of this Series A Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Series A Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Series A Warrant, which new Series A Warrant shall in all other respects be identical with this Series A Warrant.
(iii) Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.
(iv) Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of this Series A Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of this Series A Warrant as required pursuant to the terms hereof.
(v) No Fractional Series A Warrant, Shares or Scrip. No fractional Series A Warrants, shares or scrip representing fractional shares shall be issued upon the exercise of this Series A Warrant. To the extent the Holder would be entitled to a fractional Series A Warrant, the Company shall round down to the nearest whole number of Series A Warrants to be issued to the Holder. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.
(vi) Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Series A Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
D-5

TABLE OF CONTENTS

The Company shall pay all reasonable Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to The Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.
(vii) Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Series A Warrant, pursuant to the terms hereof.
Section 3Certain Adjustments.
(a) Stock Dividends and Splits. If the Company, at any time while this Series A Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Series A Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Series A Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Series A Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.
(b) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Series A Warrant (without regard to any limitations on exercise hereof) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.
(c) Pro Rata Distributions. During such time as this Series A Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Series A Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Series A Warrant (without regard to any limitations on exercise hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution.
(d) Fundamental Transaction. If, at any time while this Series A Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the consolidated assets of the Company in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
D-6

TABLE OF CONTENTS

agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another person or group of persons whereby such other person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other person or other persons making or party to, or associated or affiliated with the other persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Series A Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Series A Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Series A Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Series A Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Series A Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Series A Warrant from the Holder by paying to the Holder an amount equals to the Black Scholes Value (as defined below), in the form of cash, stock or any combination thereof (at the Company’s discretion), of the remaining unexercised portion of this Series A Warrant on or around the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company’s control, including not approved by the Company’s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Series A Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
(e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.
(f) Notice to Holder.
(i) Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.
(ii) Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share
D-7

TABLE OF CONTENTS

exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Series A Warrant constitutes, or contains, material, non-public information regarding the Company, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Series A Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.
(g) Voluntary Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Series A Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.
Section 4Reserved.
Section 5Transfer of Series A Warrant.
(a) Transferability. Subject to compliance with any applicable securities laws, this Series A Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Series A Warrant at the principal office of the Company or its designated Warrant Agent, which shall initially be the Company, together with a written assignment of this Series A Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Series A Warrant or Series A Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Series A Warrant evidencing the portion of this Series A Warrant not so assigned, and this Series A Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Series A Warrant to the Company unless the Holder has assigned this Series A Warrant in full, in which case, the Holder shall surrender this Series A Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Series A Warrant in full. The Series A Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Series A Warrant issued.
(b) New Series A Warrants. This Series A Warrant may be divided or combined with other Series A Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Series A Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 5(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Series A Warrant or Series A Warrants in exchange for the Series A Warrant or Series A Warrants to be divided or combined in accordance with such notice. All Series A Warrants issued on transfers or exchanges shall be dated the original issuance date and shall be identical with this Series A Warrant except as to the number of Warrant Shares issuable pursuant thereto.
(c) Series A Warrant Register. The Company shall register this Series A Warrant, upon records to be maintained by the Company for that purpose (the “Series A Warrant Register”), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat the registered Holder
D-8

TABLE OF CONTENTS

of this Series A Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. The Company has appointed the Warrant Agent to maintain the Series A Warrant Register, as the Company’s agent. The Company shall remain responsible for the contents of the Series A Warrant Register, notwithstanding the appointment of a Warrant Agent. The Company shall provide thirty (30) days’ prior written notice to the Holder of any appointment of or change in Warrant Agent and the new Warrant Agent’s contact information, including if the Company shall itself directly maintain the Series A Warrant Register after a third-party Warrant Agent has been appointed.
Section 6Miscellaneous.
(a) No Rights as Stockholder Until Exercise; No Settlement in Cash. This Series A Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof, except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Series A Warrant.
(b) Loss, Theft, Destruction or Mutilation of Series A Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Series A Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Series A Warrant, shall not include the posting of any bond), and upon surrender and cancellation of this Warrant or stock certificate, if mutilated, the Company will make and deliver a new Series A Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Series A Warrant or stock certificate.
(c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a business day, then such action may be taken or such right may be exercised on the next succeeding business day.
(d) Authorized Shares. The Company covenants that, during the period this Series A Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Series A Warrant. The Company further covenants that its issuance of this Series A Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Series A Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Series A Warrant will, upon exercise of the purchase rights represented by this Series A Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).
Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Series A Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Series A Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Series A Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Series A Warrant.
D-9

TABLE OF CONTENTS

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Series A Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.
(e) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Series A Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Series A Warrant (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Series A Warrant), and hereby irrevocably waives, and agrees not to assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Series A Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action or proceeding to enforce any provisions of this Series A Warrant, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
(f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Series A Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.
(g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Series A Warrant, if the Company willfully and knowingly fails to comply with any provision of this Series A Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.
(h) Notices. Any notice or communication required or permitted hereunder shall be in writing and either delivered personally, emailed or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, and shall be deemed to be given and received (i) when so delivered personally, (ii) when sent, with no mail undeliverable or other rejection notice, if sent by email, or (iii) three (3) business days after the date of mailing to the address below or to such other address or addresses as such person may hereafter designate by notice given hereunder:
(i) if to a Holder, to its address and/or email address set forth on the register of Holders on file with the Company, with copies to such Holder’s representatives as set forth on such register, or to such other address, email address and/or to the attention of such other person as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such change;
(ii)
if to the Company, to:
Aeva Technologies, Inc.
555 Ellis Street
Mountain View, CA
Attention:
E-mail:
D-10

TABLE OF CONTENTS

with a required copy to (which copy shall not constitute notice):
Simpson Thacher & Bartlett LLP
2475 Hanover Street
Palo Alto, CA 94304
Attention: Heidi Mayon
E-mail: heidi.mayon@stblaw.com
(i) Successors and Assigns. Subject to applicable securities laws, this Series A Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Series A Warrant are intended to be for the benefit of the Company and any Holder from time to time of this Series A Warrant and shall be enforceable by the Company and/or Holder or holder of Warrant Shares.
(j) Amendment. This Series A Warrant may be amended by the Company without the consent of any of the holders of the Series A Warrants for the purpose of (i) curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein, or making any other provisions with respect to matters or questions arising under this Series A Warrant that is not inconsistent with the provisions of this Series A Warrant, (ii) evidencing the succession of another corporation to the Company and the assumption by any such successor of the covenants of the Company contained in this Series A Warrant, (iii) evidencing and providing for the acceptance of appointment by a successor Warrant Agent with respect to the Series A Warrants, and any provisions required in connection therewith, (iv) adding to the covenants of the Company for the benefit of the Holder or surrendering any right or power conferred upon the Company under this Series A Warrant, (v) to comply with the rules of the Depositary Trust Company (“DTC”), including to permit the deposit of the Series A Warrants with the DTC and settlement through the facilities thereof, if applicable; or (vi) amending this Series A Warrant in any manner that the Company may deem to be necessary or desirable and that will not adversely affect the interests of the Holder in any material respect. All other modifications or amendments to this Series A Warrant, including any amendment to increase the Exercise Price or move the Termination Date, shall require the written consent of the holders of a majority of the then outstanding Series A Warrants; provided that any material and adverse modification, waiver or termination of the economic terms of the transactions contemplated under this Series A Warrant shall require the prior written consent of the Holder of this Series A Warrant.
(k) Severability. Wherever possible, each provision of this Series A Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Series A Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Series A Warrant.
(l) Headings. The headings used in this Series A Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Series A Warrant.
********************
(Signature Page Follows)
D-11

TABLE OF CONTENTS

IN WITNESS WHEREOF, the Company has caused this Series A Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
AEVA TECHNOLOGIES, INC.
By:
Name:
Title:
D-12

TABLE OF CONTENTS

NOTICE OF EXERCISE
To: AEVA TECHNOLOGIES, INC.
CC: WARRANT AGENT
(1) The undersigned hereby elects to purchase Warrant Shares of the Company pursuant to the terms of the attached Series A Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.
(2) Payment shall take the form of (check applicable box):
in lawful money of the United States;
or if otherwise permitted, the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).
(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:
The Warrant Shares shall be delivered to the following DWAC Account Number:
(4) Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.
Name of Investing Entity:
Signature of Authorized Signatory of Investing Entity:
Name of Authorized Signatory:
Title of Authorized Signatory:
Date:
(5) Qualified Institutional. The undersigned is a “qualified institutional buyer” as defined by Rule 144A promulgated under the Securities Act of 1933, as amended.
Name of Investing Entity:
Signature of Authorized Signatory of Investing Entity:
Name of Authorized Signatory:
Title of Authorized Signatory:
Date:
D-13

TABLE OF CONTENTS

EXHIBIT B
ASSIGNMENT FORM
(To assign the foregoing Series A Warrant, execute this form and supply required information.
Do not use this form to purchase shares.)
FOR VALUE RECEIVED, the foregoing Series A Warrant and all rights evidenced thereby are hereby assigned to:
Name:
(Please Print)
Address:
(Please Print)
Phone Number:
Email Address:
Dated: ,,
Holder’s Signature:
Holder’s Address:
D-14